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Abstract
is thesis explores the eects of lithium on the human brain using structural,
functional and spectroscopic magnetic resonance techniques. Contemporary issues
surrounding the pharmacological eects of lithium are investigated and aspects of its
pharmacokinetics examined.
Bipolar disorder is known to be associated with dysfunction of themonoaminergic
neurotransmitter systems of the brain. It is proposed that the antimanic properties
of lithium derive from its attenuation of the actions of dopamine. In a randomised,
placebo-controlled study of lithium involving 24 healthy men, mania was modelled by
the administration of methamphetamine. Sustained attention, known to be disturbed
in mania, was assessed during functional magnetic resonance imaging. Within the
lithium group, response times were slowed and the eects of methamphetamine
on functional magnetic resonance imaging contrast diminished. ese ndings are
discussed in the context of current theories and contrasted with existent data.
Lithium has been reported to increase the volume of grey matter in the brain
in numerous magnetic resonance imaging studies. is observation was replicated
in a longitudinal, voxel-based morphometry study of 31 healthy men. Combining
quantitative imaging with various structural analysis techniques, it is argued that the
grey matter change may be better accounted for by lithium altering the relaxation
characteristics of protons; that is to say, signal change not true volume expansion.
e biophysical basis of this theory is discussed, together with its implications.
e pharmacokinetic properties of lithium in man are incompletely characterised,
in particular its distribution in various tissues of the brain. e development of a
magnetic resonance spectroscopy tool is described; its purpose was to determine the
concentration of lithium in grey and white matter in a time-scale suited to clinical
practice. Lithium was found to be evenly distributed in the brain regions examined,
with total acquisition times constrained to less than 20 minutes. e applications and
future developments of in vivo lithium spectroscopy are considered.
It is concluded that variousmagnetic resonance techniquesmay be usefully applied
to the investigation of the interactions between lithium and the human brain.
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1 introduction
Lithium is beguiling.e simplest of drugs with the most complex eects, its discov-
ery fundamentally altered the treatment of the recurrent depressive disorders but the
manner by which it confers therapeutic advantage remains unclear.is introductory
chapter describes the properties of lithium as both ion and drug, considering its
principal indications in psychiatry and outlining the pertinent explanations of its
eects. It should be acknowledged that our understanding of lithium is inextricably
linked to the ailments for which it is prescribed, and vice versa to some extent.us,
by rst considering lithium’s principal indications, the scene can be set for the phar-
macodynamic theories. Given the breadth and depth of the eld this introduction is
brief – in the chapters that follow, a more detailed appraisal of the literature relevant
to the each hypothesis is presented.
1.1 physical properties of lithium
Classied as an alkali metal and being the least dense of the solid elements, lithium has
both typical and anomalous properties within its group. Lithium easily yields its single Even its name
speaks of anomaly,
originally lithion
(Greek: lithos,
stone), so named
because unlike
other members of
its group it was
discovered in
non-plant material.
Ironically petalite,
its mineral ore, was
named for its
leaf-like qualities.
valence electron to form a cation and is highly reactive, not being found naturally in
its elemental form. Having a small ionic radius and a large eld density at its surface,
lithium behaves anomalously in aqueous solution compared to sodium and potassium
(Stern and Amis, 1959).is is most likely the consequence of a disproportionately
large hydration shell which restricts its ionic mobility, in physiological terms resulting
in properties such as low lipid solubility. If comparisons to the behaviour of other ions
in biology are to be drawn, then magnesium and calcium would be suitable choices
(Birch, 1976) – the so called diagonal relationship.
Lithium has ve isotopes, only two of which are suciently stable to be of any
relevance to biological sciences – 7Li and 6Li, with respective natural abundances of
approximately 93% and 7% (Brevard, 1981). In terms of human and animal physiology,
it is not clear how much of a distinction need be made between the two isotopes;
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physically and chemically, the dierence can be crucial. 6Li absorbs neutrons, a
property that can be used to chart its distribution in tissues (ellier et al., 1976), whilst
7Li possesses net-spin and has favourable magnetic resonance (mr) characteristics
(Komoroski, 2000).
1.2 clinical use of lithium
e most common contemporary medicinal use of lithium is in the management of
recurrentmood disorders, bipolar disorder in particular. Of itsmany other indications,
its potential role in the treatment of neurodegenerative conditions is most pertinent
to this thesis.
1.2.1 Historical perspective
As early as 1843, the aptly named physician Alexander Ure proposed that lithium Essentially. . . from
panacea to poison
and back again;
repeatedly.
Its current place is a
matter of
perspective.
carbonate should be used as a treatment for urinary calculi, based largely on its
anity for uric acid (Ure A. 1860). Subsequently advocated for topical application
to gouty joints – gout being associated with high uric acid levels – lithium soon
found favour in related conditions (Garrod, 1859). Its virtues were extolled for the
myriad ailments considered to be a consequence of the uric acid diathesis, including
psychiatric maladies such as melancholia and folie (somewhat similar to mania).us,
within 100 years of its discovery by man, eminent psychiatrists such as the Lange
brothers were in a position to systematically examine lithium’s ecacy in depression,
concluding in its favour (Shorter, 2009).
Around that time – the turn of the 19th century – there developed something of
a fervour for bottledLithiumWaters, which fuelled spa resorts, entrepreneurs and
round-the-world cyclists (Johnson, 1984). In truth, such waters contained minuscule
quantities of lithium; their use, together with the uric acid diathesis, soon fell into
disrepute.e proprietary solution was to add lithium in more substantial quantities
to tonics and carbonated so drinks such as 7·up, but public opinion was against it
and their popularity declined.
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A further 50 years down the line, two near simultaneous publications dictated
the future course of lithium prescription. e Australian psychiatrist John Cade
found it to be eective in mania (Cade, 1949), whilst Corcoran et al. (1949) reported
on its toxicity as a table salt substitute in those with cardiac disease.e American
Food and Drugs Administration decreed it to be too toxic for use, imposing a 15
year ban. Some European psychiatrists championed its cause, others opposed it;
their counterparts in North America were unable to do either directly (Lieberman,
2006).e pioneering work on lithium continued through this conict, comprising
some of the rst systematic trials of any treatment in psychiatry (Schou et al., 1954).
Clinical practice followed at a pace once monitoring and safety parameters had been
established. Lithium is now accepted world-wide as a core treatment for the recurrent
mood disorders (Grunze et al., 2009, 2010).
Once more, the passage of half a century has brought a change in the perception
of lithium, widening the breadth of indications. Stemming from theoretical reasoning
and preclinical experiments (Wada, 2009), the current outlook is optimistic and the
diathesis that of neuroplasticity – a matter which is considered later in this thesis.
1.2.2 Clinical indications
e principal clinical application of lithium is in the management of recurrent mood Guidelines and
algorithms vary in
their positioning of
lithium within the
hierarchy of
antimanic drugs,
acknowledgement
of its antidepressant
properties and role
in maintenance
treatment. . .
thus, in almost
every respect.
disorders (outlined in the textbox on page 6).ese common conditions present a
huge burden to the suerer and to society, accounting for a substantial proportion of
morbidity and mortality worldwide (Lopez et al., 2006).e importance, therefore,
of any intervention that can lessen their detriment should not be underestimated.
bipolar disorder
All recent guidelines for the pharmacological management of bipolar disorder have
advocated the use of lithium, though with variable emphasis on its role in dierent
phases of the illness (Grunze et al., 2004, 2009, 2010). Despite recent pharmacological
advances, it remains a core treatment of this condition (Cousins and Young, 2007).
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Manic episodes Approximately two thirds of patients with mania respond to lithium,
nearly twice the placebo rate (Poolsup et al., 2000). Response evolves over days to
weeks, treatment ideally continuing for at least threemonths aer remission is secured
in order to prevent relapse.
Depressive episodes Lithium is now rarely initiated solely to treat acute bipolar
depression, though it can be eective in this capacity (Nolen and Bloemkolk, 2000). In
those already taking lithium, their dose should be optimised – additional or alternative
medications may be considered if this proves ineective.
Mixed presentations Although some benet may be conferred, lithium is not as
eective in mixed states as it is in mania (Swann et al., 1997).
Prophylaxis Lithium can be the mainstay of maintenance treatment, either alone or
in combination with other medications. It reduces the risk of both depressive and
manic relapses, but analysis of all but the most recent studies suggests it is most eca-
cious in preventing the latter (relative risk reductions of 28% and 38% for depression
and mania respectively; Geddes et al., 2004).
Suicide prevention For reasons not entirely accounted for by its amelioration of
episode frequency and severity – nor entirely understood – lithium reduces the risk
of completing suicide whilst it is being taken (Cipriani et al., 2005).
ere is a discrepancy between the ecacy and eectiveness of lithium, naturalistic
studies indicating poorer outcomes than the controlled trials. is in itself is not
unusual, but with lithium there are two specic caveats: patients tend to stop taking
lithium (Maj et al., 1998) and rapid cessation may hasten relapse (Baldessarini et al.,
1999). It has been argued that if lithium is stopped suddenly – especially aer a short
treatment period – the increased risk of relapse may counterbalance the prophylactic
gains and overall, lithium may be detrimental (Goodwin, 1994).
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unipolar disorder
Acute depression Lithium is superior to placebo in the treatment of episodes of major
depression (Adli et al., 1998), though it is now rarely used in this capacity. As with
most antidepressant drugs, about two thirds of patients respond, entering remission
aer several weeks (Baron et al., 1975). It can also be eective in the prevention of
relapse in unipolar disorder (Cipriani et al., 2006), but the nature of the empirical data
makes it dicult to establish the magnitude of this eect in comparison to traditional
antidepressants.
Augmentation In those with a depression refractory to treatment, lithium can be Augmentation is a
strategy wherein an
agent is added to an
antidepressant
regime in order to
enhance its eects.
If the augmenter
has its own
antidepressant
properties, the
combination should
be synergistic.
used to good eect as an augmenting agent (Crossley and Bauer, 2007). Approxi-
mately half of those so treated can be expected to respond (Price et al., 1986), a not
inconsiderable eect given the severity and intractability of the depressive states for
which augmentation is indicated. A small proportion of cases improve within 48
hours, the majority take 4–6 weeks (Bauer et al., 2003). Swi responses most likely
have a basis in the enhancement of serotonergic functioning whilst late responses
may be due to lithium fostering neuronal resilience and recovery.
1.2.3 erapeutic levels
In establishing the correct dose of lithium, clinicians usually rely on a combination of With lithium, blood
tests guide rather
than guarantee the
outcome.
experience and regular serum monitoring, the therapeutic window of lithium being
narrow. In acute mania, serum concentrations of 0.8–1.2 mm are typically required,
with levels at the lower end of this range the usual target in the treatment of depression.
e optimum serum concentration for prophylaxis is still a matter for debate – some
advocate reducing the level to 0.6–0.8 mm whilst others council the continuation
of the dose which resolved the acute episode. At the heart of this debate is the fear Regrettably there is
insucient data,
observational or
experimental, to
resolve this matter
with certainty.
that patients are either inadequately protected or unnecessarily poisoned. To further
compound matters, there are no indices which robustly predict response to treatment
or predict relapse, adherence to treatment aside.
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mood disorders
ese common psychiatric disorders are syndromal diagnoses, arising from a complex
interplay of genetic, environmental and psychosocial factors.ey are considered the result
of stress on predisposed individuals in both psychological and biological models.
unipolar disorder
Also known asMajor Depressive Disorder, the lifetime risk of developing this condition is
about 10%. It most commonly aects women but spans race, class and age (though onset is
typically in the fourth decade). It has a propensity to recur. Episodes generally last for several
months, considered ‘chronic’ once unresolved for more than two years.
e core symptoms of depression are a pervasive lowering of mood and/or a loss of interest
or pleasure. ese are associated with changes in sleep, appetite and libido, together with
impaired concentration and psychomotor retardation.oughts are dominated by pessimism,
guilt, worthlessness and hopelessness, oen culminating in suicidal ideation. Delusions and
hallucinations may develop in severe cases, most oen mood-congruent.
Treatment comprises antidepressants, various psychological interventions or a combination
of the two. Recovery can be expected in the majority of cases, as can recurrence. Chronic
illness is common and about one in ten cases become refractory to treatment.
bipolar disorder
Formally known asManic Depressive Disorder, this highly recurrent condition is less common
than unipolar disorder, having a prevalence of 1–2%. It aects men and women equally, most
frequently emerging in the late teens to early twenties. Bipolar depressive and manic episodes
span weeks to months, hypomania is generally shorter lived.
Bipolar disorder can be subclassied: bd-i— episodes mania with or without depression;
bd-ii — episodes of hypomania and depression; bd-iii — induced by electroconvulsive
therapy (ect) or antidepressants.
Mania comprises an abnormally and persistently elevated, expansive or irritable mood
together with increased psychomotor activity, excessive optimism, grandiosity, social
disinhibition and unrestrained hedonism; psychosis may occur. Hypomania is similar but
less severe. Bipolar depression is akin to unipolar disorder, but retardation and excessive
sleep can predominate. In mixed episodes, features of depression and mania co-occur.
Mania usually responds to lithium, sodium valproate, antipsychotics or benzodiazepines,
alone or in combination. e optimal approach to bipolar depression is unclear, as the
antidepressants may trigger mania and worsen the course of the illness; second-generation
antipsychotics and lamotrigine are proving eective without this risk. Maintenance treatment
is commonly required— oen involving the continuation of lithium and/or sodium valproate,
latterly the second-generation antipsychotics have come to the fore.
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1.2.4 Safety considerations
Lithium can be rightly viewed as a harmful substance, for an excess can lead to serious
adverse consequences – careful monitoring is thus required during initiation and
throughout long-term administration. Toxicity must, however, be distinguished from
the more common and less harmful side-eects which frequently accompany its use.
e safe use of lithium has been reviewed by Berghofer et al. (2006).
side-effects
Lithium has the potential to induce a wide range of side-eects, many of which appear
shortly aer initiation and subside within a matter of weeks.e most frequent of
these – nausea, abdominal pain, diarrhoea, increased thirst and urination, ne tremor
– are usually well tolerated. Very oen, the most troublesome side-eects are in the
neuropsychiatric domain and principally comprise fatigue, impaired concentration
and poormemory; these can be dicult to separate from the symptoms of the illnesses
for which lithium is prescribed.
Vigilance for progressive or late side-eects of lithium is also required. Weight
gain can be considerable and is probably multifactorial. Kidney function must be
monitored as renal impairment is an uncommon but serious consequence of lithium
treatment. Endocrine dysfunction, especially goitre and hypothyroidism, should
be enquired about and investigated regularly. e development of acne and the
exacerbation of psoriasis can occur at any point during treatment, the latter being a
relative contraindication.
intoxication
Lithium intoxication is a serious matter, over-shadowing much of its use. Overt intox-
ication presents with the symptoms listed below and commonly has an identiable
cause – impaired renal function, dehydration and the co-administration of certain
drugs for example. A substantial risk may be posed by undetected ‘subthreshold’
intoxication, whereby symptoms are not marked but tissue damage accrues.
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• Mild: nausea · loose stools · polyuria · thirst · impaired concentration · marked ne
tremor
• Moderate: nausea · vomiting · diarrhoea · excessive thirst · coarse tremor · slurred
speech · incoordination · disorientation · drowsiness
• Severe: vomiting · incontinence · excessive thirst · ataxia · parkinsonism · myoclonus ·
seizures · apathy · somnolence · coma
Toxicity would be expected at levels of 1.5 mm and above, though it can occur with
serum levels in the standard therapeutic range.e reasons for this are incompletely
understood, but a plausible explanation would be that some individuals have a higher
tissue concentration of lithium for a given serum level.
1.3 pharmacokinetics of lithium
1.3.1 Absorption
Lithium is readily absorbed from the gastrointestinal tract, reaching peak plasma
levels between one and three hours. Its absorption is unaected by food and following
a standard dose is usually complete within six to eight hours (Alda, 2006).
1.3.2 Distribution
e distribution of lithium is both wide and swi. Lithium is thought not to be Our knowledge of
the distribution of
lithium in tissues
comes largely from
preclinical studies.
e scarcity of data
from human
subjects is mainly
due to the logistical
and technical
challenges in
assaying it.
bound to plasma proteins to any signicant degree and enters tissues readily, the
tissue concentration generally being lower than that of the serum (Komoroski, 2000).
It enters and exits cells by a variety of mechanisms including: Na-K atpase, Na-K co-
transport, anion exchange, leakage and Na-Li exchange (Duhm, 1992).e balance of
these mechanisms determine its intracellular concentration. Cellular and subcellular
concentrations are dicult to establish, but are again thought to be lower than serum
levels (Riddell et al., 1990).
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1.3.3 Elimination
Lithium is almost exclusively eliminated by the kidneys, described by rst-order
kinetics and determined primarily by the glomerular ltration rate.e serum half-
life of elimination is typically 18–24 hours, but this can increase with age by as much as
a factor of two (Alda, 2006). Tissue elimination half-life may be longer still (ornhill
and Field, 1982). Medications such as non-steroidal anti-inammatory drugs (nsaid)
and certain diuretics delay elimination and risk toxicity if concurrently prescribed
with lithium (Shalmi andomsen, 1991).
1.4 pharmacodynamics of lithium
1.4.1 Conceptual frameworks
In short, the matter of how lithium works is unresolved – in reality, its actions and
eects are highly contextual. In this thesis, we refer to the eects of lithium as the Lithium induces
many eects, but
may actually have
few actions.
Plurality within
theories can thus be
embraced or
avoided.
apparent changes it brings about, be they subjective, neuropsychological, physiological,
cellular, therapeutic or otherwise; we reserve the term actions for the direct inuence
the lithium ion exerts on its surroundings in order to bring about its eects. By
making this distinction we can clarify some aspects of the research into the workings
of this drug. Much of our understanding of lithium is nested within the constructs of
mood disorders, which in turn have been dominated by psychopharmacologically
derived – or driven – theories.e actions of lithium may be unchanging, but the
investigation and interpretation of its eects are vulnerable to contextual trends.
candidate systems
e major mood disorders have been said to be due to a functional derangement is clearly limited
view was neither
destined nor
intended to
completely explain
the fragility of the
human condition; it
provided a valuable
framework for
discussion and
research.
of the serotonergic, noradrenergic and dopaminergic neurotransmitter systems of
the brain – the monoamine hypothesis. In depression there is a decit of eective
monoaminergic transmission; in mania an excess.
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emonoaminergic neurotransmitter systems of the central nervous system (cns)
are well dened and share common characteristics. Serotonin, dopamine and nora-
drenaline – the neurotransmitters in question – are synthesised in specic neurones
from amino-acid precursors, determined and driven by key enzymes. Synthesis takes
place in the cytosol and whilst a portion of the transmitters remain in this cellular
compartment, most are stored in vesicles, increasing the eciency of release. Upon
neuronal ring, transmitter release occurs by vesicular merger with the presynaptic
membrane. Once in the synapse, the monoamines bind to specic receptors to bring
about changes in cellular functioning, either in the postsynaptic neurone or their
neurone of origin via autoreceptor activation. Typifying g-protein coupled receptor
(gpcr) slow-neurotransmission, their eects manifest over milliseconds to minutes
(Greengard, 2001b). Termination of action occurs by reuptake and/or molecular
breakdown with the dominant mode of termination varying by brain region and
transmitter. All of the monoamine neurotransmitters can be degraded by monoamine
oxidase (mao), though additional enzyme pathways are well recognised.
e monoaminergic neurones arise from cell bodies in distinct, closely approxi-
mated brainstem nuclei and project to discrete, widely distributed regions in spinal,
cerebellar, striatal, limbic and cortical areas.ey modulate a vast array of functions
including, but by no means limited to, mood, cognition, movement, sensory-gating
and vegetative processes. Understandably, these systems are the target for numerous
psychotropic medications.
the position of lithium
Lithium has always been something of a cuckoo in the monoamine nest, its eects
not conned to neurotransmitter release and receptor activation. Indeed many of its
eects occur downstream of receptors, involving the modulation of complex cellular
transduction pathways in the postsynaptic neurone (Beaulieu and Caron, 2008). Of
late, these eects have been interpreted in terms of neuronal viability in addition to
signal transduction (Quiroz et al., 2010).
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1.4.2 Lithium and the monoamines
serotonergic neurotransmission
Emotional processing circuits are richly innervated by serotonin (5-ht) and it is con-
sidered central to moodmodulation, with a dominant role in the mediation of anxiety
(Stein and Stahl, 2000). Lithium is thought to enhance serotonergic functioning,
preclinical studies indicating that it achieves this enhancement through a variety of e tryptamine
serotonin is
synthesised from
the essential
amino-acid
tryptophan, the
steps catalysed by
tryptophan
hydroxylase and
amino acid
decarboxylase.
Monoamine
oxidase governs its
metabolism to
5-hiaa.
eects.e uptake of tryptophan is increased with short term administration (Aragon
et al., 1987), and more 5-ht is presumably synthesised with an abundance of precursor.
e release of 5-ht is enhanced by acute and chronic lithium treatment (Gottberg
et al., 1989), with a reduction in the density of 5-ht receptors in the hippocampus
more so than other brain regions (Subhash et al., 1999), receptor density reduction
reecting increased presynaptic 5-ht activity. Lithium also induces changes in 5-ht1a
receptors, again localising to the hippocampus (Treiser et al., 1981).
In healthy humans the prolactin response to l-tryptophan administration is in- e rate limiting
step in serotonin
synthesis is not
enzyme activity but
precursor
abundance.
Depleting dietary
tryptophan lowers
mood in those with
a history of
depression whilst
l-tryptophan
administration can
be an eective
antidepressant
augmentation
strategy.
creased by acute and chronic treatment with lithium, indicating an enhancement of
serotonergic activity (Price et al., 1989). In depression, the prolactin response to l-
tryptophan is diminished and lithium corrects this in the short-term, though it is not
clear whether this is sustained (Deakin et al., 1990; Price et al., 1990).ese eects may
be due to enhanced synthesis and release rather than receptor changes; short-term
lithium administration does not appear to alter the sensitivity of key receptors in man,
as it fails to attenuate the eects of the 5-ht1a receptor agonist gepirone (Walsh et al.,
1991). In patients with aective disorders stabilised by lithium, tryptophan depletion
fails to alter mood (Hughes et al., 2000; Johnson et al., 2001), such that lithium may
protect against transient reductions in serotonergic function.
dopaminergic neurotransmission
In addition to its established roles in working memory, attentional processes and Dopaminergic
interpretations of
bipolar disorder are
returning to the
fore, dragging
lithium in their
wake.
bodily movement, dopamine modulates mood systems, crucially contributing to
drive and pleasure seeking (Greengard, 2001a). Evidence for an interaction between
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lithium and dopamine is most consistently found in its ability to attenuate the eects
of stimulants. Preclinical behavioural models in the rat support an attenuation of
dopaminergic transmission by lithium, evidenced by a reduction in spontaneous
exploration of new environments (Gray et al., 1976; Bloom et al., 1983; Hines and
Poling, 1984) and a diminution of the eects of amphetamines aer acute and chronic
administration (Flemenbaum, 1975; Borison et al., 1978; Berggren et al., 1978, 1981;
Berggren, 1985; Lerer et al., 1984; Gould et al., 2001). ere are, however, negative
ndings from comparable studies (Ebstein et al., 1980; Fessler et al., 1982; Pittman
et al., 1984; Arriaga et al., 1988; Cappeliez and Moore, 1990)e neurobiological
correlates of the eects are unclear – aer chronic administration of lithium to rats,
the synthesis and release of dopamine has been shown to decrease (Rastogi and
Singhal, 1977; Baptista et al., 1993), increase (Berggren, 1985) or remain unaltered
(Reches et al., 1984). Studies of dopamine metabolites are similarly mixed (Hesketh
et al., 1978; Gottberg et al., 1989). Inactivation of dopamine through cellular uptake is
increased in vivo in the rat brain following chronic lithium administration (Ahluwalia
and Singhal, 1981). e application of lithium to cells in vitro provides support to
this observation (Dunigan and Shamoo, 1995) and the elevation in the dopamine
transporter (dat) binding of [125i]rt-121 alludes to the mechanism (Carli et al., 1997).
Lithium also has an eect on dopamine receptor expression, preventing neuroleptic-
induced postsynaptic supersensitivity but not reversing it (Bloom et al., 1983; Bunney
and Garland, 1983). Comparable studies have been conducted in man, the ndings of
which are considered in Chapter 4.
noradrenergic neurotransmission
Underpinning vigilance and motivation in healthy subjects, disturbing the noradren-
ergic systems impairs such functions and also generates anxiety and irritability.e
evidence that lithium modies this system is somewhat inconsistent and so a consen-
sus on its eects is dicult to establish (Juckel and Mavrogiorgou, 2006). Studies in
rodents yield a mixed picture, suggesting that the manner in which lithium aects
noradrenergic systems may be sensitive to the dose, duration and region examined.
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Soon aer lithium injection, noradrenaline concentrations in the mediobasal hy-
pothalamus fall (Otero Losada and Rubio, 1992); aer an hour, levels are elevated
in the visual cortex (Gottberg et al., 1988). Iontophoretic application of lithium to
the prefrontal cortex attenuates noradrenergic modulation of ring rates (Kovacs
and Hernadi, 2002). Peripheral assays of the turnover of the transmitter in healthy
subjects have shown that whilst lithium does not alter noradrenergic functioning
aer treatment periods of 1–3 weeks (Rudorfer et al., 1985; Grof et al., 1986), longer
term administration appears to increase its release (Manji et al., 1991). In mania,
lithium may reduce noradrenaline excretion but in depression the reverse can occur
(Greenspan et al., 1970; Beckmann et al., 1975; Bowers and Heninger, 1977). e
eects of lithium on the release of noradrenaline may be driven by it altering the
sensitivity of α2-autoreceptors (Brambilla et al., 1988); its prevention of β-adrenergic
supersensitivity may be important in chronic treatment (Risby et al., 1991; Lenox et al.,
1998)
1.4.3 Signal transduction pathways
Monoaminergic neurotransmitters can bring about long term changes in postsynaptic
cells, receptor activation triggering a cascade of intracellular signalling systems which
may modify cellular functions by altering gene expression and protein transcription
(Greengard, 2001b). In addition to modifying neurotransmitter activity, lithium
aects these second-messenger systems in various ways.
e inositol depletion hypothesis is the most established in this eld (Berridge
et al., 1989). In brief, lithium alters the balance of the phosphatidylinositol cycle (pi-
cycle) by inhibiting inositol monophosphatase, increasing inositol monophosphate
and decreasing free myoinositol concentrations in the brain. It it thought that in
reducing free myoinositol, intracellular processes that depend on it are slowed and
signal transduction altered. Moreover, the eects may be more marked in cells where
the pi-cycle is functioning in such a way that free myoinositol levels are high (Gani
et al., 1993) – an abnormality purported to occur in mania.e functioning of the
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pi-cycle is dependent upon the presence of ionic co-factors such as calcium and
magnesium. Lithium, with its diagonal relationship to these ions, may inhibit inositol
monophosphatase by displacing or altering the concentration of its co-factors.
e actions of second-messenger systems are not restricted to cellular transduction
as they interact with molecular pathways governing cellular integrity and survival.
at lithiummay alter the balance of activity in these systems, and so cellular viability,
is attracting much interest.
1.4.4 Neuroplasticity
Lithium has been found to limit the damage caused to neurones by a variety of insults. e neuroplastic
eects of lithium
are increasingly
well dened in
preclinincal studies;
whether these
eects can be
demonstrated in
the human brain in
vivo is uncertain.
Oen described as neuroprotective or neurotrophic, there is an emerging consensus
that an eect on neuroplasticity is the preferred expression. It is thought that lithium’s
enhancement of neuronal viability and resilience is not simply a consequence of its
therapeutic eect, but central to it.is topic has been extensively reviewed, (with
the reviews synthesised by Wada, 2009).e key points are summarised below.
lithium and apoptosis
A wealth of data from neuronal cell cultures and rodent brain studies demonstrates
or supports the neuroprotective eects of lithium, mediated through a variety of
mechanisms but principally by the modulation of apoptotic pathways. Central in this apoptosis :
the process of
programmed cell
death.
Its prevention is the
microscopic
embodiment of
lithium’s
antisuicidal
properties.
regard is glycogen synthase kinase-3β (gsk-3β), a serine/threonine kinase ubiquitously
expressed in tissues and extensively in the brain.is protein kinase is constitutionally
active and by phosphorylating its substrates, leads to their inactivation or degradation.
Expression of gsk-3β is tightly regulated as when activated or inactivated, numerous
cellular processes come to pass that are generally pro- or anti-apoptotic respectively;
inactivation thus favours neuroprotection. Inhibition of gsk-3β usually comes about
through the actions of akt (Ak transforming), another serine/threonine kinase whose
activity is increased by various growth factors including brain-derived neurotrophic
factor (bdnf) and the insulin-like growth factors (igf).
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Lithium inhibits gsk-3β, the consequences of which are pertinent to is psychophar-
macological prole.e mechanism of this inhibition is largely unresolved, but may
occur directly though lithium competing with the cofactor magnesium and indirectly
via the facilitation of akt. Amongst other things, inhibition of gsk-3β by lithium
brings about an accumulation of β-catenin, facilitating the processes of down-stream
pathways.e products of the Wnt/β-catenin pathway include bdnf and igf-i and
igf-ii. Receiving much attention for its putative role in the development and mainte-
nance of the mood disorders as well as their treatment, bdnf levels are lowered in
episodes, improve with recovery, and are increased by lithium and antidepressants.
Other components of the neuroprotective pathways are aected by lithium, notably
bcl-2. Shown to encode cytoprotective protein in cells of human neuronal origin, bcl-2
has been found to foster the regeneration of cns axons. Lithium appears to up-regulate
bcl-2, enriching hippocampal neurogenesis in the dentate gyrus of mice.
1.5 aims of this thesis
e literature on lithium is vast, but on appraising the eld three topics attracted
our attention, variously begging conrmation, explanation or exploration. First, the
disorders for which lithium is prescribed have long been associated with abnormalities
of the monoaminergic neurotransmission and of late there has been a resurgence of
interest in the role of dopamine in bipolar disorder. Driven most recently by the clear
antimanic properties of dopaminergic antagonists, it is of interest to examine whether
lithium’s therapeutic eect may in part be due to a modulation of dopaminergic
neurotransmission.e following hypothesis was therefore proposed:
Lithium carbonate will lessen the eects of methamphetamine by attenu-
ating dopaminergic neurotransmission in healthy men, gauged by subjec-
tive ratings, performance on a task of sustained attention and fmri signal
change; these eects will be evident at serum levels advocated for the treat-
ment of mania and not with a lower dose schedule.
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Second, the proposal that lithium has neuroprotective properties is gaining a great
deal of attention and widespread acceptance.e extensive and consistent preclinical
evidence has begun to inuence clinical research, with investigators examining the
potential role of lithium in various neurodegenerative conditions. Neuroprotective
eects of lithium have not, however, been convincingly demonstrated in man.e
mechanism underlying the most commonly cited supporting evidence, the observa-
tion of increases in grey matter volume on mri scanning, has yet to be explained.
In this thesis it is proposed that the imaging ndings are better accounted for by an
alteration in mri contrast, more specically:
e increase in grey matter volume following lithium treatment is artefac-
tual, arising from a misclassication of tissue types during intensity-based
image analysis, in turn due to lithium reducing the T1 relaxation time of
protons.
ird, there is still relatively little known about the relationship between serum
and brain concentrations of lithium in man.e feasibility of detecting lithium using
mrs was established two decades ago but progress has been slow, the eld restricted
to a few specialist centres. Whilst quantitative spectroscopic and imaging-based
techniques have been developed, comparison of the concentration of lithium in grey
and white matter has not been achieved. Furthermore, the reported signal resolutions
remain too low and the scan times too long for this technique to have clinical utility.
As part of this thesis, the development of lithium mrs equipment and techniques was
undertaken, setting the following targets:
A lithiummrs technique should be developed for use on a clinical scanner,
with the aim of enabling the concentration of lithium in the human brain
to be quantied in vivo. Acquisition times should be short enough that
the technique could be used clinically, with a resolution such that signal
derived from grey and white matter can be discriminated.
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2 magnetic resonance
e eld of magnetic resonance (mr) is attractive to neuroscientists and clinicians
alike, enabling the structure, function and composition of the human brain to be
probed in vivo. As a complete account of the mr phenomenon is beyond the scope of
this thesis, the aim of this chapter is to provide an overview that is sucient to permit
the critical appraisal of the techniques used. Following an outline of the fundamental
principles, the acquisition and analysis of structural and functional data is reviewed
before moving on to magnetic resonance spectroscopy (mrs).
2.1 fundamental principles
2.1.1 Nuclear properties
Certain atomic nuclei possess net-spin, a property central to mr that arises from the
inherent spin of subatomic particles. Spin is intrinsic and although it does not derive
from a rotational motion, it is said to have a direction.e spins of paired particles are
in opposite directions and so balanced; if a nucleus has an uneven sum of protons and
neutrons, imbalance exists and net-spin emerges.e angular momentum associated
with spin gives rise to amagnetic moment (µ) which characterises the microscopic
magnetic eld surrounding the nucleus (gure 2.1 on page 20). At equilibrium in the
absence of a macroscopic magnetic eld, the individual nuclear magnetic moments
are randomly orientated and cancel out, resulting in zero net magnetisation.
e situation changes in the presence of an external magnetic eld and aspects of
the interaction can bemanipulated by the application of electromagnetic (em) waves in
the radiofrequency (rf) range. In magnetic resonance imaging (mri), the interaction
is restricted to hydrogen nuclei (hereaer referred to as protons, since a single proton
comprises the nucleus of 1H). Protons have well characterised spin properties which
will be used to outline the principles of mr; spectroscopy and multinuclear detection
is considered later in this chapter.
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2.1.2 Nuclear behaviour in a magnetic eld
individual nuclei
When exposed to a static magnetic eld (B0), the magnetic moment of a nucleus is
said to align with respect to that eld (itself traditionally orientated along the z-axis).
Quantum mechanics tells us that this alignment can be in any direction but that its
z-axis component is restricted to a number of states, characterised by the quantum
number m. is m can take 2I + 1 values running from −I to +I in unit steps, in
which I is the spin quantum number of the nucleus. Protons have two possible energy
states (I = 1⁄2 ;m = +1⁄2 andm = −1⁄2); in them = +1⁄2 state the z-axis component of µ is
parallel toB0 whilst in them=−1⁄2 state it is antiparallel (gure 2.1 on page 20). Excited-
state and ground-state are synonymous with antiparallel and parallel. Opposing B0,
antiparallel is oen described as the higher energy level.
Particles with spin have angular momentum and an associated magnetic moment;
both are vectors, the angular momentum vector being referred to as the spin polar-
ization axis. For protons, µ and the spin polarization axis are aligned and in the same
direction. When exposed to an external magnetic eld these vectors move around it,
describing a circular path in the plane perpendicular to the axis of B0.is is called
precession (gures 2.1 and 2.2 on page 20), classically analogous to the motion of an
angled gyroscope.e rotating mass of a gyroscope gives it an angular momentum
parallel to its axis – when the axis deviates from the vertical, the net angle between
it and the force of gravity results in a torque which causes the whole gyroscope to
precess. Within the vector model, the external magnetic eld is analogous to gravity
and the nucleus to the gyroscope.
e frequency of precession – Larmor frequency – is dependent upon the direction
and strength of the applied magnetic eld, as well as the properties of the nucleus
itself.is is expressed formally in equation 2.1, where ω0 is the angular frequency of
the precession (in rad·s−1), γ is the gyromagnetic ratio of the nucleus and B0 is the
strength of the applied magnetic eld (in Tesla).e sign in the formula indicates the
direction of the precessional rotation; negative in the case of protons.
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ω0 = −γB0 (2.1)
e Larmor frequency can also be expressed in Hertz, requiring the simple trans-
formation apparent in equation 2.2 and a change of notation (ν0).
ν0 = − 12pi γB0 (2.2)
multiple nuclei
Individual protons are not observed in mr experiments but rather great swathes
of them. A group of protons which are experiencing the same magnetic eld is
called a spin packet, their behaviour usually explained using classical theory and
the principles of the vector model. At equilibrium in an applied magnetic eld the
magnetic moments of the protons in a spin packet are not randomly aligned but
anisotropically distributed – fractionally more are in the ground-state (gure 2.2
on the next page). When they are summed they do not fully cancel out and so a
magnetic eld emerges, each spin packet vector subsequently contributing to the
net magnetisation vector of the whole sample. At equilibrium, the net magnetisation
vector emerges parallel to the applied eld because fractionally more protons are in
the ground-state. e behaviour and manipulation of this vector is central to the
magnetic resonance technique.
2.1.3 Signal preparation
e net magnetisation vector can induce a voltage dierence in a conducting array as
it sweeps round its precessional path – the basis of signal detection. At equilibrium,
however, the vector evades detection for two reasons: rst, being small and in the
z-axis, it is subsumed into the B0 eld; second, it is static and so does not meet the
criteria for magnetic induction.is situation would alter were the net magnetisation
vector temporarily shied into the x-y plane.is can be achieved by the application
of an rf pulse though a transmitter coil.
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Figure 2.1: a) Spin of an individual proton generates a magnetic moment µ, aligned with the spin
polarisation axis; b) In the presence of an externalmagnetic field B0 applied along the z-axis, there
are two possible quantum energy states that describe the alignment of the z-axis component
of µ for an I = 1⁄2 spin; c) Precession of an individual proton’s µ about the axis of the applied
magnetic field − at equilibrium the path is circular because the angle subtended to B0 is constant
for that proton.
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Figure 2.2: Precession in a B0 field − a) Right-handed axis diagram indicating the alignment of the
applied magnetic field B0 and the typical placement of a subject; b) Precessional path of µ about
the z-axis for a single proton, the direction indicating its negative Larmor frequency; c) Multiple
phase-incoherent vectors precessingwith the samedirection and frequency, their position above
and below the x-y plane indicative of their parallel and antiparallel spin state respectively.
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Pulse application e rf pulse is an em wave and by arranging the angle at which it
is applied, an additional magnetic eld (B1) arises, perpendicular to B0 and rotating
at the frequency of the em wave. If the rotation matches the Larmor frequency,
phase cohesion is induced and vector tipping occurs. e net magnetisation vector
experiences a combined magnetic eld, angled to the z-axis and rotating around it.
is new eld generates a new torque onM, rotating it towards the x-y plane.
Vector path It is important to consider how the path of the net magnetisation vector
can be visualised. Viewed as a xed observer in a space external to the nucleus, the so-
called laboratory frame, the net magnetisation vector would rotate down towards the
x-y plane with the tip of its axis describing a spiral within a sphere.is complicated
trajectory can be simplied by adopting the rotating frame of reference, in which the x
and y axes themselves rotate at the Larmor frequency. Travelling with the precessing
vector enables one to describe the path as a simple arc (gure 2.3 on page 24). In the
diagrams which follow, we consider the behaviour of the net magnetisation vectors of
several spin packets at once. As these can be made to precess at dierent frequencies,
the rotating frame is more correctly described as moving with the B1 eld.
precessional phase
e net magnetisation vector undergoes precession. When fully aligned with the B0
eld, the angle subtended by the net magnetisation vector in the ‘precession cone’ is
zero but when it is shied toward the x-y plane, the familiar situation of precession as
a sweeping arc of motion is encountered.e net magnetisation vector is a composite
of all the vectors in the spin packets; at equilibrium, these vectors do not precess in
phase and at any given point in time they are randomly distributed around the circular
precessional path.ey will, however, be rotating at largely the same frequency. If
the B1 eld created by the rf pulse rotates synchronously with the precessing vectors,
then their frequencies are matched and the vectors are brought into phase (gure 2.4
on page 24). As phase cohesion is a requirement for realigning the net magnetisation
vector, the rf pulse needs to be circularly polarized at the Larmor frequency.
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transverse magnetisation
It takes energy to create a sizeable transverse component to the net magnetisation
vector and this is delivered by making use of the phenomenon of resonance. For our
purpose, this can be much simplied (gure 2.4 on page 24).
Resonance When an object it is exposed to an oscillation which matches its natural
frequency, it gains a great deal of energy from that oscillating force. Essentially,
an rf pulse of Larmor frequency will resonate with the protons in the spin packet,
delivering energy which elevates a proportion to a higher state.e ratio of protons in
the ground-state and excited-state equalises, progressively depleting the longitudinal
magnetization at the expense of which a transverse component arises.
Tipping As the transverse component emerges, the net magnetisation vector moves
away from the z-axis, with the angle subtended to this axis usually denoted by θ. A Strictly, θ is the
angle dierence
between the net
magnetisation
vector before and
aer the rf
excitation pulse.
is becomes
important in
multiple pulse
sequences. Note
that tip angle is
synonymous with
ip angle and
nutation angle.
tip angle of 90° means that the net magnetisation vector has been fully shied from
the longitudinal plane into the transverse; 180° sees it realigned with the z-axis but in
the opposite direction. Precession occurs all the while.
2.1.4 Signal detection
When the net magnetisation vector is precessing in the transverse plane, it is capable
of inducing an electrical voltage in a conductor and thereby generating a current
(gure 2.5 on page 26). An rf receiver coil can now be used to detect and convey this
signal. Coils come in many forms; some systems use separate coils for transmitting
and receiving signals, other use transceiver coils to do both.
characteristics of the signal
e current induced in the rf coil is small and requires amplication before it can be
processed further. In its purest form it should be a periodic oscillation at the Larmor
frequency but, for reasons we will discuss later, other ‘o-resonance’ frequencies are
also detected. Following a simple 90° tip, the signal is of maximal amplitude just aer
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the excitatory rf pulse is removed – this being the point when the net magnetisation
vector is wholly in the transverse plane.is position is not sustained and with time,
the longitudinal magnetisation returns and phase cohesion is lost.
e spin packet regains its equilibrium through relaxation processes, described
by the time-constants T1 and T2.ese two relaxation processes are important in mri
image creation, providing dierent information on tissue characteristics and disease
states. Both types of relaxation occur concurrently for all protons, but T1 relaxation
takes longer than T2.e construction of the rf pulse sequence dictates which process
dominates in the signal detected (see §2.1.5 on page 25).
longitudinal relaxation (t1)
When protons regain equilibrium, the energy they absorbed from the rf pulse is
dissipated into their surroundings.is is called longitudinal, T1 or spin-lattice re-
laxation, the term lattice harking back to the origins of the eld in the analysis of
crystal structures. Longitudinal relaxation represents the recovery of the longitudinal
component of the net magnetisation vector, which occurs in an exponential manner.
e time-constant T1 is the time taken for the longitudinal component to return to
63% of its equilibrium value, and is heavily dependent on the strength of the applied
magnetic eld.
transverse relaxation (t2)
Transverse, T2 or spin-spin relaxation derives from the interactions of the protons
with each other and not the lattice. In this form of signal decay it is the transverse
component of the magnetisation vector which diminishes.ere is no actual energy
dissipation from the tissue with T2 relaxation, but rather a redistribution amongst
spins as they lose phase coherence. Such dephasing can be thought of as reducing
how much of the transverse signal can be detected rather than how much is actually
present. e transverse magnetisation decays in an exponential manner with the
time-constant T2 being the time taken for it to lose 63% of its original value. T2 times
are relatively independent of the strength of the applied magnetic eld.
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Figure 2.3: The net magnetisation vector M at equilibrium (a) and following a 90○ radiofrequency
pulse (b and c). In the laboratory frame, each µ spirals towards the x-y plane, them = +1⁄2 spins
moving top-down and them = −1⁄2 spins bottom-up (not depicted). M follows suit, rotating about
the z-axis at the Larmor frequency. In the rotating frame, the x-y plane turns with a frequency
equal to ω0 so that from the perspective of M, the 90○ tip is a simple arc.
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Figure 2.4: Application of a B1 field − a) at equilibrium there are more spins in the ground state and
so M, the net magnetisation vector, emerges parallel to the B0 field. The spins, however, are not in
phase; b) a radiofrequency pulse generates a B1 field along the x-axis, elevating a proportion of
the spins to the excited state and diminishing the longitudinal component of M. The resultant
transverse component of M is diffusely distributed because of spin phase incoherence; c) when
the radiofrequency pulse is circularly polarized at the Larmor frequency, the B1 field draws the
precessing spins into phase and a coherent transverse component of M emerges.
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2.1.5 Signal manipulation
e most basic of mr investigations is the application of an rf pulse and the collection
of whatever signal emerges – the pulse-acquire experiment.e data so produced is
of interest in spectroscopy, but of limited use in structural or functional imaging. In
order to produce images, the transverse magnetisation is manipulated in such a way as
to emphasise specic relaxation processes in the signal and encode that information
spatially. is can be achieved by running sequences of rf pulses to create echoes,
oen in conjunction with the application of additional magnetic elds. Note that the
time interval between successive pulse sequences applied to the same slice is known
as the repetition time (tr). In addition to the basic signal collection, two of the most
important components of such sequences will be considered, namely the spin-echo
and the gradient echo.
pulse-acquire
Following a single rf pulse, the signal returned progressively diminishes over time
(gure 2.6 on the following page).is sort of signal prole is called a free-induction
decay, having the characteristics of a damped sinusoid. e oscillations are at the
Larmor frequency and the time-constant T2⋆ describes the decay of the observed
transverse magnetisation. T2⋆ decay is not a pure process but rather an admixture
of relaxation mechanisms and the eects of magnetic eld inhomogeneities, which
together result in a rapid loss of signal.
In a perfectly uniform magnetic eld, protons dephase though spin-spin interac-
tions whilst maintaining precession at the Larmor frequency. With clinical scanners,
B0 is ever so slightly inhomogeneous as local tissue conditions cause small pertur-
bations in the magnetic eld and as a consequence, adjacent spin packets precess at
slightly dierent rates. At an arbitrary time aer an rf pulse (t = τ), the transverse
magnetisation will be composed of lead-vectors and lag-vectors from spin packets
in stronger and weaker eld areas with faster and slower frequencies of precession
respectively. It will have dephased to a greater extent than that predicted by its T2 time.
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Figure 2.5: MR signal detection − a) the signal is time-varying (voltage × time); b) a voltage
difference is induced as the transverse magnetisation sweeps past the radiofrequency coil, the
highlighted 180○ arc matching the coloured portion of the sine wave.
time
V
Figure 2.6: Simulated profile of a free-induction decay − after a radiofrequency pulse the voltage
amplitude (V) of the signal diminishes over time, decaying by the function T2⋆.
time
V
Figure 2.7: Simulated profiles for T2⋆ (solid line) and T2 (broken line) in a free-induction decay. The
decay of signal occurs more swiftly than predicted from the T2 of the subject matter because of
the effects of local field inhomogeneities.
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Consequently, T2⋆ is always shorter than T2 and rarely follows a simple exponential
function (gure 2.7 on the previous page). To isolate T2 relaxation from the corrupting
eects of eld inhomogeneities, a spin-echo is created.
spin-echo sequence
Consider a partially dephased transverse magnetisation at t = τ following a 90° tip
(gure 2.8 on page 30). If a 180° tip is performed at t = τ, the vectors will be ipped
into mirror-image positions; lead-vectors now lag behind but they continue to precess
at a greater frequency. If a second time period equal to τ is allowed to pass, the
fastest precessing spins will have caught up with the slower ones and the transverse
magnetisation will be as one.is refocussing occurs at a time t = 2τ. All the while,
a decay of the transverse magnetisation due to dephasing occurs. us, when the
transverse magnetisation at t = 2τ has returned to its original position it will be of
lesser magnitude. If this magnitude has reduced to 63% of its original value, then
t = 2τ is equal to the T2 of that sample.e time taken from the application of the
rst rf pulse to the peak of the echo is called the echo-time (te), equal to t = 2τ in the
sequence described.e te is a determinant of image contrast and scan acquisition
time. Spin-echoes are used in many pulse sequences, but are particularly valuable in
creating T2 contrast.
gradient-echo sequence
If spin-echo sequences negate the eects of variable rates of precession, then gradient-
echoes can be said to capitalise upon them. Following an rf pulse, a transverse mag-
netisation will emerge and precess at the Larmor frequency. If an external magnetic
gradient is deliberately applied across the sample, some spin packets will experience
a greater eld strength than others and consequently precess at a higher frequency.
Dephasing is thus exaggerated. When that gradient is removed and an opposing one
applied, the modication to the precessional frequencies is reversed. Importantly, the
direction of precession is also reversed so that the vectors rephase and an echo signal
can be obtained.
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As a gradient-echo can be obtained with a single rf pulse which need not be a full
90° tip, acquisition times are shorter than spin-echo techniques.e te is determined
by the application of the gradients, and is typically short. As a 180° rephasing pulse
is not applied, the eects of local eld inhomogeneities are upheld and the signal
is eectively a free induction decay (fid) governed by T2⋆ relaxation. With careful
selection of timing parameters and tip angles, good T1 contrast can be generated
whilst maintaining short acquisition times. Gradient-echo sequences are therefore
the mainstay of structural imaging techniques, but also nd application in fmri.
2.1.6 Image generation
e signals thus far described would, if processed as images, produce a single point
whose intensity would reect the signal returned from the whole eld of view of the
coil. In order to produce an image, this space must be parcellated and the signal
acquired in a way that denotes its spatial location. Since the voltage induced by the
transverse magnetisation is what we have to work with, spatial encoding is largely
achieved by altering the frequency and phase of the vector precession through the
application of additional magnetic gradients. It is now common practice to directly
acquire 3d volumetric images, but the concepts underpinning spatial location aremore
easily understood by considering earlier 2d volumetric techniques. Here, the specimen
volume is divided into slices and each slice into a matrix before reconstruction of the
data points as a 3d image. Each spatial location is rendered as a volume element or
voxel (volumetric pixel).
slice selection
Acquiring a signal from a designated 2d slice simply involves making the spin packets
in that space precess at a specic frequency whilst setting the receiver coil to detect
that – and only that – frequency. Recalling equation 2.1 on page 19, the frequency
of precession is proportional to the magnitude of the applied magnetic eld and so
largely determined by the strength of the scanner. Subtle but predictable shis in
the Larmor frequency can be brought about by changing the eld strength, typically
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through the application of magnetic gradients. Applying restricted frequency rf
pulses will excite spin packets at specic points on this gradient, with the width of the
slice determined by the breadth of the frequency composition of the rf pulse and the
slope of the gradient.e orientation of the gradient governs the plane of the slice,
broadly considered as axial, sagittal or coronal but oen with a degree of angulation.
encoding location
When the slice selection rf pulse is applied, the spin packets in that slice precess in
phase and at the same frequency but those in neighbouring slices do not. However,
there is no localisation within the slice. Consider the selected slice as a square with
vertical and horizontal axes. With two axes come two modes of manipulation. If a
magnetic gradient is applied along the horizontal axis, a series of columns can be
envisaged inwhich each spin packet precesses at a progressively higher frequency. One
dimension is thus encoded. If a second gradient is briey applied along the vertical
axis, the phase of the spins is altered. Spins in the strongest part of the gradient will
be phase advanced compared to those in the weakest, emerging as a series of rows
with designated phase positions. Acquisition can be timed to each phase position
and location encoded. A matrix can thus be created in which spin packets have a
determined phase and frequency of precession (gure 2.9 on the following page).
For each slice, the phase-encoding gradient is applied just aer slice-encoding (t =
zero) and the frequency-encoding gradient during signal acquisition (t = te). e
procedure is repeated many times for each slice, with progressively steeper phase-
encoding gradients, the number of which determines the matrix resolution.
decoding the signal
e received signal is a mixture of oscillating signals at dierent frequencies which
must be analysed to determine which components are present.is is done mathe-
matically using the Fourier transform.
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Figure 2.8: Spin echo sequence − a) a 90○ radiofrequency pulse is used to create the transverse
magnetisation; b) as this precesses in the x-y plane, field inhomogeneities contribute to the
dephasing of the vectors and some spins precess faster than others; c) at t = τ, a 180○ pulse
flips the vectors over in the x-y plane and precession continues at the same rate for each spin;
d) the faster spins therefore catch up with the slower ones, such that at t = 2τ the transverse
magnetisation is rephased.
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Figure 2.9: Spatial encoding − a) the frequency and phase of precession throughout the
selected slice is uniform; b) phase encoding gradient at t = 0, the spin packets at the top are
phase-advanced; c) frequency encoding gradient at t = TE, the spin packets on the right precess
more rapidly; d) with combined encoding, pixel 1 will be both at a lower frequency and less phase
advanced than pixel 2.
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2.2 structural imaging
Anatomical images are a necessary part of most magnetic resonance studies and the
experiments described in this thesis are no exception. In addition to our investigation
of the eects of lithium on assessments of brain structure, we make use of anatomical
images when processing both our functional and spectroscopic data. An appreciation
of the nature of signal contrast, tissue characterisation and image analysis techniques
will aid the appraisal of our methods.
2.2.1 Signal contrast
On a typical T1-weighted anatomical image the csf appears dark and, conveniently,
white matter is white and grey matter grey. e grey-scale intensity of each pixel
in the image reects the intensity of the signal arising from its sister voxel. e
magnitude of this signal is proportional to the size of the transverse component of
the net magnetisation vector at the time of acquisition, which in turn is dependent
upon a number of factors. Some of these are inherent to the tissue, others related to
the acquisition parameters. It follows that tissue contrast is largely determined by the
pulse sequence applied.
2.2.2 Tissue characterisation
Were the brain homogeneous, all areas would have the same magnetization and be-
have identically, so the returning signal would be uniform throughout – we can be
thankful because this is not the case.e absorption of rf energy is greatest in the
areas with the highest density of spins and so it follows that overall, csf is capable of
returning more signal than brain tissue.is form of intrinsic contrast can be thought
of as determining the absolute amount of signal available, but further contrast can
be achieved by utilising variations in the rate of signal return. In other words, the
contrasting T1 and T2 times of the dierent tissues come into play and we can choose
which relaxation mechanism to emphasize. Contrast in anatomical images is most
commonly weighted towards T1 relaxation, which occurs when the energy delivered
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by an rf pulse is absorbed by the lattice and the longitudinal component of the net
magnetisation vector restored (see §2.1.4; text on page 23). T1 relaxation is governed
by a number of dierent tissue properties, which for brain tissues are outlined in table
2.1 below.
tissue lipid content tumbling t1 time signal
White matter High = ω0 Short High
Grey matter Low < ω0 Long Medium
Cerebrospinal uid Negligible > ω0 Very long Low
Table 2.1: Tissue characteristics determining T1 and signal intensity
Energy transfer to the lattice – in this case tissue – is most ecient if the tumbling
rate of its molecules closely matches the Larmor frequency of the spins. is is
the situation for white matter, explaining its short T1 and high signal intensity on
anatomical images. Grey matter molecular tumbling rates are less than the Larmor
frequency, giving a long T1 time. For csf the tumbling rate is much higher than the
Larmor frequency, but as this results in inecient energy transfer its T1 is much longer
than that of brain tissue.
e T1 times of brain tissues can be measured by charting the signal returned at
various time points and tting these values to an exponential function.is, however,
is not the basis of tissue dierentiation in structural imaging. In T1-weighted imaging,
data is collected at a single time point on the relaxation curve. In essence, tissues
with a short T1 will have recovered more of their longitudinal component of the net
magnetisation vector than tissues with a long T1. Contrast is therefore relative and
the timing of data acquisition crucial (gure 2.10 on page 34). In practice, each voxel
contains a proportion of dierent tissue types with varying rates of recovery. e
longitudinal vector therefore comprises swily and slowly relaxing elements, the
ratios of which can be used to decipher the dominant tissue type.
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2.2.3 Image acquisition
e magnitude of the signal detected by the coil array is proportional to the transverse
component of the net magnetisation vector, but the longitudinal component is that
which denes T1 relaxation. As this aligns with the B0 eld it cannot be detected.
T1-weighted sequences must therefore contain a second rf pulse which brings the
recovering longitudinal component into the transverse plane. e signal detected
immediately aer this second pulse is proportional to the T1 recovery (gure 2.11).
High resolution images can be obtained relatively swily by using gradient-echo
techniques and low ip angles, but sucient time must be allowed for T1 relaxation
to occur, otherwise contrast will be inadequate. As T1 is proportional to B0, structural
scans take longer to perform on stronger magnet systems.
2.3 structural image analysis
It is a basic tenet of image analysis that the dimensions of a voxel genuinely represent
a volume of tissue in space.us, the volume of a structure or tissue can be calculated
by summating the voxels its image contains. All that is required is a technique for
selecting the correct voxels. Later in this thesis, attention is directed to a number of
mri studies in which brain grey matter volumes are reported. Strictly, grey matter is a
tissue class rather than a macroscopically distinct structure. It can be measured in a
variety of ways, broadly classiable into manual, semi-automated and fully automated
techniques; the most commonly used methods are outlined below.
2.3.1 Manual techniques
region of interest
Selecting a brain structure and dening it on an image is a strategy with a long history
spanning numerous technological advances. Currently, a fairly standard approach
involves an investigator viewing the images on a computer screen, identifying the
relevant structure and manually outlining it using a mouse or similar device. e
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Figure 2.10: Simulated T1 recovery for brain tissues. The longitudinal component of the net
magnetisation vector recovers more swiftly in white matter (∎) compared to grey matter (∎) and
CSF (∎). Its signal is therefore relatively greater and contrast can be established. The timing of
data acquisition determines the contrast: at time = τ, good contrast is achieved; at shorter and
long acquisition times, contrast is inadequate. Overall, the greater spin-density of cerebrospinal
fluid means that is is able to return more signal than brain matter.
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Figure 2.11: T1-weighted imaging − (a) following the application of a 90○ radiofrequency pulse,
the netmagnetisation vector is fully in the transverse plane; (b) spin packets in tissueswith a short
T1 recover more swiftly than their counterparts in tissues with a long T1 . At t = τ, the longitudinal
component of their magnetisation vectors will have recovered to a greater extent; (c) in order
to be detected, the longitudinal components of the vectors must be tipped into the transverse
plane by a second 90○ radiofrequency pulse. The time period τ is a determinant of tissue contrast.
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number of voxels in the region are summed and a volume derived. To perform
a region of interest (roi) analysis well, the soware package does not need to be
sophisticated but the operator’s knowledge of neuroanatomy should be.e pro’s
and con’s of this approach are linked; investigators are able to draw on their experience
to gauge the boundaries of a structure, but with that judgement comes subjectivity.
Estimates of the reliability of the measurement within and between investigators are
therefore important, but these values are inuenced by the complexity of the roi.
More recently, roi studies have made use of standardised imaging atlases in which key
anatomical areas have been dened. In applying these regions, the subject’s scan must
be normalised to the brain template or the roimorphed to the individuals image.
2.3.2 Semi-automated techniques
thresholding
When viewed on a computer screen, images are typically presented in grey-scale.
Since grey matter is of intermediate intensity between white matter and csf, it can be
delineated by setting upper and lower intensity thresholds. Such thresholds may be
set manually on each image slice, which results in a bounding box that encapsulates
the grey matter. Additional editing may be required to remove extraneous areas.e
sum of the voxels that lie between these threshold values is the grey matter volume;
those beneath the lower summate to the csf volume and those above the upper to the
white matter volume.resholding is eectively a large scale, semi-automated roi
analysis and so open to subjectivity, though reliabilities are usually very good.
An important limitation of this technique is the loss of intensity information
along the data path. At the point of encoding, voxels are 16-bit which gives 216
intensity values (65,536). A standard monitor presents 8-bits, giving 28 shades (256). Intensities could be
rendered in
True-colour, but
such a strategy
brings its own
problems, not least
of which is the
standardisation of
the palette.
e human eye, however, can probably discern about 85 shades of grey. Automated
techniques can scrutinise the intensity prole of the each voxel at its original resolution,
potentially oering a more powerful analysis but not resolving the delineation of
specic anatomical structures.
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2.3.3 Automated techniques
voxel-based morphometry
In this fully automated technique, specic brain structures need not be nominated as
the entire brain is surveyed for global and regional dierences in tissue volumes.e
voxel-by-voxel approach means that the amounts of grey matter, white matter and csf
are compared between subject groups for each individual voxel. Images pass though
a number of preprocessing stages before the voxel-wise statistical analysis, performed
using computer soware packages such as statistical parametric mapping (spm).
Normalisation When using voxel-based morphometry (vbm) to compare groups
of subjects, the brain structures of one individual need to be in alignment with the
corresponding structures of the other subjects; voxel-by-voxel should be like-with-
like. Clearly this will not be the case with the raw images as the size and shape of the
brain diers considerably between individuals. What is required then, is that each
image occupies a standard space, that each brain structure generally occupies the
same co-ordinates in this space, and that these co-ordinates have some anatomical
meaning.e normalisation process aims to achieve this.
• Templates: e icbm152, an average of 152 normal mri scans created by the
Montreal Neurological Institute (mni), is the current standard template for
image analysis; a common alternative is to generate a study-specic template.
• Transformations: rst, a 12 parameter linear ane transformation is applied
(translation, rotation, scaling and skew in the x, y and z axes); second, a non-
linear deformation process nalises the matching of the image to the template.
Transformed images are said to be in standard space.
• Co-ordinates: themni standard space approximates to the Talairach stereotactic
co-ordinate system, but the matching is not exact. Although conversion algo-
rithms exist, co-ordinates should be cross-referenced to an appropriate atlas
and interpretation of the results guided by neuroanatomical knowledge.
36
Segmentation Individual images are divided by tissue class, typically into three
compartments – grey matter, white matter and csf.e result for each subject is three
discrete 3d-images in standard space; one for each tissue compartment. Segmentation
is achieved by examining the intensity of each voxel, matching its characteristics to
the established proles of each tissue class. e chance of allocating a voxel to a
particular tissue class is adjusted according its location in standard space using a
priori probability images, as well as considering the classication of its neighbours.
Modulation Transforming an image in the way described approximates its volume e stages of
normalisation,
segmentation and
modulation are
described as
individual
processes but in
practice they are
launched by a
single spm script
and cycled through
until the criteria are
met.
to that of standard space. Early vbm studies would therefore discuss tissue densities
or concentration dierences rather than volumes. Addressing this problem led to the
development of optimized vbm, with subsequent incorporation into the algorithms of
recent versions of spm (spm8). Selecting ‘normalisation with modulation’ retains the
transformation parameters and applies them to the individual segmented standard
space images, weighting the ‘density’ of the tissue in each voxel by the deformation
it underwent. is is oen described as multiplication by Jacobian determinants.
When the transformed voxels are compared, intensity dierences can be considered
to reect changes in volume.
Smoothing e nal stage of preprocessing is spatial smoothing, in which the seg-
mented images are convolved with an isotropic Gaussian kernel. In essence, each
voxel becomes the weighted average of itself and its surrounding voxels.is process
reduces the small scale dierences between each subject, corrects for inaccuracies in
normalisation, improves the signal-to-noise ratio and renders the data more normally
distributed. Gaussian distributed data is a requirement for the parametric statistics
of spm to be valid.e upshot is an improved chance of detecting a dierence when
multiple parametric statistical comparisons are made. However, spatial resolution is
dramatically reduced and the choice of kernel size can have a marked eect on the
results. Most commonly the lter size matches the expected eect size, equating to a
kernel of full-width half-maximum (fwhm) between 8 and 14 mm.
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Statistical analysis In a typical experiment, the smoothed images of one group of
subjects are compared to another, with the results expressed as a map of voxel intensi-
ties which represent the volume of the tissue in question. Regional volume dierences
are determined by the application of t or F contrast conditions, ranked by cluster
size and degree of signicance, and depicted in the glass brain view. e standard
threshold for a signicant dierence for each measurement is set at p < 0.05, but as
millions of t-tests are performed the problem of false positive results is sizeable.e
conservative technique of Bonferroni correction is generally considered excessively
strict and probably inappropriate, given that it assumes each measurement is entirely
independent of the others.e intensity of a voxel, however, is not independent of its
neighbours – recall that this characteristic was used to aid segmentation. Smooth-
ing the images improves the predictability of these voxel intensity correlations and
allows the more lenient Gaussian Random Fieldeory to be used in calculating the
corrected p values. It is commonplace to perform a family-wise error correction.
siena algorithm
e siena algorithm (structural image evaluation, using normalisation, of atrophy) is
a fully automated analysis tool from the fmrib group, permitting the longitudinal
estimation of changes in brain structure – atrophy or loss of volume in particular.
Two structural images of the head of a single subject, taken at dierent time points,
are submitted to the program; the output is an estimate of percentage brain volume
change (pbvc) and an image depicting the change. To achieve this, siena segments
brain from non-brain in each image using the brain extraction tool (bet) in fsl,
estimating the external surface of the skull in each case.e two brain images are
registered using flirt, a linear registration tool in which the skull images are applied
to constrain scaling and skew, correcting for changes in imaging geometry over time.
Using the registered brain images, internal and external brain surface points are
determined and the surface motion estimated on the basis of these points.e pbvc
is estimated from the mean perpendicular edge motion across the entire brain surface.
Accuracy of the technique is approximately 0.2% brain volume change error.
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With vbm techniques, volumes are derived by counting the number of voxels allo-
cated to each tissue class following segmentation; estimates rely on the classication
being correct and consistent.e siena algorithm calculates volumes by determining
the edges of tissues, scrutinising intensity gradients at the subvoxel level to derive
surface points. Within a given tissue class, changes in intensity are small and gradients
shallow but between classes the gradient will be steep. Encountering a sharp change
in intensity values within or between voxels leads siena to denote the presence of a
tissue boundary. Specifying a two-compartment model – brain and csf – robustly and
accurately detects tangible changes in the volume of the brain, relatively independent
of interscan uctuations in voxel intensity that can hinder tissue classication.
2.4 relaxometry
In T1-weighted imaging, contrast is relative. is suces for most situations but
in some circumstances it may be desirable to quantify the actual T1 times of the
tissues under investigation. If signal is acquired from a sample at various points in
the relaxation process and the intensities charted as a function of time, the rate of
longitudinal relaxation may be determined. T1 times can be accurately measured
in this way using the inversion recovery technique. Here, a 180° pulse inverts the
longitudinal component of the net magnetisation vector, aer which it recovers to
its equilibrium position passing though a null en route.e extent of the recovery is
sampled by the application of a 90° pulse at selected time points. Only a single 90°
pulse is permitted aer an inversion – the sample must then be allowed to relax fully
before the process is repeated with a new acquisition time. Several runs are performed
over a range of sampling times, with a plot of signal intensity against the tr allowing
the T1 to be derived.
e inversion recovery technique is inecient as equilibrium must be restored
for the collection of each data point. As full relaxation takes three to four times the
T1 of the sample, a substantial amount of time can be spent acquiring the necessary
data – multiply this by the number of voxels sampled and scan durations become
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prohibitive if anything other than the crudest resolution is desired.e problem has
been overcome by the development of T1-reordering sequences.
quantitative t1 mapping
Consider a sample divided into four voxels (A, B, C and D), each containing tissue
whose T1 needs to be determined. If data is acquired at four time points for each voxel
in turn, and equilibrium restored by leaving a gap of four-fold T1 between inversions,
the total scan duration will be 64 times the longest T1 in the sample. Eciency
is increased by applying the inversion pulse to all four voxels simultaneously, but
subjecting each voxel to the 90° sampling pulse at dierent times. Starting in order,
scant relaxation will have occurred when voxelA is sampled but by the time the fourth
90° pulse is applied, the tissues in voxel D will be near-fully relaxed. On the next
run the acquisition begins with voxel B, then progressing in order so that this time
it is voxel A that is near-fully relaxed. Once four runs have been completed, data at
the necessary times points will have been acquired from all voxels – the data is then
rearranged, plotting the signals from each voxel as a function of the time between the
180° and 90° pulses rather than the order in which they were acquired. Scaling up the
complexity in terms of sampling times, voxels and slices, high resolution images may
be constructed in which voxel intensity denotes actual T1 time – a T1 map.
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2.5 functional imaging
Usingmri, inferences can bemade about changes in brain activity, oen in the context
of a presented stimulus orwhilst a task is performed.emost commonly used formof
fmri relies on the association betweenmetabolic demand, local blood ow and oxygen
consumption, the oxygenation level of blood inuencing the relaxation behaviour of
tissue water and so signal strength.e contrast in signal strength that arises from
this relationship is referred to as blood oxygen level dependent, hence the term bold
fmri. As such functional imaging indirectly assesses brain activity, the physiological
basis of bold contrast will be described before moving on to the analysis process.
2.5.1 Brain activity and blood ow
Blood is delivered throughout the body in a pulsatile manner, reaching the cerebrum
through the bilateral carotid and vertebral arteries. Descending the arterial tree,
pulsatility is smoothed out by the elastic walls of the vessels so that blood ow is
relatively steady at the capillary level. Here, nutrients and metabolites are exchanged
across the blood brain barrier and oxygen is absorbed. Venous blood therefore has a
proportion of deoxyhaemoglobin, in contrast to the fully saturated arterial blood.
neurovascular coupling
When neurones are transmitting signals their metabolic activity increases and their
oxygen requirements rise; local blood ow follows suit, a phenomenon known as
neurovascular coupling. Regional increases in blood ow develop slowly compared
to neuronal activity and resolve more gradually still (Blamire et al., 1992), being
described by the haemodynamic response function (hrf) depicted in gure 2.12 on
page 42.e mechanisms linking neuronal activity to such increases in blood ow are
incompletely understood, with theories variously focussing on oxygen consumption,
energy demands and synaptic processes as the principal drives. Still the topic of
debate, a consensus view of neurovascular coupling is emerging that links blood ow
to synaptic activity more strongly than to the energy requirements of the cell.
41
e energy requirements of a signalling neurone are largely directed to restoring
ion concentrations aer postsynaptic depolarisation (Attwell and Iadecola, 2002). In
primates, increased bold contrast more closely correlates with local eld potentials
thanmulti-unit activity (Logothetis, 2002). Local eld potentials are thought to reect
the summation of postsynaptic potentials and so the input to a neuronal population;
multi-unit activity most likely reects the outgoing action potentials. e bold
contrast, therefore, may be a composite measure of the input and intrinsic processing
of a neuronal population rather than that population’s output.e dominant factors
under-pinning the bold signal change may not be the energy consuming ones.
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Figure 2.12: Depiction of the haemodynamic response function.
Classical neurotransmission involves the release of eector molecules from the
presynpatic terminal which, on binding to postsynaptic receptors, trigger depolari-
sation and so signal conveyance. Many neurotransmitters are vasoactive and so are
causally implicated in neurovascular coupling. Glutamate, an excitatory neurotrans-
mitter, has received much attention, with a feed-forward system of controlling blood
ow proposed (Attwell and Iadecola, 2002). On binding neuronal nmda receptors,
glutamate causes an inux of calcium which activates nitric oxide synthase, the prod-
uct of which diuses out of the cell to relax arteriolar smooth muscles and so increase
local blood ow. Glutamate-triggered intracellular cascades through phospholipase
a2 (pla2) and arachidonic acid (aa) pathways in astrocytes increase concentrations
of the vasodilator cyclo-oxygenase (cox) (Zonta and Carmignoto, 2003).
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superabundant perfusion
In terms of magnitude, the increase in regional cerebral blood ow is not tightly
coupled to the increase in cerebral oxygen requirements, with perfusion outstripping
demand.e looseness of the coupling is paramount to bold fmri. Although more
oxygen is extracted into the tissues, neuronal activation results in a surplus of oxy-
haemoglobin in the local capillary bed such that the proportion of deoxyhaemoglobin
in the venous blood decreases. e oxygenation status of haemoglobin inuences
its magnetic properties, in turn altering its eects on the relaxation times of protons.
Transverse decay is particularly susceptible in this regard, so functional imaging
sequences are usually T2⋆-weighted.
2.5.2 BOLD contrast
Oxyhaemoglobin is diamagnetic and has little eect on the relaxation rates of neigh-
bouring spins; deoxyhaemoglobin is paramagnetic and its eects are marked. Para-
magnetic substances induce dephasing and shorten the T2⋆ of water, decreasing the
strength of the signal when they are present.e decrease in the proportion of deoxy-
haemoglobin that occurs with neuronal activation diminishes this eect, lengthening
the T2⋆ and increasing the signal intensity.is intensity change is the basis of con-
trast in bold fmri, the increased signal of the active state being compared with the
decreased signal either at rest, or in a less demanding condition.e magnitude of the
signal change is dependent on many factors, including but not limited to: subject’s
age, blood pressure and vascular structure; magnetic eld strength, echo time and
voxel size; task characteristics, diculty and duration. Overall, the percentage change
in signal rarely enters double gures.
utilising the contrast
e bold contrast is qualitative and because of its complex basis, there are limits to
what can be said about the actual levels of activation between subjects, across sessions
and to some extent within scans.e prole of the hrfmeans that the maximal signal
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intensity change will always be oset from the neuronal activation that triggered it,
though the oset and prole are considered to be suciently predictable that theymay
be modelled during the analysis of images. Anatomical, physiological and medical
factors may, however, aect the characteristics of the haemodynamic response.e
transient nature of the hrf, and so the bold contrast, limits the range of experiments
suited to fmri.
signal change
e relative nature of the bold contrast means that signal change is paramount, whilst
statements about absolute levels of brain activity are inappropriate. Changes in bold
signal intensity that occur aer the presentation of a stimulus, for example, can of
course be quantied but the derived values are necessarily described with respect to
a specied or dened condition. Conditions such as neutral stimuli or periods in
which the subject is instructed to rest are commonly used. Signal intensities in excess
of the specied baseline are termed activations, whilst reductions are described as
deactivations.
Given the ow of events from neuronal signalling to increased blood ow and
so greater signal intensity on fmri, it makes intuitive sense to describe the contrast
change as an activation.e notion that deactivations reect a reduction in neuronal
ring is conceptually more challenging and in terms of neurovascular physiology,
incompletely established.e signicance of bold deactivations will be considered
in greater detail later in this thesis.
2.5.3 Image acquisition
In order to detect bold contrast, a fast sequence sensitive to changes in T2⋆ relaxation
is required. Echo planar imaging (epi) is most commonly used, with which complete
slices can be be acquired swily and whole brains imaged in seconds. Images acquired
using epi sequences are prone to susceptibility artefacts which manifest as regions
of signal dropout. Magnetic eld gradients are generated when tissues or substances
with dierent magnetic susceptibilities are situated close together and these gradients
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cause distortions which give rise to the image artefacts.e orientation and nature of
the boundary determines the distortion, with air-tissue regions being most aected,
particularly the frontal and paranasal sinuses. Signal from orbitofrontal regions
especially may be absent or warped. Such artefacts are generally more marked at
higher eld strengths, osetting to some degree the gains in bold contrast sensitivity
that also come with more powerful magnet systems.
2.5.4 Image analysis
e data acquired during an fmri session can be analysed in numerous ways, with
several dierent sorts of output objectives. Frequently, the goal is to generate a
statistical parametric map of voxel resolution, from which regional increases and
decreases in bold contrast can be discerned. In creating such maps, the time series of
a subject’s image are commonly processed through realignment, motion correction,
transformation into standard-space followed by smoothing. A study specic design
matrix specifying the task parameters provides the framework in which the General
Linear Model (glm) is applied in rst and second level analyses. Activations and
deactivations in bold signal are calculated by statistical inference methods using
Gaussian random eld theory.
preprocessing
Imagesmust be processed before statistical analysis can begin. Soware packages such
as spm and fsl can be used throughout, but it is important that a consistent approach
is adopted. e rst stage of any fmri analysis is to ensure that the problem of T1
saturation has been addressed. Echo planar image intensity takes several seconds
to stabilise so a ‘run in period’ is required. is can be achieved by deliberately
acquiring a number of dummy scans before data collection begins in earnest, or
simply excluding the rst few images from the time series.
Realignment Movement of a subject’s head is a frequent occurrence during func-
tional imaging, due to the long scan times and motor responses required. is is
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generally minimised by the judicious use of head restraints, but even then needs
addressing in the rst stages of analysis. Realignment of the images typically involves
taking the rst scan dynamic and adjusting each subsequent image in the time series
so that they match its position. A mean image and a log le of the realignment are
generated for use in subsequent analysis stages.
Spatial normalisation Akin to the stage in vbm (detailed in §2.3.3 on page 36), the
principal dierence is the choice of templates to which the epi images of the subject
may be normalised. In addition to standard T1-weighted templates, epi equivalents
are available to which the epi data for subjects in a study can be normalised directly
and swily. A degree of caution must be advised – as signal dropout is sensitive to
eld strength, the quality of normalisation may be compromised in studies using e epi template
supplied with spm8
is the smoothed,
segmented,
normalised average
of the mean fmri
images of 13
subjects, acquired
on a 2T machine.
stronger or weaker magnet systems than the one used to generate the template. Alter-
natively, individual T1-weighted images may be normalised to the icbm152 template,
yielding a subject-specic transformation matrix; if the epi data is in coregistration
with the structural scans, the transformation matrix may be applied to complete the
normalisation to standard-space.
Smoothing e rationale for smoothing is similar to the situation for vbm. Inter-
subject variability is reduced, snr is increased and statistical requirements are met. It
is generally the case that kernel sizes are smaller, tending toward 8 mm.
statistical analysis
In fmri studies involving the presentation of stimuli or the performance of tasks,
analysis aims to establish whether or not uctuations in bold signal intensity are
related to the experimental conditions applied. Consider a simple blocked design
study in which a group of subjects view either a ashing checkerboard or a xation
cross, presentations lasting 20 seconds and alternating over time. It could reasonably
be envisaged that neural activity would increase when the visually intense stimulus
was presented, leading to the hypothesis that the bold signal would be greater during
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Figure 2.13: Convolution model of the BOLD response for a simple blocked task.
such blocks compared to the ones in which the xation cross appeared. Two stages of
analysis are required: the description and modelling of events (gure 2.13) followed
by the comparison of derived conditions.
First-level analysis Information about the onset and duration of each block is sub- In this example, a
model-driven
approach would be
appropriate. Other
methods can be
applied to the
analysis of fmri
data, including
model-free analyses
which make no
assumptions about
the observed signal.
mitted to a model which is then applied to the preprocessed epi time series. Neuronal
activity should closely match the stimuli but given the nature of the haemodynamic
response, bold signal change will be oset.is matter is addressed by convolving the
specied design with the hrf, the result of which is a hypothesised pattern of bold
signal for the experiment conducted. Amodied t-test is applied to every voxel in each
image of the time series, individually for all subjects studies, examining how closely
its intensity correlates with the hypothesised bold signal.e result is a t-map image
for each subject, each voxel in the map having an associated uncorrected p value.e
conditions specied in the model applied are labelled and a contrast-vector dened,
these rst-level contrasts being suitable for submission to higher level analyses.
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Second-level analysis In many respects, data emerging from the rst-level analysis
is handled in the same way as any other empirical observation made on a subject;
the peculiarities arise from the subtle nature of the signal change combined with
the sheer volume of the data and the number of comparisons that must be made.
For studies involving numerous subjects, consideration must be given to how data
from individuals will be combined. It is now common practice to perform a random-
eects analysis, accounting for condition-to-condition variations within-subjects and
between-subjects, thus permitting inferences to be made about population eects.
e alternative xed-eects analysis does not take the inter-subject variability into
account and with small groups, it is prone to bias if strong areas of signal change
occur in individuals. Contrasts compiled in either manner can be analysed using
statistics such as t-tests, analysis of variance or correlations – all based on the glm.
Statistical inference Within the glm, responses are assumed to have a linear relation-
ship to the stimulus or task intensity. Statistical scores derived from these analyses
indicate the degree of matching between the signal intensity of a voxel and that pre-
dicted in the hypothesised model. is matching can be gauged by testing one’s
hypothesis against the null hypothesis, with the probability of obtaining the experi- e null hypothesis
in such a setting
would state that no
relationship exists
between the voxel
intensity observed
and the presence of
the stimulus or the
performance of a
task.
mental result by chance denoted by the p value, itself an indicator of the reliability
of the conclusion. Voxels are said to show activation only if the statistical score and
the p value cross a specied threshold. Active voxels fall into clusters; the expected
number of clusters, and voxels within a cluster (k), can be calculated using Gaussian
random eld theory, accounting for the eects of spatial smoothing. Comparing the
observed and expected clusters allows statements to be made about the signicance
of the ndings.e analysis of fmri data involves multiple comparisons, the eects of
which must be controlled. As with voxel-based morphometry (§2.3.3; text on page
38), Bonferonni correction is considered too harsh and largely inappropriate. Family-
wise error correction is commonly adopted, though less conservative strategies such
as false detection rate corrections may be applied. Regardless, the technique and
threshold should be stipulated a priori.
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2.6 magnetic resonance spectroscopy
As the principles and practice of mri are derived from those of nuclear magnetic
resonance spectroscopy, this section does not present a new set of basic concepts,
simply the process of analysing the signal on the basis of subtle dierences in resonance
frequencies of spins.is introduction is restricted to the most rudimentary form of mri can actually be
considered as a
special form of mrs
in which the proton
singlet from water
is isolated and
manipulated.
mrs: the acquisition of data from the free induction decay. Here, the basic premise
is that within the mrs signal, spins have discernibly dierent frequencies which are
specic to certain compounds and whose signal-magnitude reects the concentration
of the substance that gave rise to the signal. e nature of mrs is outlined using
examples from proton spectroscopy, later moving to the basics of multinuclear work.
2.6.1 Free induction decay
e fid has previously been presented as an oscillating signal of mixed frequencies
whose magnitude diminishes over time, decaying by the function T2⋆. In the simulated
example provided (gure 2.6 on page 26), Fourier transformation would yield a
spectral singlet of a height and width respectively determined by the amplitude and
decay of the time-domain fid. If an fid were to be derived from a sample containing
spins with distinct Larmor frequencies, numerous peaks would be apparent aer
transformation (gure 2.14 on page 50).e prole of peaks is the magnetic resonance
spectra of the sample, the area under each peak being the concentration of specic
spins.
2.6.2 Resonance frequencies
e Larmor frequency of a spin is directly proportional to themagnitude of the applied
external magnetic eld, but spins are not exposed to B0 only, nor to that eld in its
entirety. Nuclei with spin – even simple ones such as the proton of hydrogen – have
electron shells which possess both charge and movement, so generating their own
magnetic moments.e magnetic eld experienced by a nucleus during magnetic
resonance investigations must therefore include that induced by its electrons.e
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Figure 2.14: Fourier transformation of the free induction decay, a mathematical process by which
the function of time is converted into the function of frequency − a) decay of a single nuclear
species gives rise to one narrow peak; b) with a rapid decay of the signal the spectral singlet is
wide but the integral of the peak, reflecting the concentration of spins, is constant; c) spins with
different Larmor frequencies contribute to a more complex FID, resolving to two spectral peaks.
local environment and molecular bonding of a nucleus determines the behaviour
of its electrons, and so the magnitude of their magnetic moments. e magnetic
moments of an electron may eectively shield the nucleus, thus determining total
eld to which the nucleus is exposed when the B0 eld is applied.ese inuences
manifest as a range of resonance frequencies for kindred spins in complex samples, a
phenomenon termed chemical shi. Although themagnitude of the shimay be small,
it is detectable and underpins much clinical mrs work. Unlike mri, the relaxation
properties of the spins are not the primary concern but can be of some importance.
spectral form
Within complex molecules, chemical shi for protons is largely determined by the
geometry of their bonds to other atoms. For the metabolic compounds typically
encountered in vivo, proton bonding congurations are suciently consistent and
characteristic that the associated chemical shismay be used to identify them, metabo-
lites having a spectral ‘signature’ as it were. To capture such signatures the rf pulse
must be suciently hard to excite spins across a range of frequencies, with the re-
ceive prole of the coil comparably broad. With these provisos in place, a simple
pulse-acquire sequence with collection of the fid will oen suce.
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e spectral signature of a metabolite emerges as a peak localised to a specic
position relative to the ‘on-resonance’ signal of water.e size of each peak in the
frequency spectrum is proportional to the amount of metabolite present – concentra-
tions of compounds may therefore be derived by integrating the area under the peak
at a specied resonance.
spectral analysis
e analysis of proton mrs spectra from tissues such as the brain can be a challenge.
Whilst abundant compounds may be easily identied, those of a lesser concentration
may be dicult to discern from noise. Further, some metabolites generate suciently
similar chemical shis that their peaks can barely be distinguished. ere exist
numerous techniques to extract, delineate and integrate the data from an fid, but
these are beyond the scope of this introduction.
2.6.3 Calibration
e signal intensity – and so the area under a peak – is also a function of the tip angle
induced by the rf pulse. Although maximum signal intensity arises with a 90° tip,
whatever nutation is chosen its prole across the sample must be known if meaningful
concentrations are to be derived. It is therefore standard practice to calibrate the pulse
sequence at the outset of an experimental series.
For on-resonance hard pulses, tip angle is related to rf exposure and signal
intensity is a sinusoidal function of the tip angle achieved. A series of pulse-acquire
experiments in which the duration of the rf pulse is progressively increased will yield
a range of signal intensities, as depicted in gure 2.15 on page 52. Whilst the maximum
signal can be demonstrated empirically in this way, it is easier to identify the null
signal from a 180° tip – halving the duration of that pulse will result in a 90° tip.
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Figure 2.15: Pulse calibration. With hard pulses, increasing the energy delivered increases the tip
angle induced. Signal intensity varies sinusoidally − spectra collected after various pulse durations
will fit this pattern. The maximum signal represents a 90° tip, the null point is 180° after which the
signal becomes negative (Replicated from lecture notes by James Keeler, University of Cambridge).
2.6.4 Quantication strategies
Remaining with the example of proton spectroscopy, the concentration of onemetabo-
lite relative to others in the spectra can be established by deriving the ratio of each to
an easily recognisable and universally present metabolite such as n-acetylaspartate
(naa) or creatine. In principle,mrsmay also enable the concentration to be measured
in absolute terms; in practice this proves dicult – although the area under the peak
is proportional to the metabolite concentration, other factors also aect the results.
reference compounds
For absolute quantication, the signal acquired from the sample must be calibrated
against one derived from a reference substance of known concentration. Suitable
reference compounds may either be internal to the subject (a stable metabolite, for
example) or external (a solution placed within the sampling volume of the coil). For the studies
conducted in this
thesis, external
references were the
only option as
lithium is not found
naturally to an
appreciable degree
in vivo.
In either situation there will be dierences between the sample and the reference
compound which will have a bearing on the magnitude and quality of the spectra,
independent of their respective concentrations.e position of the samples within
the coil, the temperature of the calibration compound, dierences in the relaxation
properties of the various substances and many more factors require consideration if
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absolute quantication is to be achieved. Of these, the most pertinent to our thesis Other factors such
as diusion, mr
visibility, nuclear
Overhauser eects,
dierences in the
localised sampling
volume and T2
losses have less of a
bearing on simple
pulse-acquire
experiments.
are the occurrence of partial saturation of the mr signal and the related eects of B1
eld inhomogeneities that characterise surface coils.
partial saturation
If spins are not permitted to return to their original state between applied pulses, the
longitudinal component of their net magnetisation vector will adopt a new steady-
state equilibrium of diminished magnitude (equation 2.3 below). When a 90° pulse is
applied to a spin packet that has not achieved full longitudinal relaxation, the resultant
signal will be smaller than the original. is eect is called partial saturation and
occurs if the pulse repetition time is less than three to four times the T1 of the sample.
Mz = M0 (1 − e−TR/T1)sinθ1 − cosθe−TR/T1 (2.3)
If the sample and reference compound have dierent T1 values, there exists the
possibility that partial saturation may occur in one but not the other, or in both to a
dierent degree.ere are many reasons why dierences in T1 times should exist –
the characteristics of the tissue and reference compound rarely match and if tissue
pathology is present, its distribution may be uneven. If the magnitude of the partial
saturation eect is known, the reduction in signal amplitude can be systematically
corrected using equation 2.3, at least for simple pulse-acquire experiments. is,
however, requires precise knowledge of the T1 relaxation time for the sample and
reference compound.
Such corrections are unnecessary if partial saturation is avoided – achieved by
setting the tr to greater than at least three times the T1 of the most slowly relaxing
sample under investigation. With this approach, T1 data is still required but its
accuracy is less of a concern than with correction techniques, especially if estimates
err on the side of caution.e duration of experiments may be greater, but so is one’s
certainty in the validity of the data.
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field inhomogeneities
Proton mrs studies of man oen use volume coils, advantageous because of the even
B1 eld they provide. In some situations – multinuclear mrs for example – surface
coils may confer certain benets, principally better signal-to-noise ratios (snr). A
standard pulse delivered by a surface coil generates an inhomogeneous B1 eld and so
a range of tip angles will arise across the sample for a given excitation. Consequently,
signal strength will be low in areas with a tip less than 90° and partial saturation a
possibility in regions where spins are recovering from tips of greater magnitude.e
eld inhomogeneities of surface coils may be overcome by the application of adiabatic
pulse sequences.
2.6.5 Determining T1
In order for spectroscopic quantication to be valid, the relaxation times of the samples
must be understood. For simple pulse-acquire experiments, knowledge of the T1
suces and T2 times need not be considered.e T1 time of a sample can bemeasured
in several ways, most commonly using inversion-recovery or saturation-recovery
methods.
Inversion-recovery e inversion recovery techniques applied in mrs are identical
to those using the eld of imaging (described in §2.4). Determining the T1 time of
a sample using inversion recovery is not time ecient. With multinuclear mrs, the
experiments can be very lengthy as the longitudinal relaxation of some nuclear species
is substantially longer than that of protons.
Saturation-recovery is technique allows T1 times to be estimated swily, being
more ecient in the acquisition of data early in the relaxation process. In essence, two
or more 90° pulses are applied in succession with the fid signal acquired immediately
aer the nal excitation.e magnitude of recovery of the longitudinal magnetisation
is related to the interval between the pulses and it is the extent of this recovery that is
detected aer the second tip.
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2.6.6 Multinuclear mrs
Magnetic resonance spectroscopy is not restricted to probing protons and of the
numerous nuclei that can detected, several are suited to investigation in vivo (table
2.2 on page 56). It is a requirement that the spins have gyromagnetic ratios that, at
clinical eld strengths, equate to Larmor frequencies excitable by rf waves. Detection
is simply a matter of retuning the scanner to the appropriate frequency; generating a
useful signal is somewhat more challenging.e properties of the spins detectable
with mrs dictate the snr that can be achieved and thus the feasibility of in vivo
studies in man. In terms of the spin, the major determinants of snr are its sensitivity,
relaxation properties and concentration, each of which will be considered in turn.
sensitivity
Sensitivity is a measure of the number of spins detectable, usually expressed relative
to that of protons. Recall that the magnetic moments of spins are anisotropically
distributed and that the signal arises from a change in the proportions of parallel and
antiparallel spins (§2.1.2; page 18).e mr sensitivity is related to the ratio of spins in mri and mrs can be
described as low
sensitivity
techniques.is
should not be
confused with their
sensitivity as
diagnostic tools,
which can be
impressive.
the ground and excited states, together with their propensity to move from the former
to the latter following the application of rf waves. Sensitivity thus increases with
eld-strength, though its relative value remains unchanged. For protons in the eld
strengths typical of clinical scanners, the asymmetry at equilibrium is of the order of
a few spins per million and so the signal is derived from a tiny fraction of the whole.
All of the isotopes commonly used in clinical multinuclear mrs investigations have
low sensitivities, such that high eld strength scanners are generally a requirement.
relaxation
If the T1 of a sample is short, spins may evade detection; if it is long, the duration of
experiments may become prohibitive. As T1 is proportional to eld strength, scans
lengthen as B0 increases, osetting the gains in sensitivity to an extent. Transverse
relaxation determines the spectral prole; spins with long T2 times yield narrow lines.
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isotope spin (i) abundance (%) γ (×107) sensitivity
1H 1⁄2 99.985 26.7510 1.00
7Li 3⁄2 92.4 10.3964 0.29
13C 1⁄2 1.10 6.7263 0.0159
23Na 3⁄2 100 7.0761 0.0925
31P 1⁄2 100 10.8289 0.0663
Table 2.2: Properties of various nuclear species that are amenable to detection with mrs.e
gyromagnetic ratio (γ) is expressed in rad T−1s−1 (reproduced from Ramaprasad (2005)).
For nuclei which are not spin-half, relaxation may not t a simple exponential
decay. e nuclear quantum spin number I denes the number of energy states a
nucleus can adopt (§2.1.2; page 18); four in the case of 3⁄2spins. In such quadrupolar
nuclei the z component of the net magnetisation vector can align along one of two
axes, typically resulting in biexponential relaxation behaviour.ese proles must be
characterised lest fast and slow components be confused.
concentration
As the magnitude of the spectral peak is related to the number of spins in the sampled
volume, higher concentrations are easier to discern from noise. It is generally the case
with multinuclear mrs that spin concentration is not open to manipulation. Absolute
concentrations are constrained by physiology oen reduced to undetectable levels
by the presence pathology.ere are two obvious exceptions to this scenario. First,
if the favourable isotope of an element has a low natural abundance, as with 13C, its
concentrations can be enriched by exogenous administration without altering physio-
logical systems or total spin number. Second, if the substance is being administered
anyway, 7Li for example, concentrations can be maximised within safe limits.
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3 fmri task preparation
In the psychological laboratory setting, researchers have innumerable tasks at their
disposal; a proportion of these are suited to fmri experimentation but almost all
require modication prior to application. Specically, fmri tasks must be logistically
possible in the scanner environment with stimulus presentations or task onsets pre-
dictably linked to the acquisition of images. With bold fmri, the physiological basis
of the contrast places constraints on the duration of the task and the frequency of
stimulus presentation. When fmri is combined with a pharmacological intervention,
task brevity and repeatability oen become important considerations. In anticipa-
tion of the fmri study described presently, this chapter introduces the principal task
and outlines the modications made to ensure that it was t for purpose. Two pilot
studies were performed to this eect: one established the block parameters whilst the
other gauged our adaptations.e methodological developments are the focus of this
chapter, the pertinence of the task is considered later in this thesis.
3.1 neuropsychological testing
is thesis examines whether lithium attenuates the eects of methamphetamine,
a stimulant which acts to increase synaptic dopamine concentrations. Dopamine
modulates numerous brain functions including attention, workingmemory, drive and
various aspects of emotional processing (Greengard, 2001a) and patients with bipolar
disorder may have impairments across these domains. Sustained attention has been
found to be disturbed in various phases of the illness. Continuous performance tasks
(cpt) engage sustained attention and are known to be sensitive to the manipulation
of dopaminergic systems (McTavish et al., 2001; Hearn et al., 2004) as well as being
suited to functional imaging work (Coull et al., 1996; Lawrence et al., 2003). Building
on local experience, the Rapid Visual Information Processing task (rvip) was selected
for use (see §3.2) and through collaboration, a blocked version suitable for bold fmri
was prepared.
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Continuous performance tasks oen involve the subject attending to a series of
stimuli for several minutes. In partitioning tasks into a blocked format, their diculty
and/or nature may be fundamentally altered. Validation of the rvip task in blocked
format was therefore necessary. Before addressing this matter, the logistics of task
presentation and performance rating require consideration.
3.1.1 Task presentation
When performing the rvip task, subjects view numbers set against a plain background
screen – black on white in most settings (see gure 3.1 on page 62). Sans serif letter-
forms in yellow or white against a blue background provide good visual contrast, with
the advantage that aer-image eects are negated. is format was used in all the
experiments in this thesis, be they developmental, practice or proper.
Development and training In the rvip task validation series and study training ses- Laptop computer
ergo microlite™
12.1′′ xga lcd
screen 1024 × 768
resolution.
sions, subjects performed the tasks on a laptop computer. Responses were recorded
by a single keystroke using the index nger of the dominant hand, the subject seated
a comfortable distance from the screen.
fmri presentation Imageswere back-projected onto a screen at the foot of the scanner Projector
canon xeed sx6;
max resolution
1400 × 1050,
contrast ratio
1000:1, uniformity
88%, 3500 lumens.
bed and viewed through a front-silvered mirror angled at 45○ to the supine subject.
e arrangement was such that the arc subtended by the letterforms and the extent of
the visual eld occupied by the background matched those on the personal computer.
Responses were recorded through a hand-held optical-bre device, subjects using the
thumb of the dominant hand for reasons of comfort.
Soware systems e rvip task was prepared for presentation using proprietary
soware (E-prime® Psychology Soware Tools, www.pstnet.com) on a personal com-
puter running the Windows®xp operating system (Microso®Corporation). During
fmri conditions, each block was triggered by the scanner to ensure that the image
acquisitions matched the task presentations, and so the specied analysis model.
58
3.1.2 Task performance
In the continuous performance tasks, subjects typically view sequential stimuli with
the aim of responding in the armative when certain conditions are met.e time
taken to respond is recorded and the appropriateness of the response determined
by cross-reference to the stimulus order. From these values, the rates of correct and
incorrect responses can be calculated, together with the performance indices derived
from the principles of Signal Detectioneory (sdt; Grier, 1971) – see the textbox on
page 60. According to sdt, decisions are based on the acquisition of information and
the application of rules. If one focusses on acquisition, most targets are identied but
false responses are likely; attending to the rules reduces errors but at the expense of
target detection. A subject’s strategy can be gleaned from the calculated parameters
of sensitivity index (A′) and response bias (B′′).
3.2 rapid visual information processing task
3.2.1 Task description
is simple continuous performance task requires a substantial degree of attention e rvip task taxes
both attention and
memory, but the
burden on memory
is slight.e target
strings are short
and displayed on
the screen whilst
the task runs.
(Wesnes and Warburton, 1983a). Subjects view a series of single integers from the
range 2 to 9 displayed in quick succession, typically 100 per minute. As these digits
ow past, subjects attend to the order of presentation and respond if they spot one of
a number of prespecied patterns.e target sequences span three digit presentations,
being discretely grouped runs of odd or even integers of increasing numerical value.
Suitable groupings are 246, 468, 357 and 579. Target strings are nested in a pseuo-
random series of digits and appear several times per minute, the gap between target
sequences varying so that subjects are unable to predict the occurrence of the next
presentation. A subject’s response is valid for up to three digit presentations inclusive
of the last digit in the target sequence, with responses at other times deemed false (see
gure 3.2 on page 62). Very short response latencies are typically excluded, deemed
chance occurrences or preemptive strikes – a lower threshold of 125 ms is standard.
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measures of task performance
In the complex eld of performance assessment, the simplest measurements are oen the most
informative.e time taken to respond to a target stimulus (response latency) exemplies this.
Categorising a response is also straightforward: correct responses are hits; failures to respond
aremisses; responses in the absence of a target are false alarms. Matters are more complicated
for the rates and patterns of response.
Response present Response absent
Target present Hit Miss
Target absent False alarm Correct rejection
accuracy & errors
If a subject responded correctly to all sequences and incorrectly to none, they would return a
result of 1.0 for the fraction of correct responses (h; equation 3.1). Such a score could also be
achieved simply by pressing the button aer every single digit – the lack of selectivity would
be evidenced as a high fraction of false responses ( f ; equation 3.2). Clearly, h is of limited use
in isolation and the interpretation needs to factor in the number of mistakes made; derived
from sdt, A′ and B′′ serve this purpose.
h = correct responses
total number of target digits
(3.1)
f = false alarms
total number of non-target digits
(3.2)
sensitivity index (a′)
e sensitivity index reects the selectivity of a subject and is denoted by A′ (equation 3.3). It
shows the sensitivity to errors regardless of error tendency, and is calculated from the fraction
of correct and false responses (range 0 to 1; poor to good).
A′ = 0.5 + (h − f ) + (h + f )2
4h(1 − f ) (3.3)
response bias (b′′)
A′ can be identical for dierent response patterns. For example, a cautious but accurate
responder (h = 0.6; f = 0.001) and a ‘trigger-happy’ subject (h = 0.8; f = 0.13) would both
have an A′ of 0.9. Here, the response bias, B′′ (equation 3.4), comes into play. Values of 0.992
and 0.171 are returned for our example subjects. Note that with perfect score (h = 1; f = 0), B′′
is indeterminable as the denominator is zero.
B′′ = (h − h2) − ( f − f 2)(h − h2) + ( f − f 2) (3.4)
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e control task condition is similar in structure to the rvip task condition but
places fewer demands on attention. Here, a similar series of digits are presented and
subjects respond when they spot a prespecied single target digit.e timings and
target frequencies match those of the rvip task condition. In the standard clinical
laboratory rvip task condition (Cambridge Neuropsychological Test Automated
Battery, cantab), digits are presented every 600 ms for about seven minutes. Targets
occur on average eight times per minute, separated by a variable gap of 8 to 15 digits.
e control task condition lasts around two minutes and is usually performed aer
the rvip task condition. Given the stimulus duration used in these tasks, responses
are permissible within 1800 ms of the onset of the target presentation.
3.2.2 Task performance and the eects of methamphetamine
determining performance
Whilst subjects dier in their aptitude and performance, uctuations in a given
individual’s response latency and accuracy are thought to reect changes in their
level of attention. Performance, and to some extent strategy, may be dictated by the
construction of the rvip task. Modulating the number of target sequences to attend to,
the rate of digit presentation and the frequency of target or false-start sequences alters
its diculty and nature. In setting or altering these parameters, consideration must
be given to the population studied as well as the envisaged eects of any intervention.
anticipated effects of methamphetamine
Task performance Following methamphetamine, subjects would be expected to
react more swily and to be more attentive, but with the potential for an impairment
in the inhibition of false responses – the response latency should shorten whilst h
and f most likely rise, increasing A′ but decreasing B′′ scores. Given the anticipated
increase in h, the version of the rvip task employed had to be suciently taxing lest a
ceiling eect be encountered. A baseline accuracy of 50–75% was considered suitable,
permitting the detection of change without making the task too demoralising.
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Figure 3.1: Presentation format of the RVIP task condition (a) and the control task condition (b). In
both situations the central digit changes whilst the subject tries to spot the sequences on the right
of the screen. For the control condition, the digit 3 is shown onmultiple lines so that the visual
field occupancy largely matches that of the RVIP task proper.
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Response window
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Figure 3.2: An excerpt from the sequence presentation for the RVIP task condition. Each digit
is displayed for a specified period, on screen time (OST), before being replaced by the next digit.
There is no interstimulus interval in the RVIP task. The run of digits depicted contains the target
sequence 246. On spotting the sequence, subjects have a period equal to 3 × OST in which to
respond.
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Task format With an unbroken task in the absence of stimulant medication, a sub-
ject’s performance would be expected to worsen over the run because their attention
will most likely wane (assuming practice eects have been overcome). Hits, false
responses and reaction times are usually averaged over the entire run, so this decline
may not be described. In reporting that methamphetamine increases the hit rate, for
example, reliance on averaged values leaves two potential patterns of eect unresolved:
target detection rates may have genuinely risen or the deterioration over time may
have been prevented (gure 3.3; page 64). In theory, the latter may go undetected in a
blocked version of a task if average scores for the whole run are relied upon.
e principal issue with a blocked task is the pattern of deterioration in perfor-
mance with time. If attention were to wane steadily over the entire run of blocks, the
nuances of methamphetamine’s eects are of no consequence. Should a subject’s level
of attention return to baseline at the start of each block, there is cause for concern;
blocks may be too short to detect a pure ‘prevention of the deterioration in attention’
action of methamphetamine (see gure 3.4 on the following page). Alternating the
rvip task condition with the easier control task condition may permit a period of rest
and foster such a recovery to baseline.
Existing empirical data enabled an exploration of this issue (Hearn et al., 2005). e help and
support of Peter
Gallagher, who
made this data
available for
analysis, is
gratefully
acknowledged.
From this blinded cross-over study of methamphetamine and hydrocortisone, data
from eight male subjects (mean age in years ± sd: 24.3 ± 7.5) was extracted and re-
analysed. Each subject completed a cantab version of the rvip task on two occasions,
punctuated by a week in which they took placebo tablets daily; methamphetamine
preceded the second session (0.15 mgkg−1 i.v.), a placebo injection the rst. As a
standard version of the rvip task was used, performance over time was investigated
by dividing the data into seven periods of 60 seconds. Methamphetamine was found
to increase the hit rate and A′ scores over the entire task period, with a similar pattern
for reductions in response latency time (gure 3.5 on the next page). On the basis of
this nding, the eects of methamphetamine should be detectable using a blocked
version of the rvip task.
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Figure 3.3: Simulation of a standard RVIP task during which performance wanes. The mean
baseline accuracy is 70% and in this example, methamphetamine increases accuracy by 10%,
either by elevating target detection (1) or reducing fatigue (2).
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Figure 3.4: Simulated data modelling blocks of 42 seconds in which it is assumed that attention
is refocused with each new block. In theory, the effects of methamphetamine would only be
detected in a blocked RVIP if it were to demonstrate action 1.
0 1 2 3 4 5 6 7
20
40
60
80
100
A
cc
ur
ac
y
(%
)
Pre-methamphetamine
Post-methamphetamine
Time (mins)
Figure 3.5: Empirically derived data from a standard RVIP task before and after methamphetamine,
with accuracy scores determined for each minute of the task. The pattern of scores suggests that
the postulated action 1 predominates.
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3.2.3 Adapting the RVIP task
e pilot studies examined two versions of the rvip task: a standard one running
without interruption and another comprised of shorter bursts – the ‘continuous’ and
‘blocked’ designs (rvip-c and rvip-b respectively). For reasons which will become
apparent, each developmental version attracted an additional identier, that of the
duration of stimulus presentation.us, rvip-c600 refers to a sedate, uninterrupted
version in which the stimuli are on-screen for 600 ms, whilst the rvip-b400 was
pacier and in blocked format.
continuous design
e index format – rvip-c600 – comprised exposure to sevenminutes of the rvip task is design
replicated the
standard cantab
version of the rvip
condition followed by two minutes of the control condition.ree target sequences
were used in the rvip task condition (246 · 468 · 357); a single digit (3) in the control
condition. Digits were drawn from a programmed list of numbers, the order of
presentation xed by trial and identical for all subjects. On this list were 700 digits in anks are due to
Matthew Kempton,
who graciously
divulged his
method and lists.
pseudo-random order, with target sequences interspersed throughout. At the rate
of presentation of 100 digits per minute (on-screen time 600 ms, no interstimulus
interval), targets appeared at an average frequency of eight per minute.e interval
between targets varied from 8 to 15 digits.
blocked design
e rvip-b600 was based on the work of Kempton (2006), its content adapted to Kempton used four
targets in the rvip
condition, zero as
the control target
and included a
‘xation-cross’
block. In this thesis,
three rvip task
targets were used
(emphasising
attention by
lessening the
memory load), ‘3’
replaced zero (it
being too easily
recognised) and the
‘xation-only‘ task
was omitted.
match our continuous design. Blocks lasted 40 seconds, separated by an interval of
two seconds during which instructions appeared indicating the nature of the task to
follow.e blocks were presented in pseuo-random order, nomore than two blocks of
the same type appearing consecutively. For each condition, six blocks were contrived
by partitioning rvip-c600 digit-list (without repetition or overlap). Comparing the
rvip-c600 with the rvip-b600, the total duration of the rvip task condition was
shorter, and the control condition longer, in the blocked version.
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3.2.4 Pilot study I — Continuous versus blocked
methods
Subjects Five subjectswere recruited – friends and colleagueswhohadnot previously
undergone neuropsychological testing. All were healthy right-handed men (mean
age in years ± sd: 31 ± 3.1) with a high level of education (mean duration in years ± sd:
20 ± 1) and no history of psychiatric illness.
Task delivery Subjects completed the tasks in a quiet room during the morning, the
rvip-c600 preceding the rvip-b600. An interval of 30 minutes separated the sessions,
during which time other tasks in development were completed.
Analysis Hit rates, false alarm rates, response latencies, A′ and B′′ were derived from
the raw E-prime® data using spreadsheet functions, analysed using spss (v.17, spss
inc., usa). Responses occurring less than 125 ms aer stimulus presentation were
excluded, these representing either guesses or chance occurrences. Given the likely
distribution of the data, median response latencies were analysed. All measured and
derived variables were treated as continuous, with group values reported as the mean± sd.e small sample size favoured the use of nonparametric statistical tests; the
Mann-Whitney U test was applied as the observations were considered unpaired.
results (rvip-600)
Continuous versus blocked design Compared to the continuous design, the hit rate
appeared higher in the blocked version of the rvip task condition but the dierence
did not reach signicance; no dierence was observed when the dierent designs
of control task condition were contrasted (table 3.1, page 67). False alarm rates were
low and did not dier according to design. Sensitivity index scores demonstrated
the same pattern of results as the hit rates, not diering on formal comparison. As
some subjects committed no false alarms, the group mean B′′ could not be calculated.
Subjects responded more swily in the blocked versions of the tasks, signicant at
trend level for the rvip task condition but not the control task condition.
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task performance mann-whitney u
rvip-c600 rvip-b600 ranks Z p
rvip task condition
Hit rate (%) 77 ± 19 94 ± 10 10 − 1.51 .131
False alarm rate (%) 0.62 ± 0.9 0.65 ± 0.7 10 − .108 .914
Sensitivity index (A′) 0.95 ± 0.04 0.98 ± 0.02 10 − 1.52 .129
Median response latency (ms) 362 ± 22 336 ± 26 10 − 1.78 .076
control condition
Hit rate (%) 99 ± 3 98 ± 2 10 − .837 .403
False alarm rate (%) 0.22 ± 0.3 0.11 ± 0.2 10 − .904 .366
Sensitivity index (A′) 0.99 ± 0.01 0.99 ± 0.00 10 − .837 .403
Median response latency (ms) 465 ± 38 489 ± 17 10 − .943 .421
Table 3.1: Continuous versus blocked version of the rvip (stimulus duration 600 ms, n = 5), in which
the rate of presentation of digits was 100 per minute. Group values are reported as the mean ± sd.
Statistical scores and signicance levels refer to the comparison of the continuous and blocked ver-
sions for each measure.e statistical statements for the comparison of the rvip task and control task
conditions are presented in the body of the text.
RVIP condition versus control condition e hit rate was higher in the control task
condition compared to the rvip task condition for the continuous version (77 ± 19
versus 99 ± 3; 10 ranks, z −2.12, p = 0.034) but not the blocked version (94 ± 10
versus 98 ± 2; 10 ranks, z −0.11, p = 0.910). False alarm rates did not dier between
the conditions in either the continuous or blocked versions. Subjects took longer to
respond in the control task condition during the continuous version (control task
versus rvip task, median response latency: 465 ± 38 versus 362 ± 22; 10 ranks, z −2.61,
p = 0.009) and the blocked version (control task versus rvip task, median response
latency: 489 ± 17 versus 336 ± 26; 10 ranks, z −2.62, p = 0.009).
interpretation
Comparison of tasks As expected, the control task was easier; in this scenario the
swier responses in the rvip task condition reect the anticipation of sequence
completion rather than diculty. Performance was superior on the blocked design
compared to the continuous design of the rvip task.
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Overall performance Subjects performed extremely well on the rvip-b600 task, with
accuracies close to the ceiling for that level of diculty.us, in order to detect the
proposed eects of methamphetamine the task needed to be more taxing.
Within-task performance In restructuring the rvip task, the major concern was that
its nature and/or diculty could be altered. Continuous tasks may be more sensitive
to the eects of a xed strategy, fatigue and wandering attention whilst the brief
interludes in a blocked task permit the refocussing of attention and adjustment of
strategies. is possibility was explored by dividing the data from the rvip-c600
into pseudo-blocks of 40 seconds, contrasting the pattern of scores and response
times with those of the rvip-b600. No deterioration in performance with time was
observed for either design (data not shown). Subjects simply performed better on the
blocked version.e dierence in performance by task design was therefore most
likely due to a practice eect, all subjects having completed the blocked design aer
rst performing the continuous version.
3.2.5 Modifying the RVIP task
e demand placed on a subject’s attention during the rvip task can be raised either
by introducing a fourth target sequence or by increasing the rate of presentation of
digits. Introducing an additional target sequence alters both the attentional demand
and the memory load of the task, with the limiting disadvantage that only four
target sequences can be derived from the available integers. Increasing the rate of
presentation of digits oers a parametric, unrestricted variation in the level of diculty
and was the preferred option.
Revisions: e stimulus duration was reduced from 600 to 400 ms, resulting in a
rate of presentation of 150 digits per minute. To retain the block duration, the number
of presentations – and targets – was increased. Targets thus appeared at a frequency
of approximately 12 per minute in both the task and control conditions.
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3.2.6 Pilot study II — Evaluating the modied task
methods
Subjects Five volunteers were recruited from amongst colleagues who had not taken
part in the rst pilot study. All subjects were right-handed men (age 37.6 ± 3.7) with
a high level of education (years in education 21 ± 2). Subjects were healthy, had no
history of psychiatric illness and were not regularly taking medication.
Task presentation e tasks were conducted in the same manner as the rst pilot
study, the continuous design followed by the modied blocked design task. Unlike
the rst pilot study there was only a short interval between the sessions.
results (rvip-400)
Continuous versus blocked design Between task designs, no dierence in hit rate,
sensitivity index or median response latency was observed (see table 3.2 below). In
the control task condition, false alarm rates were higher in the blocked version.
task performance mann-whitney u
rvip-c400 rvip-b400 ranks Z p
rvip task condition
Hit rate (%) 52 ± 22 59 ± 12 10 − .314 .753
False alarm rate (%) 0.19 ± 0.2 0.26 ± 0.3 10 − .321 .748
Sensitivity index (A′) 0.88 ± 0.06 0.90 ± 0.03 10 − .530 .596
Median response latency (ms) 450 ± 59 395 ± 51 10 − 1.36 .175
control condition
Hit rate (%) 88 ± 4 91 ± 4 10 − .862 .389
False alarm rate (%) 0.00 ± 0.0 0.25 ± 0.3 10 − 2.39 .017
Sensitivity index (A′) 0.97 ± 0.01 0.98 ± 0.01 10 − 1.12 .262
Median response latency (ms) 431 ± 45 445 ± 41 10 − .838 .402
Table 3.2: Continuous versus blocked version of the rvip (stimulus duration 400 ms, n = 5), in which
the rate of presentation of digits was 150 per minute. Group values are reported as the mean ± sd.
Statistical scores and signicance levels refer to the comparison of the continuous and blocked ver-
sions for each measure.e statistical statements for the comparison of the rvip task and control task
conditions are presented in the body of the text.
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RVIP condition versus control condition With the revised timings, hit rates were
higher in the control task condition than the rvip task condition in the continuous
(88 ± 4 versus 52 ± 22; 10 ranks, z −2.65, p = 0.008) and blocked versions (91 ± 4
versus 59 ± 12; 10 ranks, z −2.62, p = 0.009). More false responses were made during
the rvip task condition for the continuous version only (false alarm rate, rvip task
condition versus control condition: 0.19 ± 0.2 versus 0.00 ± 0.00). Sensitivity scores
mirrored the pattern for hit rates. Subjects responded more slowly in the control
condition, most notably on the rvip-b400 version.
Comparing presentation rates Performance on the blocked rvip task conditions was
compared (rvip-b400 versus rvip-b600).ose subjects undertaking the more rapid
version had lower hit rates (59 ± 12 versus 94 ± 10; 10 ranks, z −2.64, p < 0.01), and
A′ scores (0.90 ± 0.03 versus 0.98 ± 0.02; 10 ranks, z −2.65, p < 0.01), together with
slower response times (395 ± 51 versus 336 ± 26; 10 ranks, z −1.98, p < 0.05). False
alarm rates did not dier. Comparing the blocked control task conditions (rvip-b400
versus rvip-b600), those exposed to the swier rate of presentation similarly had
lower hit rates (91 ± 4 versus 98 ± 2; 10 ranks, z −2.65, p < 0.01) and A′ scores (0.98 ±
0.01 versus 0.99 ± 0.00; 10 ranks, z −1.47, p = 0.017), but did not dier in response
times or false alarm rates when compared to the subjects in the rst pilot study.
interpretation
Hastening the rate of presentation of digits in the rvip task ostensibly increased its
diculty, subjects making fewer correct detections and reacting less swily.e resul-
tant baseline scores are better suited to our stimulant model in which an improvement
in performance is anticipated.
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4 lithium & brain function
Dysfunction of the various monoamine neurotransmitter systems has long been
implicated in the conditions for which which lithium is commonly prescribed; it
follows that lithium may act on such neuronal pathways. In this chapter, the pro-
posal that lithium attenuates dopaminergic neurotransmission in man is examined,
principally though the use of a stimulant model of mania. By way of introduction,
the role of dopamine in the brain is outlined and its relevance to bipolar disorder
and lithium use explored.e assessment tools are then justied, before moving to
a description of the study proper – a randomised, single-blind, placebo-controlled
investigation of lithium’s eects on methamphetamine administration, gauged by
measuring performance on a task of sustained attention together with signal change
on bold fmri.
4.1 background
4.1.1 Dopamine in the central nervous system
Fourmajor dopaminergic pathways have been identied in the human brain (Seamans
and Yang, 2004).e tuberoinfundibular pathway is constrained to the hypothalamus
and regulates some functions of the anterior pituitary through the release of dopamine
into the portal vessels. e nigrostriatal pathway originates in the substantia nigra
pars compacta and terminates in the dorsal striatum, modulating the functions of
motor systems.emesolimbic pathway arises in the ventral tegmental area (vta) and
projects to the ventral striatum, bed-nucleus of the stria terminalis, hippocampus and
septum. Although the neuronal cell bodies of themesocortical pathway are located
in the vta, they may be distinguished from those of the mesolimbic pathway and
project more widely to the frontal and temporal cortical regions.ese distributed
pathways modulate domains such as attention, impulsivity, reward seeking, emotional
processing, working memory and executive functions (Adler et al., 2006).
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synthesis and breakdown
e metabolic pathways of dopamine are well dened (Westerink, 1985) and only
certain points merit attention. First, once tyrosine has crossed the blood-brain barrier
and entered neurones, the rate of its conversion to dopamine via l-dopa is limited
by the activity of tyrosine hydroxylase; the metabolic pathway is usually saturated so
increasing precursor concentrations does not aect production. Second, the actions
of dopamine can be terminated by a number of processes: simple diusion away
from receptor sites; enzymatic breakdown by catechol o-methyl transferase (comt)
and monoamine oxidase (mao) to produce homovanillic acid (hva); active cellular
reuptake mechanisms involving various transporters. e dominant mechanism
varies with brain site – whilst the dat is active in the striatum, its absence in the
prefrontal cortex (pfc) means that comt activity and uptake into noradrenergic
cells are the major determinants in cortical regions. ird, as both the de novo
synthesised and recycled dopamine are rapidly broken-down by intraneuronal mao,
vesicular storage is necessary if large quantities are to be released; concentration into
vesicles is determined by the monoamine transporters (vmat2). Finally, dopamine
neurones exhibit tonic and phasic patterns of ring, governed in part by comt allele
polymorphisms and the actions of dat. High-activity comt allele status results in low
tonic levels overall, with low levels of dopamine in the pfc and high levels subcortically
aer phasic release; the reverse with low-activity comt status (Tunbridge et al., 2004).
signal transmission
Dopamine is a slow-acting neurotransmitter, its mode of action distinct from the pro-
cesses of fast neurotransmission in which sub-millisecond response times permit the
very rapid conveyance of signal between brain regions (Greengard, 2001b). Dopamine,
on binding to a receptor, invokes the actions of second messengers, protein kinases
and protein phosphatases to bring about its eects; these manifest over hundreds of
milliseconds to minutes (Greengard, 2001a). Slow-acting neurotransmitters act to
modulate the eciency of fast neurotransmission systems, both inhibitory (gaba)
and excitatory (glutamate).
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e vesicular release of dopamine is calcium-dependent and is usually triggered
by incoming depolarisation (Westerink, 2006).e rate and pattern of neuronal ring,
together with the occupation and activity of presynaptic dopamine autoreceptors, de-
termines the extent of dopamine release. Dopamine receptors have been grouped into
two families: d1-type and d2-type (Kebabian and Calne, 1979).e d1-type receptors
(d1 andd5) aremostly coupled to stimulatory subunits of g-proteins (gas) and increase
the production of the second messenger camp by activating adenylate cyclase (ac).
e resulting cascade through protein kinase a (pka), protein phosphatase 1 (pp1)
and darpp-32 (dopamine and camp regulated phosphoprotein of 32 kDa) achieves
their cellular eect.e d2-type receptors (d2, d3, and d4) are coupled to inhibitory
subunits (gai) and deactivate ac, reducing the production of camp and its eects on
downstream pathways (Greengard, 2001a). Protein kinases such as darp-32 are also
inhibited by increased intracellular calcium concentrations, such as that which occurs
as a consequence of glutamate receptor occupation (Lindskog et al., 2006).
Dopaminergic gpcr signalling is thought to conclude within around 30 minutes
of transmitter release, terminated by receptor internalisation and desensitisation.
Desensitisation is achieved by β-arrestin proteins decoupling the receptors from
the g-proteins, but this in itself does not appear to mark the end of dopaminergic
signalling (Beaulieu et al., 2004). On binding internalised d2-type receptors and
pp2a, β-arrestin inactivates akt and so reduces the inhibition of the constitutionally
active gsk-3β (Beaulieu et al., 2007).is signalling pathway has a slower response
time compared to those traditionally associated with gpcr transmission; it is also a
putative site of action of lithium (Beaulieu and Caron, 2008).
4.1.2 Dopamine and bipolar disorder
e role of dopamine and the importance of brain network dysfunction in bipolar
disorder have recently been reviewed (Cousins et al., 2009; Palaniyappan and Cousins,
2010), the key points being summarised below. Much of the available evidence pertains
to mania, long-argued to be a hyperdopaminergic state (Silverstone, 1985).
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manic presentations
Conceptual frameworks Dopamine governs reward-seeking behaviour, potentially
mediating impulsivity and risk-taking in mania (Seamans and Yang, 2004).rough
modulating activity in frontal regions, dopamine could be central to the well recog-
nised alterations in cognition that may accompany bipolar disorder (Adler et al., 2006;
Robinson and Ferrier, 2006). Although striatal systems are less clearly implicated
in mania, patients with bipolar disorders demonstrate an excess of so neurological
signs (Goswami et al., 2006) and more commonly develop extrapyramidal side eects
with antipsychotics than other diagnostic groups (Hamra et al., 1983; Gao et al., 2008).
Drug challenges Psychostimulants which increase dopaminergic activity in the brain
can mimic or induce manic presentations (Jacobs and Silverstone, 1986). Mania
can also be triggered by l-dopa, dopaminergic agonists and dopamine reuptake
inhibitors (van Praag and Korf, 1975; Gerner et al., 1976; Silverstone, 1984). Reducing
the synthesis of catecholamines improves the symptoms of mania in those already
receiving standard treatment (McTavish et al., 1999, 2001; Scarnà et al., 2003).
Neurotransmitter metabolites e concentration of hva in the cerebrospinal uid
(csf) is usually, but not invariably, found to be increased during mania (Gerner et al.,
1984); likewise urinary dopamine (Koslow et al., 1983).
Presynaptic imaging Investigated using the [18f]6-uoro-l-dopa positron emission
tomography (pet) ligand, the rate of synthesis of dopamine appears to be normal
in mania (Yatham et al., 2002b); vesicular storage and release has not been similarly
investigated.e vmat2 can be visualised with pet, [11c]dtbz ligand binding linearly
reecting the density of monoaminergic synaptic projections in the brain (Vander-
borght et al., 1995). In euthymic patients with bipolar disorder, [11c]dtbz binding is
greater than normal in the thalamus and ventral midbrain, the binding potentials cor-
relating with impaired performance on tests of verbal learning and executive function,
though not with ratings of mood (Zubieta et al., 2001).
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Receptor imaging In patients with bipolar disorder, d1-receptor binding, assessed by
[11c]sch23390 pet, is reduced in the frontal cortex but not in the striatum (Suhara et al.,
1992). Striatal d2-receptor density is normal in mania, as gauged by [11c]raclopride
binding (Yatham et al., 2002a). Whilst d2-receptor density is unrelated to mood
symptoms, the presence of psychosis in mania is associated with increased binding
(Pearlson et al., 1995). Euthymic patients do not dier from healthy subjects in the
amphetamine displacement of [123i]izbm binding, suggesting normal striatal d2 and
d3-receptor expression in this phase of the illness (Anand et al., 2000).
Second-messenger systems Concentrations of pka regulatory subunits are reduced
in the cytosolic fractions of the cortex in patients with bipolar disorder examined
post-mortem (Rahman et al., 1997), potentially reecting disrupted dopaminergic
signalling through camp and pp1 pathways. Located downstream of d2-receptors,
platelet phosphatidylinositol bisphosphate (pip2) concentrations are elevated inmania
(Brown et al., 1993); levels of inositol within the frontal and occipital cortex are lowered
in bipolar disorder (Silverstone et al., 2005) whilst protein kinase c (pkc) activity is
enhanced in frontal brain regions (Wang and Friedman, 1996).
depressive states
Historically, dopaminergic models of bipolar disorder are presented as dichotomous,
with depression considered to be a hypodopaminergic state. Simply stated, there
are notable conicts between theory and observation. Lowering of mood can occur
with drugs that deplete dopamine (Schatzberg and Nemero, 1998) or antagonise its
receptors (Willner, 1983), but antidepressant eects have also been ascribed to such
medications (Davies and Shepherd, 1955; Mulholland and Cooper, 2000; Berk et al.,
2007). In Parkinson’s disease (the prototypical hypodopaminergic state) depression
commonly occurs (Lieberman, 2006), especially in those with degeneration of the vta
(Torack andMorris, 1988); the association, however, is highly inconsistent (Lieberman,
2006), non-specic (Gotham et al., 1986), not related to illness duration (Brown,
1995) nor invariably resolved with dopamine replacement strategies. Metabolite
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studies generally support a reduction in dopamine turnover in bipolar depression
(Subrahmanyam, 1975; Gerner et al., 1984), but the assessments are confounded
by the level of physical activity and the presence of psychosis; for that matter, the
reality of psychotic depression means that theories purporting a global reduction in
dopaminergic functioning in depression are most likely an oversimplication.
4.1.3 Bipolar disorder and lithium
Lithium is an established treatment for bipolar disorder (see §1.2.2 on page 3), with
evidence to support its use in all phases of the illness.ere is a widespread consensus
that its greatest ecacy is observed whilst managing acute mania. As a maintenance
treatment, it may be more eective in preventing relapse into mania than into de-
pression (Geddes et al., 2004; Nivoli et al., 2010), but this asymmetry in ecacy may
balance out as new data is entered into meta-analysis. Lithium confers protection
against completing suicide, but this eect is lost on withdrawal (Cipriani et al., 2005).
Treatment with lithium is not eective in all cases and much work has focussed
on identifying the prole of those who respond. Characterised on clinical grounds,
the best response is seen in those with episodic presentations resolving to normal
functioning, euphoric symptoms whilst manic, a family history of bipolar disorder
in rst-degree relatives and the absence of a personality disorder (Maj, 1992). De-
spite numerous endeavours, no biological markers that consistently identify lithium
responders have been found (Grof, 2006).
4.1.4 Lithium and dopamine
If mania is a hyperdopaminergic state and lithium an eective antimanic agent, it may
follow that lithium acts to attenuate dopaminergic neurotransmission. In accepting
this conclusion, caution must be advised. Mania is not purely driven by dopaminergic
dysfunction and lithium has numerous, wide-ranging eects; the explorations of its
eects on dopaminergic systems may have been skewed by the observation that is
more eective in mania than depression, leading to a degree of circularity.
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effects on cognition
e inuence of lithium on cognitive functioning has been investigated in various
subject groups; its eects are subtle and the interpretation of studies hindered by such
matters as illness state, treatment duration and serum level achieved. Nevertheless,
consistent ndings have emerged from reviews of the eld (Pachet andWisniewski,
2003; Wingo et al., 2009). Lithium impairs performance on tasks assessing verbal
memory and psychomotor speed, whilst attention, visual memory and constructional
ability appear to be largely unaected. By inference, modulation of dopaminergic
functioning could be proposed to underlie these eects.
neuroendocrine measures
Serum prolactin levels are determined in large part by the activity of the tuberoin-
fundibular pathway, dopamine acting to inhibit the release of the hormone. us,
an elevated prolactin level may reect a reduction in dopaminergic activity, at least
in this pathway. Lithium has been associated with increases in prolactin (Joe et al.,
1986), but negative and opposite ndings abound (Lanng Nielsen et al., 1977; Baptista
et al., 2000; Basturk et al., 2001). Prolactin release is governed by various systems
including serotonergic ones, sensitive to the eects of stress and illness as well as
many of the commonly prescribed psychotropic medications. It is not a particularly
specic outcome measure.
pharmacological models
Lithium has been shown to attenuate the eects of amphetamines in some, but not
all, rodent studies (see §1.4.2 on pages 11–12). In patients with aective disorders, the
euphoria, arousal and sense of activation that follows amphetamine administration
are diminished by lithium (Vankammen and Murphy, 1975); a similar eect is seen in
recreational users (Flemenbaum, 1975). Application of a stimulant model of mania
forms the basis of the study described in this chapter, the rationale for which is
considered in the sections that follow.
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4.2 models & measures
Mania is a severe condition that presents a challenge to ethical research because it
is frequently associated with impaired judgement and loss of insight. Interventions
are therefore oen investigated using healthy subjects in which the illness is partially
replicated. Amphetamine administration to healthy subjects has been extensively
used as a model of mania (Jacobs and Silverstone, 1986). Illness models have certain
merits in research: specic aspects of syndromal presentations may be isolated or
emphasised, pharmacological interventions can be investigated in a focussed manner
and the preclinical to clinical gap bridged. Logistical diculties arising from orid
presentations – consent, polypharmacy, timing, containment – are also bypassed.
Models of illness, however, are never fully accurate and their specic limitations
must be recognised. In addition to ensuring a model replicates the pertinent clinical
features and proposed neurochemical derangements, the assessments undertaken are
of some importance. Whilst a model of mania may consistently induce hyperactivity,
for example, quantifying such changes may be challenging and problematic in some
research settings, not least imaging studies. Drawing from the extensive battery of
neuropsychological tasks, cognitive and emotional processing can be assessed easily
and reliably in various environments; consequently, dysfunction in these domains has
been investigated in studies of mania and in models of mania. In the study described
in this thesis, subjects completed a task which required their sustained attention
before and aer receiving methamphetamine.
4.2.1 Amphetamine models of mania
Amphetamines act to increase the synaptic concentrations ofmonoamines (principally
the catecholamines) and to a lesser extent the excitatory neurotransmitter glutamate
(Sulzer et al., 2005). Administration to healthy human subjects consistently elevates
mood, alertness and arousal, with increases in energy and mental speed reported;
appetite is generally reduced, as is the need for sleep (Jacobs and Silverstone, 1986).
ese subjective and behavioural eects mirror some of the key features of mania.
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mode of action
Whilst it is clear that many of the eects of the amphetamines are driven through the
elevation of extracellular concentration of dopamine and noradrenaline, the mecha-
nisms of their actions remain incompletely dened – for a comprehensive review of
the topic, see Sulzer et al. (2005). Amphetamines are dopamine-releasing agents, with
scant anity for dopamine receptors. In eect, they reverse the direction of passage of
dopamine across key membranes. Extracellular amphetamine at a low concentration
is readily exchanged for cytosolic dopamine via the dat; at higher concentrations
the drug enters neurones by diusion and releases dopamine from its intracellular
binding sites, resulting in an outpouring of dopamine into the synapse through reverse
transport involving the dat. Release by eux may occur though a rapid, channel-like
route and a slower exchange process. e channel-like route resembles vesicular
release and so likely mediates the psychoactive eects of amphetamines.
Amphetamines, by increasing the activity of pkc, alsomodify the functional status
of the dat by phosphorylation and internalisation. Activation of presynaptic pkc has
several consequences, including the downregulation of the dat with a subsequent
reduction in the reuptake of dopamine, and the induction of dopamine eux. An
increase in the cytosolic concentrations of dopamine may also be brought about by
changes in vesicular storage. Amphetamines cause a redistribution of the vmat2
protein, reducing the uptake of dopamine into vesicles. Furthermore, when the drug
accumulates in vesicles, its weak base properties disrupt the proton electrochemical
gradients that encourage monoamine storage, increasing the fraction of dopamine in
the cytosol with subsequent eux by the mechanisms previously described.
differential effects of amphetamine derivatives
It is commonly thought that dextroamphetamine (d-amphetamine) and its principal
derivative methamphetamine have dierent eects, at least subjectively. Metham-
phetamine is oen touted as the more potent, addictive and cns specic of the two
stimulants; these claims generally do not stand up to scrutiny (Shoblock et al., 2003a),
the two compounds having similar pharmacokinetic properties with a substantial
79
overlap in subjective eects (Sevak et al., 2009). Both drugs increase synaptic nora-
drenaline, dopamine and glutamate, but the regional eects (Shoblock et al., 2003b)
and ratios of the transmitters released may vary subtly. Striatal dopamine release
underpins at least part of the model of mania, as the reduction in [11c]raclopride
binding that follows d-amphetamine administration correlates inversely with ratings
of euphoria in healthy subjects (Drevets et al., 2001).
regional effects
Functional imaging studies have favoured d-amphetamine as the intervention, though
the doses used have been quite wide ranging. e ndings have been somewhat
mixed and inconclusive. Assessed using [18f]-uorodeoxyglucose pet, very high oral
doses of d-amphetamine induce a global increase in cerebral glucose metabolism
(Vollenweider et al., 1998). In healthy subjects, regional changes in cerebral blood ow
and glucose metabolism occur in brain areas innervated by dopamine, with increases
(Devous et al., 2001) and decreases (Mathew and Wilson, 1985; Wolkin et al., 1987;
Kahn et al., 1989) observed. Some fmri studies have found d-amphetamine to increase
bold signal in task-specic regions during sensory, motor and working memory
paradigms (Mattay et al., 2000; Uring et al., 2001); others have reported decreases
in similar experimental conditions (Howard et al., 1996; Willson et al., 2004).
practical considerations
When d-amphetamine is administered in clinical studies, it is most oen given orally.
is results in a delayed onset of action which peaks, on average, at about 75 minutes
aer administration (Jacobs and Silverstone, 1986; Silverstone et al., 2004). Absorption
of amphetamines can be aected by concurrent medications and physiological factors,
making timing of the peak eect dicult to predict. Methamphetamine may be
administered intravenously to humans, bypassing rst-pass metabolism and resulting
in near immediate eects.is predictability, combined with local expertise (Hearn
et al., 2004), made methamphetamine the more desirable derivative for the study
undertaken in this thesis.
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4.2.2 Sustained attention
Impairments in cognition are now well recognised in bipolar disorder, delineated in
numerous studies and synthesised by meta-analysis (Robinson et al., 2006). Several
cognitive domains are aected during acute episodes and the abnormalities remain
detectable in euthymia (Ferrier et al., 1999), even when medications are considered
(Goswami et al., 2009; Balanzá-Martínez et al., 2010). Sustained attention is one such
domain. Whilst manic, patients perform poorly on tasks requiring sustained attention
(Sax et al., 1999; Clark et al., 2001), including the rvip task.is disruption to attention
is particularly marked in patients who are psychotic (Quraishi and Frangou, 2002).
Once euthymic, attentional decits are demonstrable in some (El-Badri et al., 2001;
Wilder-Willis et al., 2001; Harmer et al., 2002; Liu et al., 2002; Clark et al., 2002, 2005)
but not all tasks (Addington and Addington, 1997).e impairments in attention are
not the most striking abnormality evident in patients with bipolar disorder, being
gauged as of moderate eect size (Kurtz and Gerraty, 2009).
Engaging and sustaining attention is necessary for the completion of most tasks,
be they formal neuropsychological tests or mundane matters of day to day life. Distur-
bances in attention can have wide ranging consequences for social and occupational
functioning, inuencing or masquerading as impairments over a number of cogni-
tive domains. Investigation of attention in its own right is therefore of importance.
Attention has long been conceptualised as a tripartite system comprising alerting,
orienting and executive functions (Miller and Cohen, 2001). Each component may
be considered in its own regard and, for the purposes of investigation, emphasised in
the construction of individual tasks. In this way, neuronal networks have separately
been identied that serve to obtain the alert state (alerting – Coull et al., 1996), en-
hance the processing of target information (orienting – Corbetta et al., 2000) and
resolve the conict in whether or not to respond (executive – Botvinick et al., 1999).
Using the single, sophisticated Attentional Network Task (ant), Posner’s group have
demonstrated that whilst all three networks are engaged with attention, each may be
dissociated by varying the demands of the task (Fan et al., 2005).
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Figure 4.1: Attentional networks demonstrated using BOLD fMRI. The three networks − alerting,
orienting, executive−demonstrate independence, but are all engagedby tasks requiring sustained
attention. The images above were acquired whilst the Attention Network Task was performed by
healthy subjects (figure reproduced from Fan et al., 2005).
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e alerting network comprises the thalamus together with anterior and posterior
cortical regions; in orienting to visual stimuli, the frontal eye elds and parietal areas
are engaged whilst the anterior cingulate cortex is dominant in conict resolution
(gure 4.1 on page 82). Alerting is sensitive to manipulations of noradrenergic neu-
rotransmission (Marrocco and Davidson, 1998; Coull et al., 2000, 2001) whilst the
executive network is modulated by dopaminergic systems (MacDonald et al., 2000).
the rapid visual information processing task
Tasks which require sustained attention can be simply constructed and are well suited
to functional imaging investigations.e principal requirements of the task used in
this thesis were that it should invoke changes in brain activity detectable with bold
fmri, be sensitive to methamphetamine and be of relevance to – or disturbed by – the
presence of mania. e rvip task was considered suitable for these purposes (see
Chapter 3 for a description of the task).
Regional eects In performing the rvip, healthy subjects engage alerting and orient-
ing networks as well as prefrontal regions, evidenced by an increase in cerebral blood
ow using pet (Coull et al., 1996). e pattern of activation demonstrated by pet
(gure 4.2 on the following page) has since been replicated in an fmri investigation,
validating the use of a blocked design (Lawrence et al., 2003). Regional deactivations Deactivations occur
in these regions
regardless of the
task in hand.e
signicance of this
observation is
considered in
greater detail later
in this chapter.
that arise when subjects engage with the rvip task condition are seen in anterior and
posterior medial cortical regions as well as the precuneus.
Sensitivity to stimulants Performance on the rvip task is modied by stimulants
(Wesnes and Warburton, 1983b), with methamphetamine consistently shortening the
response latency (McTavish et al., 2001; Hearn et al., 2004). Some studies have found it
to increase sensitivity index scores (Hearn et al., 2004) whilst others report a tendency
for impulsive responding (McTavish et al., 2001). Methamphetamine may inuence
all attentional networks, but the executive component is implicated by its eects on
response bias, eects prevented by tyrosine depletion (McTavish et al., 2001).
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Figure 4.2: Regional cerebral blood flow by PET during the RVIP task. The RVIP−Control contrast
demonstrates increased blood flow on performing the RVIP task condition; the Control−RVIP
contrast shows regional reductions in blood flow (figure reproduced from Coull et al., 1996.)
Dysfunction in bipolar disorder Mania is associated with abnormal performance on
the rvip task (Clark et al., 2001), principally a lower response sensitivity and with
a tendency to respond impulsively, reected in lower A′ and B′′ values respectively.
Response latency times are disrupted in mania and slowed in euthymic patients
compared to control subjects and healthy rst-degree relatives (Clark et al., 2005).
Imaging studies of bipolar disorder utilising the rvip task have yet to be reported.
4.2.3 Existing studies
Silverstone’s group extended the amphetamine model into the fmri eld, their exper-
iments culminating in a study of the attenuating eects of the medications used in
mania.e eects of d-amphetamine on bold fmri were examined using motor, ver-
bal memory and spatial attention paradigms (Willson et al., 2004). Signal intensity in
the regions of activation was compared before and aer d-amphetamine. In the tasks
of cognitive function, d-amphetamine reduced bold signal intensity.e regions of
interest identied in the Willson et al. (2004) study were applied in the analysis of a
second study (Bell et al., 2005a) – the tasks and the d-amphetamine intervention were
unchanged, but subjects had been randomised to receive either lithium, valproate or
placebo prior to the sessions. Lithium attenuated the eects of d-amphetamine on
signal change in the spatial attention task, but not the memory or motor task.
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4.3 study objectives
ere is evidence that mania can be considered a hyperdopaminergic state and that
lithium may act to reduce neuronal activity in dopaminergic pathways. Tasks that re-
quire sustained attention engage brain regions innervated by monoaminergic systems
and are sensitive to manipulations of dopamine synthesis and release. By combining
tasks, fmri assessment and amphetamine administration, the monoaminergic systems
of the brain may be probed in vivo in man. Within this framework, lithium has
been shown to modify the eects of d-amphetamine on regional activation during
attentional processing. A more predictable onset of action can be achieved by giving
intravenous methamphetamine in preference to oral d-amphetamine, and method-
ological strength may be gained by the use of a longitudinal design with examination
of dose related eects. On the basis of these assertions and in light of the evidence
presented, the following hypothesis was proposed:
Lithium carbonate will lessen the eects of methamphetamine by attenuat-
ing dopaminergic neurotransmission in healthy men, gauged by subjective
ratings, performance on a task of sustained attention and bold fmri sig-
nal change; the eects will be evident at serum levels advocated for the
treatment of mania and not with a lower dose schedule.
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4.4 study methodology
4.4.1 Study design
e experiment, hereaer referred to as the mrc-lamp study, was a randomised,
single-blind, placebo-controlled study of healthy male subjects in which the eects
of lithium on a stimulant model of mania were investigated. In brief, all subjects
underwent fmri investigation on two occasions, separated by a period in which they
received either lithium or placebo tablets for 11 days. Subjects were randomly allocated e study duration
derived from the
pharmacokinetics
of lithium and its
anticipated acute
eects (see §1.3).
to one of three groups: high dose lithium, low dose lithium, placebo. During each
fmri session the subjects completed the blocked rvip task twice, the second occasion
immediately preceded by an intravenous dose of methamphetamine.
e study was funded by the Medical Research Council (mrc) and approved by a
Local Research Ethics Committee (lrec) for the Newcastle upon Tyne region.
4.4.2 Subject recruitment
Healthy male subjects were recruited from the population of Newcastle upon Tyne,
attracted by advertisements placed in various sites around the University campus,
local recreation centres and business parks.e advertisements alluded to the nature
of the research, directing interested parties to a study-specic website where a detailed
account of the study was provided, together with instructions on how to contact the
research team. All subjects were recruited by this route, it being inappropriate to
enlist friends or colleagues into this sort of study.e suitability of volunteers was
rst checked by way of a phone call or email, with eligible candidates invited to a full
screening assessment at the Newcastle Magnetic Resonance Centre.
4.4.3 Screening session
e purpose of the screening visit was threefold: enrolment, assessment and training.
A full screening visit typically lasted 2–3 hours, with all assessments undertaken
during morning hours.
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eligibility & consent
Individuals were eligible for the study if they were male, 18–45 years of age, right-
handed, in good health and naïve to prescribed or illicit stimulants. Volunteers with
any history of psychiatric illness were excluded, as were those with medical conditions
deemed to have a bearing on the study investigations or the safety of medication
administration. Individuals were assessed with the Structured Clinical Interview for
the Diagnostic and Statistical Manual of Mental Disorders (4th edition, Non-Patient
version, scid_np; ?), and amedical history was elicited by systematic enquiry. Suitable
volunteers were invited to participate, all of whom provided written and informed
consent.
baseline assessments
Subjects underwent a physical examination during which height, weight, pulse rate
and blood pressure were recorded. A urine sample was tested on-site for the presence
of illicit drugs and those testing positively for stimulants were excluded from further
participation. Breath analysis for alcohol was performed, with a negative reading
required for continuation. A venous blood sample was taken for the measurement of
urea and electrolytes, liver function, thyroid function and a full blood count.
Substance use was gauged by direct questioning, specically the units of alcohol
imbibed per week and the number of cigarettes smoked per day (or equivalent nicotine
replacement measures).e average daily consumption of caeinated drinks was also
noted. Past and present illicit drug use was recorded and whilst cannabis use was
not an absolute exclusion criterion, those judged to be heavy users were considered
inappropriate for further participation.
Subjects then completed a visual analogue scale (vas) assessing 16 domains known
to be sensitive to the eects of psychotropic medications (Bond and Lader, 1974).
is familiarised them with the tool prior to the series of assessments spanning
methamphetamine administration.ose attending the screening session considered
themselves right-handed, but this was formally assessed using the standard Edinburgh
Handedness Inventory (Oldeld, 1971).
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As aptitude determines performance on various neuropsychological tests, the
duration of education for each subject was recorded, together with their highest
qualication. Intelligence was more formally gauged by having subjects complete the
National Adult Reading Test (nart – Bright et al., 2002).
neuropsychological task training
During the screening visit, subjects completed the rvip task on two occasions; a third
training run was performed at the beginning of scan day one, subjects having slept
in the intervening period. In these sessions, subjects became familiar with the task
and through practice their performance was expected to improve to a plateau level.
Training to the level of automatic functioning was not the goal, rather the reaching of
a stable baseline against which drug interventions could be compared.e structure
and delivery of the task, both inside and out of the magnet, has previously been
described (see §3.1.1 on page 58).
4.4.4 Assessment sessions
As noted, subjects underwent fmri investigation twice.e sessions were very similar
in structure, though subjects were more familiar with the scanner environment and
the eects of methamphetamine on the second occasion. On the second assessment
day, subjects also completed the Lithium Side-Eects Rating Scale (lisers) and gave a
blood sample immediately before entering the scanner – this was used to measure the
serum lithium concentration, but was taken from all subjects to maintain blinding.
On both occasions the assessment sessions took much of a day, the shared features of
which are described in the sections that follow.
preparation
On arrival in the morning, subjects were greeted and reminded of the schedule for the
day. Consent was checked and the researcher reassured themselves that each subject
had a full understanding of the nature of the project and proposed interventions.
e mri-specic safety questions were posed by one of the duty radiographers, all of
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whom were familiar with the study protocol. Alcohol breath testing was performed
and a fresh urine sample taken to exclude recent stimulant use. Cardiovascular vital
signs were recorded, a vas completed and an intravenous cannula inserted for the
purposes of venous sampling and methamphetamine administration. Once subjects
were comfortable, they were invited to enter the scan room.
magnetic resonance image acquisition
Data was acquired from all participants using the same 3Twhole body Philips Achieva
System using an 8-channel sense head coil. Aer the acquisition of a T1-weighted
image (3d t1_ffe sequence: tr = 9.6 ms, te = 4.6 ms; ip angle = 8○, fov = 240 × 180× 240 mm, contiguous isometric voxel size 1 mm), the fmri series began (gradient
echo epi sequence: tr = 3 s, te = 30 ms; ip angle = 90○, fov = 240 × 240 × 240 mm,
matrix 80 × 80, 30 slices, slice thickness = 5 mm). On each assessment day, subjects
completed the blocked rvip protocol twice (presentation and equipment described
in §3.1.1); the well-being of the subjects was enquired aer at regular intervals and
subjects were able to indicate discomfort or distress throughout the session.
rvip functional series
e format of the task was identical on each occasion, though the actual sequence of
digits varied between sessions. Each functional run comprised ten presentation blocks,
ve each for the rvip task condition and control task condition. Blocks were presented
in a pseudo-random order (r·c·r·r·c·r·c·c·r·c, where r is the rvip condition and c is
the control condition).e block duration was 40 seconds, each block preceded by
instructions appearing on screen for 5 seconds. Inclusive of two dummy scans, the
total length of each functional series was 7.6 minutes (152 dynamics of tr = 3 s).
Being tiresome to repeatedly describe fmri sessions as ‘pre-methamphetamine
and aer the course of lithium or placebo’ for example, shorthand forms were adopted.
e assessment days before and aer the course of tablets were denoted by the numbers
1 and 2; pre- and post-methamphetamine status by the letters a and b respectively.
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methamphetamine administration
On completing the rst functional rvip task series, subjects were instructed to remain
still whilst they were moved out of the scanner bore.e principal investigator then
entered the scan room, checked their well-being and their willingness to continue
before recording their pulse rate. Methamphetamine was given intravenously (0.15
mg/kg diluted with normal saline, Martindale Pharmaceuticals™injection bp) as a slow
push over 30 seconds. Subjects were replaced in the scanner, the second functional
series conducted immediately thereaer.
recovery
Once out of the scanner, the post-methamphetamine assessments were performed.
ese comprised a vas series, cardiovascular vital signs and a review of well-being at
45 minute intervals. Once the assessments were complete and the subject comfortable,
they were allowed to go home. Subjects received a card stating that they had taken
methamphetamine as part of a clinical study, with contact details in case of emergency.
4.4.5 Lithium/Placebo administration
lithium
Lithium was administered as Priadel™ tablets in all instances, with the lowest denomi-
nator of 200 mg selected to permit exibility of dosing whilst retaining consistency
of appearance. Tablets were repackaged by pharmacy, bottles labelled as containing
‘mrc-lamp study medication’ with instructions to take a specied number at night.
e dose was calculated using the method described by Chiu et al. (2007): aer con-
verting serum creatinine levels to mg/dl (equation 4.1) and estimating the creatinine
clearance (equation 4.2; age in years, weight in kg), a target serum level of either 0.5 or
0.9 was entered into equation 4.3 and the daily dose of lithium calculated.e tablets
were given for 11 days, reecting the four days typically required for lithium to reach
steady-state (§1.3) followed by a full week at the target level. A consistent duration
was favoured over repeated cycles of checking serum levels and modifying doses.
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Serum creatinine in mg/dl (scr) = serum creatinine in mmol/l
88.4
(4.1)
Creatinine clearance (crcl) = (140 − age) × weight
(72 × scr) (4.2)
Lithium dose in mg = weight × 20 × crcl
100
× target level (4.3)
placebo tablets
As this study was a single-blind investigation without a run-in period or cross-over
phase, the placebo tablets did not have to be identical to the Priadel™ in all respects.
ey simply had to be convincingly medication-like, yet pharmacologically inert.
Plain lactose tablets were sourced from a reputable homeopathic company, certied
as free from active ingredients (no matter how low the concentration).e lactose
tablets were small, round and white; not dissimilar to many medications. Conforming
to European production standards and passing uk pharmacy quality control tests,
the placebo tablets were repackaged into generic containers and labelled in the same
manner as the lithium prescription.e number of tablets prescribed was determined
by calculating the dose of Priadel™ that the subject would have received had they been
randomised to the low-dose lithium group.
4.4.6 Analysis
clinical measures & ratings
Using spss (v.17, spss inc., usa), histograms of clinical measures and vas scores were
examined and the data tested for normality of distribution (Shapiro-Wilk test). For the
three groups, normally distributed datawas compared using ananova test, controlling
formultiple comparisons during post-hoc analysis. With the nonparametric equivalent
Friedman test, post-hoc comparisons were adjusted using the Bonferroni technique.
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sustained attention
Raw data was extracted from E-prime® and entered into a spreadsheet template
constructed to calculate hit rates, false alarm rates, response latencies and the derived
sensitivity index (A′) and response bias (B′′) for the individuals and groups. Responses
occurring within 125 ms of a stimulus presentation were excluded from analysis (see
§3.2.1).e measured and derived variables were treated as continuous and tested for
normality as previously described; use of non-parametric statistics was anticipated
for the analysis of response latency, a Gaussian distribution being unlikely given the
propensity for extreme upper values and the application of a lower threshold.
image analysis
Preparation Data was exported from the scanner in proprietary par-rec format
to a personal computer running a Linux operating system (Ubuntu 8.04 lts), on
which all subsequent processing was conducted. Images were converted into analyze
format using mricro and subsequently inspected for quality using the same program.
Orientation by the radiological convention was maintained as conversion to the
neurological orientation is a default process within the statistical parametric mapping
program used. Prior to preprocessing, the 4d epi data was converted to 3d format
using the ‘fslsplit’ command-line function in fsl. All further analysis stages were
completed using spm8.
Preprocessing For each subject and each session, the dummy scans necessary to
overcome T1 saturation eects were rejected before the 3d functional images were
realigned to the rst image in the respective time-series, thus correcting for move-
ment eects. Sampling errors were not adjusted as head movement may have been
related to the task conditions. Realignment preserved the 3d format of the data whilst
generating a mean image for time series, applied during the normalisation process.
Each subject’s mean epi le was coregistered to their T1-weighted image (acquired at
the outset of the relevant session) and resliced using a trilinear interpolation, without
a mask and with no wrap applied.e T1-weighted image was then normalised to the
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icbm152 T1 template and the parameters applied to each image in the 3d realigned
epi series. Source images were smoothed with an 8 mm fwhm Gaussian kernel to
ensure adequate matching and when writing normalised images, the default setting
for trilinear interpolation was maintained along with a voxel size of 2 × 2 × 2 mm
and the template bounding-box. e normalised images so created were spatially
smoothed with an 8 mm fwhm Gaussian kernel.
First-level analysis To prevent errors in the denition of parameters, model speci-
cation was performed using the batch mode of spm8. A template .mat le was created
in which the onset and duration of each rvip task and control condition block was
dened, interspersed by the instruction slides. A box-car model convolved with a
Canonical haemodynamic response function was specied; parametric modulation,
temporal derivatives and interactions between trials not being required.e rotational
and translational movement parameters generated by the realignment procedure for
each subject were considered nuisance covariates and entered as regressors in the
design. In keeping with current opinion, global signal intensity was le unscaled and
a high pass lter of 128 seconds was applied, the haemodynamic response function
serving as a low pass lter. A batch with 96 modules was prepared, one for each
session and subject, into which the relevant smoothed 3d images from the prepro-
cessing stages were entered. Model specication and estimation followed, resulting
in an spm.mat le for each module. Contrasts were then dened using the spm8 gui
‘contrast manager’ (rvip task condition, control task condition, rvip task condition
minus control task condition) and applied to all spm .mat les (gure 4.3).
Second-level analysis A random eects analysis was applied to investigate the main
eect of the task, the dierences between sessions determined at the group level.
Using the contrasts generated in the rst-level analysis, the main eect of the rvip
task was demonstrated with a one-sample t-test, with a paired t-test used to investigate
the eects of methamphetamine on all subjects during the rst assessment day. A
full-factorial analysis (2× 2× 2) was constructed to investigate the interaction between
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lithium, placebo and stimulant (group ×methamphetamine × assessment day). Only
the rvip-minus-control contrast (activation) was submitted to this design; multiplying Describing
contrasts as
activations or
deactivations is a
useful short-hand.
With multilevel
comparisons, the
terms can become
misleading. In such
instances, a full
description
supported by
diagrams are
favoured.
the matrix by − 1 generated the control-minus-rvip (deactivation) contrast.
Statistical inference Contrast dierences emerging from the comparisonsmade were
primarily assessed at the cluster-level, deemed to be signicant at p < 0.05 follow-
ing family-wise-error (fwe) correction. A less conservative threshold was applied
in the exploratory analyses (p < 0.001 uncorrected); results thereby derived were
considered informative, but not acceptable as evidence for the refutation of the null
hypothesis. Cluster localisation by mni coordinates in mm was maintained, with a
description of the anatomical positioning favoured over conversion to Talairach coor-
dinates. When given in text or tables, coordinates are invariably in the order x, y and z.
Pre-randomisation Post-randomisation
first-level analysis
T C T C T C T C
1A 1B 2A 2B
SCAN SESSION
methamphetamine
lithium or placebo
time
TASK SESSION
MODELLED DATA
block contrasts
methamphetamine
contrasts
lithium contrast
Figure 4.3: Schematic representation of the levels of contrasts in the MRC LAMP study. Subjects
underwent investigation on two days (1 and 2; before and after lithium or placebo), each
comprising a functional series pre- and post-methamphetamine (A and B). First level analysis
modelled the order of presentation of blocks, allowing RVIP task condition (T) and control task (C)
conditions to be specified. Subtraction contrasts T−C (RVIP−Control) were entered into the second
level analysis, in which the effects of medication across the various sessions were examined.
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4.5 results – clinical variables
4.5.1 Subject characteristics
Twenty four subjects were enrolled into the study, 18 of whom received lithium and 6
placebo.e characteristics of those completing the study are given in table 4.1 (page
96), with the ow of subjects shown in the consort diagram below (gure 4.4).e
subjects in the placebo and lithium groups did not dier in age, handedness, body
mass index, or estimates of intelligence (nart score). As the majority of subjects were
university or college students, the average duration of education was long; the groups
diered in this respect (one-way anova between the three groups: 2 df, f = 3.56, p
= 0.047), post-hoc comparison demonstrating a dierence between the placebo and
lower dose lithium group (18.0 ± 2.4 versus 15.2 ± 2.4, Tukey’s hsd p = 0.044).
Not suitable for inclusion
Left-handed (n = 12)
Stimulant use (n = 3)
Medical/MRI reasons (n = 5)
Concerned about effects (n = 3)
Reason not given (n = 84)
Excluded
Medical reasons (n = 1)
Admitted drug use (n = 1)
Scanner upgrade (n = 3)
RECRUITMENT
ENROLMENT
ASSESSMENT
RANDOMISATION
Assessed for eligibility
(n = 136)
Screening and training
(n = 29)
fMRI session one
First methamphetamine
(n = 24)
Lower dose lithium
Target level 0.5 mM
(n = 9)
No subjects lost to follow-up
Data collection complete
Higher dose lithium
Target level 0.9 mM
(n = 9)
No subjects lost to follow-up
VAS incomplete for 2 subjects
Placebo
(n = 6)
No subjects lost to follow-up
Data collection complete
Figure 4.4: CONSORT diagram for the MRC-LAMP study.
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placebo group lithium groups
lower dose higher dose
characteristics
Age (years) 25.4 ± 4.0 23.3 ± 5.5 21.2 ± 1.8
Body mass index (kg/m2) 24.3 ± 2.1 24.4 ± 2.1 24.6 ± 2.3
Handedness (right centile) 88.3 ± 15.1 80.0 ± 12.5 81.7 ± 12.5
Length of education (years) 18.0 ± 2.4 15.2 ± 2.4 15.8 ± 1.3
National Adult Reading Test 32.5 ± 5.0 35.2 ± 6.5 35.8 ± 3.6
Alcohol (units per week) 18.3 ± 9.1 17.4 ± 9.6 19.1 ± 14.8
Caeine (cups per day) 1.5 ± 1.1 1.2 ± 0.8 1.6 ± 1.8
Cigarettes (per day) 0.0 ± 0.0 0.6 ± 1.7 1.3 ± 1.9
treatment details
Duration of treatment (days) 10.2 ± 1.5 10.4 ± 1.6 10.2 ± 1.6
Side eects (lisers score) 1.3 ± 1.5 2.0 ± 2.2 5.4 ± 5.7
Priadel™dose (mg per day) — 911 ± 226 1511 ± 203
Serum lithium level (mm) — 0.44 ± 0.18 0.85 ± 0.25
Table 4.1: Descriptive statistics (mean ± sd) according to group, for the subject characteristics and
medication administered in themrc-lamp study. Formal statistical comparisons are presented in the
body of the text. Lithium group: higher dose (n = 9), lower dose (n = 9); placebo group (n = 6).
4.5.2 Medication regimes
By self-report, subjects took their tablets on the majority of days, with no individual
missing more than one dose.e mean duration of the course of tablets was 10.3 ±
1.5 days (all subjects, n = 24), with no dierence between the groups. In those who
received lithium, this resulted in a mean serum level of 0.65 ± 0.3 mm (all subjects on
lithium, n = 18).ose randomised to receive a higher dose of lithium had greater
serum concentrations of lithium than the lower dose group (high dose group 0.85 ±
0.25 versus low dose group 0.44 ± 0.18 mm ; 2-sample t-test : 16 df, t 3.93, p < 0.001).
Side eects from the lithium/placebo tablets were few and rarely more than mild
on the lisers. A one-way between-group anova of the lisers scores showed a trend-
level dierence (2 df, f = 3.56, p = 0.091), ratings numerically greatest in the higher
dose lithium group. On no occasion were side eects sucient to prevent a subject
from completing their course, and no serious adverse events were reported. All
subjects tolerated the methamphetamine injections, with no adverse events observed.
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4.6 results – neuropsychological
4.6.1 Sustained attention – practice eects
A complete series of results from the three training sessions was available for 23 of
the 24 subjects, one not completing the second practice due to personal time con-
straints. For all measures, data from at least one session did not conform to a Gaussian
distribution; for ease and uniformity, nonparametric tests were applied in all instances.
practice sessions fmri
p1 p2 p3 1a
rvip task condition
Hit rate (%) 67 ± 13 71 ± 16 78 ± 13 82 ± 14
False alarm rate (%) 0.50 ± 0.7 0.84 ± 1.4 0.55 ± 0.7 0.32 ± 0.4
Sensitivity index (A′) 0.91 ± 0.04 0.92 ± 0.06 0.94 ± 0.04 0.95 ± 0.04
Median response latency (ms) 398 ± 67 379 ± 49 358 ± 50 347 ± 46
control condition
Hit rate (%) 87 ± 6 87 ± 6 84 ± 7 90 ± 5
False alarm rate (%) 0.10 ± 0.2 0.10 ± 0.2 0.13 ± 0.2 0.10 ± 0.2
Sensitivity index (A′) 0.97 ± 0.02 0.97 ± 0.02 0.96 ± 0.02 0.98 ± 0.01
Median response latency (ms) 416 ± 35 424 ± 40 426 ± 40 426 ± 43
Table 4.2: Descriptive analysis of performance in those completing all practice sessions (n = 23).
within-subject comparisons
Summarising the analyses presented in this section, performance improved over
the course of the three training sessions, stabilising by the time subjects entered the
fmri study proper (see table 4.2 above). For the control condition, performance was
generally stable with only minor uctuations in the measures during training.us,
manipulation of performance on the tasks with methamphetamine was considered to
reect a change from a stable baseline. For the within-subject comparisons reported
here, the Friedman repeated measures analysis entailed six comparisons; to maintain
an overall alpha level of 0.05, signicance was ascribed at z ⩾ 2.63 (2-sided), p < 0.008.
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RVIP task condition Hit rate on the rvip task condition diered over the sessions
(Friedman test: χ-square 37.3, df 3, p < 0.001), increasing with practice. Post-hoc
analysis controlling formultiple comparisons revealed a signicant dierence between
the rst and last training sessions (67 ± 13 versus 78 ± 13; z −3.88, 23 ranks, p < 0.001),
but no dierence between the nal training and the baseline fmri session. False alarm
rates were low and somewhat variable, the dierence detected across the sessions
(Friedman test: χ-square 14.3, df 3, p = 0.003) due to the contrast between practice
two and 1a (0.84 ± 1.4 versus 0.32 ± 0.4; z −2.64, 23 ranks, p = 0.008), there being no
change between the nal practice and the rst scan session. As expected, the increase
in A′ closely matched that of the hit rate (Friedman test: χ-square 36.1, df 3, p < 0.001;
practice one versus three: 0.91 ± 0.04 versus 0.94 ± 0.04; z −3.89, 23 ranks, p < 0.001).
e average median response latency reduced by approximately 20 ms with each
practice; not signicant per increment but highly signicant overall (practice one to
three: 398 ± 67 versus 358 ± 50; z −3.41, 23 ranks, p = 0.001). Again, there was no
signicant dierence between the last practice and the rst fmri session.
Control task condition Stability of performance in the control task condition was
anticipated; it was observed for median response latency (Friedman test: χ-square
4.1, df 3, p = 0.26), false alarm rates (Friedman test: χ-square 2.2, df 3, p = 0.54) and
to a lesser degree for hit rates (Friedman test: χ-square 7.6, df 3, p = 0.06). For the
sensitivity index, A′, performance was equivalent in the rst two trials only, diering
between the sessions because of a relatively poor performance during practice three
(Friedman test: χ-square 12.7, df 3, p = 0.005).is translated to an increase when the
A′ data from the baseline scan session was compared to that from the nal practice
run (0.96 ± 0.02 versus 0.98 ± 0.01; z −3.42, 23 ranks, p < 0.001).
between-task comparisons
Comparing the control and rvip task conditions, the hit rate and A′ scores were
higher, with false alarm rates lower for the control task during practices one, two and
the rst fmri session (z < −3, 23 ranks, p < 0.005 in all instances).e signicance
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was absent or diminished in the nal training run (rvip task compared to control
condition: hit rate z −1.56, 23 ranks, p = 0.12; false alarm rate z −2.31, 23 ranks, p
= 0.02; sensitivity index z −1.57, 23 ranks, p = 0.12). e average median response
latency was signicantly longer in the control condition during practices two, three
and the initial scan session, but not practice one (rvip task condition versus control
condition, practice one: 398 ± 67 versus 416 ± 35; z −1.66, 23 ranks, p = 0.097).
4.6.2 Sustained attention and methamphetamine
within-group comparison
In order to gauge the eects of methamphetamine on sustained attention, subjects
were analysed as a single group with performance on all parameters compared before
and aer methamphetamine for both the rvip and control task conditions.e mean
values and analysis outcomes are presented in table 4.3, on the page that follows.e
mostmarked eect was on response times, the averagemedian response latency for the
group falling by approximately 30 ms aer methamphetamine in both task conditions.
False alarm rate increased aer methamphetamine in the rvip task condition but not
in the control condition, whilst hit rate and A′ were unaltered.
response time threshold
e eects of methamphetamine were largely as expected but the consistency in
the reduction of response times raised an important point: if subjects were reacting
more swily, could the threshold for the acceptance of responses be inappropriate? A
threshold for acceptable response times is applied because there is a limit to how fast
an individual can actually process a stimulus (see §3.2.1), with very swi responses
usually representing chance occurrences or pre-emptive strikes. During the rvip task
condition subjects may be tempted to guess at correct responses, anticipating the
completion of sequences; not so for the control condition in which response latency is
a purer test of reaction time and criterion checking. A threshold of 125ms is commonly
used, the assumption being that it is unrealistic to expect or believe that a subject could
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task performance wilcoxon s-r test
1a 1b ranks Z p
rvip task condition
Hit rate (%) 82 ± 14 83 ± 12 24 − 1.11 .268
False alarm rate (%) 0.30 ± 0.4 0.52 ± 0.6 24 − 2.16 .030
Sensitivity index (A′) 0.95 ± 0.04 0.96 ± 0.03 24 − 0.85 .394
Median response latency (ms) 347 ± 45 312 ± 32 24 − 3.97 .000
control condition
Hit rate (%) 89 ± 5 89 ± 8 24 − 0.21 .833
False alarm rate (%) 0.13 ± 0.2 0.12 ± 0.2 24 − 0.09 .928
Sensitivity index (A′) 0.98 ± 0.01 0.97 ± 0.02 24 − 1.08 .281
Median response latency (ms) 427 ± 42 400 ± 36 24 − 3.76 .000
Table 4.3: Within-group analysis of all subjects (n = 24) using the Wilcoxon Signed Ranks test to
compare task performance pre (1a) and post (1b) methamphetamine (before the course of either
lithium or placebo). Methamphetamine hastens responses and increases false alarm rates.
detect and respond to a stimulus in that time.e nding that methamphetamine
reduced the response latency across the rvip task and control conditions cast a doubt,
suggesting a genuine hastening of reaction times. If upheld, valuable data may be
being disregarded through the application of the standard threshold.
Exploring this matter, the data was re-examined using a lower threshold of 100
ms. e pattern of dierences between the pre- and post-methamphetamine con-
ditions was largely maintained, but false alarm rates no longer diered. In the data
from sessions 1a and 1b, setting the threshold at 125 and 100 ms excluded 33 and 18
responses respectively. Of the responses preserved by lowering the threshold, the
majority were in the rvip task condition and mostly aer methamphetamine had
been given (see table 4.4). Whilst this would support a lowering of the threshold
to embrace the hastened response times, an alternative explanation requires consid-
eration – that subjects became ‘trigger happy’. In keeping with this interpretation,
the more inclusive 100 ms threshold yielded a greater false alarm rate; subjects were
guessing incorrectly as well as correctly responding.is occurrence could be due to
the stimulant changing the subjects’ response style, but the proportion of responses
excluded from sessions 1a and 1b was similar for each threshold.us, lowering the
100
125 ms threshold 100 ms threshold
excluded responses 1a 1b 1a 1b
rvip task condition 4 26 2 14
control task condition 1 2 1 1
Table 4.4: When analysing task data a threshold is applied in order to exclude responses which reect
the anticipation of the completion of a sequence. Lowering the threshold to 100 ms permitted the in-
clusion of more responses, but the proportions pre- and post-methamphetamine remain unchanged.
threshold to 100 ms permitted the inclusion of guessed responses without specically
gauging an anticipated eect of methamphetamine. It was concluded that the 100 ms
threshold was inappropriate and all data was analysed with a 125 ms threshold.
4.6.3 Sustained attention and medication combinations
Aer establishing a stable level of performance that was open to manipulation with
methamphetamine, the hypothesis that lithium would attenuate the eects of the
stimulant on sustained attention was examined.e neuropsychological task data
from all 24 subjects was suitable for analysis, divided a priori into groups. Six subjects
received placebo and 18 took lithium, with equal numbers in the high and low dose
groups. For all measures the group data from at least one session in the envisaged
comparisons did not conform to a Gaussian distribution and so nonparametric tests
were applied in all instances.
within-group comparisons
In the rst instance, a within-group analysis across sessions for each measure of task
performance on the rvip and control conditions was performed using the Friedman
test, the results of which are presented in tables 4.5 and 4.6. Where indicated, post-hoc
analysis was undertaken using the Wilcoxon signed-rank test (table 4.7), with the
number of comparisons restricted to three: 1a versus 1b; 2a versus 2b; 1a versus 2a.
e results are described below and depicted in gures 4.5 to 4.10 (pages 105–106).
With three comparisons, Bonferroni correction maintaining an overall alpha level of
0.05 ascribes signicance at z ⩾ 2.39 (2-sided), p < 0.017.
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rvip task performance friedman
1a 1b 2a 2b df χ2 p
median rl
Placebo 347 ± 25 306 ± 18 337 ± 26 307 ± 34 3 12.20 .007
Lithium · all 348 ± 51 315 ± 35 361 ± 42 338 ± 37 3 25.13 .000
· low 340 ± 34 318 ± 37 359 ± 46 335 ± 40 3 11.53 .009
· high 356 ± 65 311 ± 35 364 ± 41 342 ± 35 3 15.00 .002
hit rate
Placebo 80 ± 17 85 ± 14 83 ± 13 89 ± 10 3 9.87 .020
Lithium · all 82 ± 13 83 ± 11 77 ± 16 81 ± 17 3 8.84 .032
· low 80 ± 16 81 ± 12 75 ± 19 79 ± 21 3 6.72 .081
· high 84 ± 8 85 ± 11 78 ± 14 83 ± 12 3 2.59 .460
false alarm rate
Placebo 0.33 ± 0.5 0.67 ± 1.0 0.17 ± 0.4 0.33 ± 0.5 3 5.40 .145
Lithium · all 0.29 ± 0.4 0.48 ± 0.3 0.29 ± 0.5 0.44 ± 0.6 3 5.08 .166
· low 0.42 ± 0.4 0.51 ± 0.3 0.46 ± 0.7 0.71 ± 0.7 3 2.23 .526
· high 0.17 ± 0.2 0.44 ± 0.4 0.12 ± 0.2 0.17 ± 0.4 3 4.93 .177
sensitivity index
Placebo 0.95 ± 0.05 0.96 ± 0.04 0.96 ± 0.03 0.97 ± 0.07 3 6.52 .089
Lithium · all 0.95 ± 0.03 0.96 ± 0.03 0.94 ± 0.04 0.95 ± 0.04 3 7.16 .067
· low 0.95 ± 0.04 0.95 ± 0.03 0.93 ± 0.05 0.95 ± 0.05 3 5.53 .137
· high 0.96 ± 0.02 0.96 ± 0.03 0.95 ± 0.03 0.96 ± 0.03 3 2.06 .561
Table 4.5: Group analysis for performance in the rvip task condition. Data presented as mean ±
sd, arranged by fmri session (dened in §4.4.4). Response latency in ms, hit rate and false alarm
rate as percentage.e Friedman test being the nonparametric equivalent of an anova, the post-hoc
comparisons are presented in the text.
Placebo group (n = 6) In the rvip task condition, the average median response la-
tency was reduced by methamphetamine before (1a versus 1b: z −2.20, p = 0.028)
and aer (2a versus 2b: z −2.20, p = 0.028) the course of placebo tablets, but the
dierence was not considered signicant aer correction for multiple comparisons.
Withmethamphetamine, hit rates did not change signicantly on either day (1a versus
1b: z −1.83, p = 0.068; 2a versus 2b: z −1.89, p = 0.058), the trend level dierences ex-
plaining the Friedman results which prompted the post-hoc comparison. Groupmean
response times and accuracy measures did not dier for the pre-methamphetamine
rvip task condition before and aer placebo (1a versus 2a), indicating a return to
a stable baseline performance between the assessment days. Post-hoc comparisons
were not indicated for false alarm rates or A′ in the rvip task condition, nor any of
the control task measures.
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control task performance friedman
1a 1b 2a 2b df χ2 p
median rl
Placebo 405 ± 44 381 ± 36 402 ± 41 392 ± 38 3 4.20 .241
Lithium · all 434 ± 40 407 ± 35 438 ± 42 412 ± 43 3 31.27 .000
· low 436 ± 40 420 ± 34 445 ± 38 430 ± 46 3 10.73 .013
· high 433 ± 43 394 ± 32 432 ± 47 395 ± 33 3 22.47 .000
hit rate
Placebo 91 ± 4 93 ± 4 92 ± 5 91 ± 9 3 1.02 .797
Lithium · all 89 ± 6 87 ± 9 88 ± 7 87 ± 9 3 0.19 .979
· low 88 ± 6 86 ± 9 86 ± 8 86 ± 9 3 0.38 .945
· high 90 ± 5 88 ± 8 91 ± 7 91 ± 9 3 0.45 .930
false alarm rate
Placebo 0.11 ± 0.2 0.15 ± 0.3 0.07 ± 0.1 0.15 ± 0.1 3 1.38 .711
Lithium · all 0.14 ± 0.2 0.11 ± 0.1 0.25 ± 0.4 0.22 ± 0.3 3 2.30 .513
· low 0.15 ± 0.3 0.07 ± 0.1 0.32 ± 0.5 0.20 ± 0.4 3 2.87 .413
· high 0.12 ± 0.1 0.15 ± 0.2 0.17 ± 0.3 0.24 ± 0.3 3 1.01 .797
sensitivity index
Placebo 0.98 ± 0.01 0.98 ± 0.01 0.97 ± 0.02 0.98 ± 0.03 3 1.47 .690
Lithium · all 0.97 ± 0.02 0.97 ± 0.02 0.97 ± 0.02 0.97 ± 0.02 3 2.03 .567
· low 0.97 ± 0.02 0.97 ± 0.02 0.96 ± 0.02 0.97 ± 0.02 3 2.73 .435
· high 0.97 ± 0.01 0.97 ± 0.02 0.98 ± 0.02 0.98 ± 0.01 3 0.87 .833
Table 4.6: Group analysis for performance in the control task condition. Data presented as mean± sd, arranged by fmri session (dened in §4.4.4). Response latency in ms, hit rate and false alarm
rate as percentage.e Friedman test being the nonparametric equivalent of an anova, the post-hoc
comparisons are presented in the text.
Combined lithium group (n = 18) e average mean response latency in the rvip
task and control conditions shortened with methamphetamine on the rst test day
(1a versus 1b: rvip task z −3.29, p = 0.001; control task z −3.29, p = 0.001). Aer
the course of lithium the reduction in response time induced by methamphetamine
remained and although somewhat diminished, the dierence withstood correction
for multiple comparisons (2a versus 2b: rvip task z −2.77, p = 0.006; control task
z −2.72, p = 0.006). Mean hit rates in the rvip task condition did not alter with
methamphetamine before or aer the administration of lithium (1a versus 1b: z −0.60,
p = 0.550; 2a versus 2b: z −1.90, p = 0.057). Examining the eects of lithium itself
on the rvip task condition (1a versus 2a), the average median response latency was
prolonged (z −2.46, p = 0.014) and the hit rate lower (z −2.59, p = 0.009) following
the course of tablets.
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wilcoxon signed-rank
1a vs 1b 2a vs 2b 1a vs 2a
placebo group
rvip task · median response latency z −2.20 −2.20 −0.73
p .028 .028 .463
· hit rate z −1.83 −1.89 −1.23
p .068 .058 .221
lithium group – all subjects
rvip task · median response latency z −3.29 −2.77 −2.46
p .001 .006 .014
· hit rate z −0.59 −1.90 −2.59
p .550 .057 .009
control · median response latency z −3.29 −2.72 −0.89
p .001 .006 .372
lithium group – higher dose
rvip task · median response latency z −2.55 −2.07 −1.48
p .011 .038 .139
control · median response latency z −2.67 −2.67 −0.18
p .008 .008 .859
lithium group – lower dose
rvip task · median response latency z −2.07 −1.72 −1.96
p .038 .086 .051
control · median response latency z −1.84 −1.24 −1.24
p .066 .214 .214
Table 4.7: Post-hoc analysis for the Friedman tests performed in tables 4.5 and 4.6.
High dose lithium group (n = 9) e average mean response latency in the rvip task
condition shortened with methamphetamine on the rst test day (1a versus 1b: rvip
task z −2.55, p = 0.011). Controlling for multiple comparisons, the lesser reduction in
subjects’ response times following a high dose of lithium failed to reach signicance
(2a versus 2b: rvip task z −2.07, p = 0.038). For the control task condition, the
reduction in the group mean response latency was marked and comparable during
both assessment days. In this smaller group of subjects, lithium alone was no longer
seen to prolong rvip task condition response times (1a versus 2a: z −1.48, p = 0.139).
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Figure 4.5: Median response latency in the RVIP task condition. Placebo versus combined
lithium group values (mean ± sd) ordered by fMRI session (1A to 2B defined in section 4.4.4).
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Figure 4.6: Hit rates in the RVIP task condition. Placebo versus combined lithium group values
(mean ± sd) ordered by fMRI session (1A to 2B defined in section 4.4.4).
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Figure 4.7: False alarm rates in the RVIP task condition. Placebo versus combined lithium
group values (mean ± sd) ordered by fMRI session (1A to 2B defined in section 4.4.4).
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Figure 4.8: Median response latency in the control task condition. Placebo versus combined
lithium group values (mean ± sd) ordered by fMRI session (1A to 2B defined in section 4.4.4).
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Figure 4.9: Hit rates in the control task condition. Placebo versus combined lithium group
values (mean ± sd) ordered by fMRI session (1A to 2B defined in section 4.4.4).
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Figure 4.10: False alarm rates in the control task condition. Placebo versus combined lithium
group values (mean ± sd) ordered by fMRI session (1A to 2B defined in section 4.4.4).
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Low dose lithium group (n = 9) e results of the Friedman test showed that post-
hoc analysis was indicated for mean response latency in the rvip task and control
conditions. Adjusting signicance thresholds to control for multiple testing, no
signicant dierences emerged in any of the comparisons.
incremental change
A subsidiary analysis was undertaken comparing the percentage change in perfor-
mance brought about by methamphetamine during the separate fmri sessions for
each group.e percentage change was calculated using equation 4.4.
percentage change = value aer − value before
value before
× 100 (4.4)
e percentage change in themedian response latencywas examined in the groups,
separately for those randomised to receive placebo or lithium (subjects allocated to
higher and lower doses were combined for this analysis). e methamphetamine-
related reduction in median response latency was numerically smaller aer subjects
had taken the course of tablets, but not signicantly so on within-group analysis
(assessment day 1 versus assessment day 2: placebo group − 11.4% ± 5.9 versus − 9.0%± 4.4, z −0.94, 6 ranks, p = 0.345; lithium group − 8.8% ± 8.0 versus − 6.1% ± 8.4, z−1.42, 18 ranks, p = 0.157). A between-group comparison (placebo versus lithium)
showed no dierence in the percentage change in median response latency on either
occasion (assessment day 1: z −0.40, p = 0.721; assessment day 2: z −.867, p = 0.415).
When all the subjects who received lithium were analysed, the percentage change
in hit rate induced by methamphetamine was greater aer the course of lithium than
before (assessment day 1 versus assessment day 2: 1.75% ± 10.7 versus 7.84% ± 18.5, z−2.37, 18 ranks, p = 0.18). Such a dierence was not observed in the placebo group
(assessment day 1 versus assessment day 2: 7.16% ± 11.7% versus 8.58 ± 12.3, z −2.37, 18
ranks, p = 0.018). Between-group comparisons showed no dierence between those
receiving lithium or placebo on either day.
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4.7 results – subjective measures
4.7.1 Subjective ratings
A complete set of results from the vas ratings of mental state was available for 22
subjects, with two subjects excluded because of missing data on the second assessment
day (both subjects received lithium). By way of clarication, the data collection points
of 45, 90 and 135 minutes refer to the time aer methamphetamine injection with
the baseline assessment performed sometime during the hour before the scan began.
e raw values grouped at these time points conformed to a Gaussian distribution
and were analysed using a within-group comparison (anova: vas scores at baseline
and 45, 90, and 135 minutes post-methamphetamine; separately for the lithium and
placebo groups) followed by post-hoc testing controlling for multiple comparisons
(Tukey’s hsd test) with signicance ascribed at α = 0.05. When a dierence between
the baseline and a post-methamphetamine score emerged in post-hoc testing, the
increment and the percentage change was calculated for each subjects. At the group
level a comparison was made with the values between the same time points on the
other study day using a paired t-test. If a dierence to baseline was found at more
than one time point, 45 and 90 minutes for example, a single comparison was made
using the baseline to maxima.
Note that in terms of the anticipated eects of methamphetamine, the poles of Raw scores equate
to the distance from
the le end of the
line to the subject’s
mark. Consider the
rst two parameters,
alert–drowsy and
calm–excited. On
the rating sheet,
alert is on the le
and excited on the
right. A mark on
alert–drowsy at 30
mm would become
a score of 70, with
the vas domain
description altered
to drowsy–alert.
the individual vas domains can be considered as counterbalanced. Aer a stimulant,
subjects are likely to place marks close to the anchors that convey a higher state of
arousal.e relevant anchors fall at alternating poles of the score line so that subjects
must consider each response rather than repeatedly placing marks on the same side
of the page. To aid analysis and discussion, some vas domains were reordered by
inversion so that in all instances the pro-stimulant anchor represented the higher
value.e order in which the domains are presented follows the arrangement of the
vas and not themagnitude of the ndings.e vas scores are expressed inmillimetres
(mm), with group data presented as the mean ± sd unless otherwise stated.
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lithium group placebo group
scan 1 scan 2 scan 1 scan 2
vas measure (reordered) F p F p F p F p
drowsy—alert 7.81 .000 4.26 .009 0.41 .749 4.59 .013
calm—excited 3.46 .022 0.48 .693 0.31 .822 0.21 .889
feeble—strong 1.74 .168 2.42 .075 1.05 .392 2.77 .068
muzzy—clear headed 3.31 .026 1.58 .203 0.44 .724 2.05 .139
clumsy—well co-ordinated 0.63 .600 0.91 .440 1.82 .176 0.60 .626
lethargic—energetic 6.33 .001 2.06 .115 0.46 .715 3.30 .041
discontented—contented 0.34 .797 1.79 .160 0.57 .642 1.42 .268
troubled—tranquil 0.35 .787 0.23 .873 0.68 .575 0.27 .848
mentally slow—quick witted 6.97 .000 2.87 .044 2.12 .130 2.31 .107
tense—relaxed 0.97 .406 0.507 .679 0.48 .699 0.12 .945
dreamy—attentive 1.57 .207 1.02 .392 0.43 .733 1.88 .166
incompetent—proficient 5.21 .003 1.60 .200 0.35 .793 0.37 .777
sad—happy 0.53 .667 0.81 .494 0.85 .482 0.64 .600
antagonistic—amicable 0.48 .696 0.12 .950 0.27 .849 0.50 .688
bored—interested 0.64 .592 1.37 .262 0.18 .911 0.49 .693
withdrawn—gregarious 3.47 .022 1.57 .206 0.43 .732 0.34 .795
Table 4.8: Visual analogue scale scores spanning the period of methamphetamine administration
submitted to anova. Results are presented for placebo and lithium groups, before and aer the period
on medication.
lithium group
Initially, seven vas domains were sensitive to the eects of methamphetamine but
aer subjects received lithium, the dierence in scores emerged for only two of these
domains.e level of signicance diminished for both measures and no new domains
emerged as signicant on the second assessment day (see table 4.8 above).
Drowsy—Alert On the rst study day there was a dierence between baseline and 45
minutes (61.3 ± 18.0 versus 85.9 ± 7.7, p < 0.000), 45 and 90 minutes (85.9 ± 7.7 versus
72 ± 13.7, p = 0.050), and 45 to 135 minutes (85.9 ± 7.7 versus 72.1 ± 16.1, p = 0.042).
e ndings were upheld on the second study day for baseline and 45 minutes (56.5 ±
24.5 versus 77.8 ± 15.2, p = 0.008) and baseline to 90 minutes only (56.5 ± 24.5 versus
73.6 ± 15.4, p = 0.046); see gure 4.11 on page 110.ere was no signicant dierence
in the baseline to 45 minute increment or percentage change in score, before and
aer lithium (increment in mm: 25.6 ± 19 versus 21.3 ± 22, t 0.91, 15 df, p = 0.378;
percentage change: 57.7 ± 71 versus 61.3 ± 75, t −0.32, 15 df, p = 0.754).
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Figure 4.11: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the alert−drowsy domain, before and after the course of lithium.
∗
ba
se
lin
e
po
st
45
po
st
90
po
st
13
5
PRE-LITHIUM
methamphetamine
ba
se
lin
e
po
st
45
po
st
90
po
st
13
5
POST-LITHIUM
methamphetamine
EXCITED
CALM
Higher scores indicate
a greater sense
of excitement.
VA
S
sc
or
e
(m
m
)
0
20
40
60
80
100
∗ p < 0.000 versus 45 mins
Note: baseline versus 45 mins; p = 0.07
Figure 4.12: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the calm−alert domain, before and after the course of lithium. This significant difference
indicated by the asterisk pertains to the decrease in scores between the 45 and 135 minute time
points.
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Calm—Excited In the post-hoc analysis, the only comparison to emerge as signicant
on the rst day was between 45 and 135 minutes (61.2 ± 26.1 versus 39.3 ± 20.5, p =
0.022), though a trend-level dierence was observed between baseline and 45 minutes
(42.7 ± 15.4 versus 61.2 ± 26.1, p = 0.070); see gure 4.12 on the previous page.ere
was a signicant dierence in the baseline to 45 minute increment before and aer
lithium (18.5 ± 26 versus 4.69 ± 24, t 2.31, 15 df, p = 0.036), consistent with lithium
attenuating the eects ofmethamphetamine.is was not upheldwhen the percentage
change in vas score was examined, before and aer lithium (54.0 ± 71 versus 31.2 ± 77,
t 1.00, 15 df, p = 0.332).
Muzzy—Clear-headed Followingmethamphetamine, subjects reported feelingmore
clear-headed, with baseline scores diering to those at 90 minutes only (56.6 ± 18.7
versus 73.9 ± 16.3, p = 0.018).e dierence was no longer present when metham-
phetamine was given aer the course of lithium carbonate (see gure 4.13 on the
following page). ere was no signicant dierence in the baseline to 90 minute
increment or percentage change in score, before and aer lithium (increment in mm:
17.3 ± 18 versus 14.5 ± 20, t 0.55, 15 df, p = 0.593; percentage change: 42.6 ± 57 versus
53.2 ± 83, t −0.70, 15 df, p = 0.492).
Lethargic—Energetic Subjects felt energised aer rst receiving methamphetamine;
compared to baseline scores, ratings were higher at 45 minutes (50 ± 19.7 versus 77.3± 17.2, p < 0.000) and 90 minutes (50 ± 19.7 versus 67.8 ± 21.0, p = 0.035), but not
thereaer.is pattern apparently dampened post-lithium.ere was a trend level
dierence in the baseline to 45 minute increment before and aer lithium (27.3 ± 26
versus 14.8 ± 24, t 1.97, 15 df, p = 0.068), consistent with lithium attenuating the eects
of methamphetamine (gure 4.14 on the following page). No dierence was observed
in the percentage change in vas between these time points, before and aer lithium
(79.5 ± 83 versus 79.9 ± 152, t −0.02, 15 df, p = 0.988).
111
∗
ba
se
lin
e
po
st
45
po
st
90
po
st
13
5
PRE-LITHIUM
methamphetamine
ba
se
lin
e
po
st
45
po
st
90
po
st
13
5
POST-LITHIUM
methamphetamine
VA
S
sc
or
e
(m
m
)
0
20
40
60
80
100
CLEAR-HEADED
MUZZY
Higher scores indicate
that the subject felt
clear-headed.
∗ p = 0.018 versus baseline
Figure 4.13: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the muzzy−clear-headed domain, before and after the course of lithium.
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Figure 4.14: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the lethargic−energetic domain, before and after the course of lithium.
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Mentally slow—Quick-witted Compared to baseline on the rst day, ratings swung
toward the quick-witted anchor with methamphetamine, reaching signicance at
45 minutes (57.6 ± 16.2 versus 81.5 ± 16.5, p < 0.000) and 90 minutes (57.6 ± 16.2
versus 72.4 ± 14.0, p = 0.040).e values during the nal vas rating approximated to
baseline scores, resulting in a signicant reduction when the 45 minute assessment
was compared to 135 minutes (81.5 ± 16.5 versus 65.8 ± 14.7, p = 0.026).e anova
applied to the data from the second assessment day indicated a signicant eect
of methamphetamine, but post-hoc analysis revealed only trend-level dierences
between baseline and 45 minutes (55 ± 23.7 versus 71 ± 14.5, p = 0.067), and baseline
to 135 minutes (55 ± 23.7 versus 71.1 ± 15.0, p = 0.066); see gure 4.15. ere was
no dierence in the baseline to 45 minute increment or percentage change in score,
before and aer lithium (increment in mm: 24.9 ± 22 versus 15.8 ± 23, t 1.22, 15 df, p =
0.240; percentage change: 53.6 ± 60 versus 61.9 ± 102, t −0.37, 15 df, p = 0.714).
Incompetent—Procient Following methamphetamine, subjects reported feeling
more procient; compared to baseline, ratings were signicantly higher at 45 minutes
(57.8 ± 19.7 versus 78.1 ± 16.1, p = 0.002) and 90 minutes (57.8 ± 19.7 versus 73.8 ± 11.8,
p = 0.023), sustained to a trend-level at 135 minutes (57.8 ± 19.7 versus 71.6 ± 12.7, p =
0.066). No signicant dierences were found on day two (gure 4.16).ere was no
signicant dierence in the baseline to 45 minute increment or percentage change in
score, before and aer lithium (increment in mm: 20.1 ± 18 versus 13.0 ± 20, t 1.42, 15
df, p = 0.175; percentage change: 50.2 ± 58 versus 34.4 ± 54, t 0.97, 15 df, p = 0.714).
Withdrawn—Gregarious Comparing baseline scores to those following metham-
phetamine, subjects felt more outgoing at 45 minutes only (61.8 ± 13.5 versus 77.3 ± 15.5,
p = 0.016). No dierence was observed between any of the assessments performed
aer the course of lithium carbonate (gure 4.17 on page 115).ere was no signicant
dierence in the baseline to 45minute increment or percentage change in score, before
and aer lithium (increment in mm: 15.4 ± 13 versus 10.7 ± 16, t 1.01, 15 df, p = 0.329;
percentage change: 27.8 ± 27 versus 26.2 ± 43, t 0.13, 15 df, p = 0.897).
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Figure 4.15: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the quick-witted−mentally slow domain, before and after the course of lithium.
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Figure 4.16: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the proficient−incompetent domain, before and after the course of lithium.
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Figure 4.17: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the gregarious−withdrawn domain, before and after the course of lithium.
placebo group
In the placebo group, dierences in vas scores attributable to methamphetamine were
found only aer the course of tablets, and for just two domains (table 4.8; page 109).
Drowsy—Alert On the second assessment only, methamphetamine increased feel-
ings of alertness; compared to baseline, ratings were higher at 45 minutes (51.8 ± 22.7
versus 83.2 ± 10.6, p = 0.012), sustained to a trend-level at 90 minutes (51.8 ± 22.7
versus 76.2 ± 8.4, p = 0.061); see gure 4.18 on the next page.ere was a trend-level
increase in the baseline to 45 minute increment and percentage score change, before
and aer placebo (increment in mm: 4.50 ± 43 versus 31.5 ± 29, t −2.03, 5 df, p = 0.098;
percentage change: 26.7 ± 92 versus 108.1 ± 133, t −2.08, 5 df, p = 0.092).
Lethargic—Energetic Subjects felt energised receiving methamphetamine on the
second occasion; compared to baseline scores, ratings were higher at 45 minutes (52.4± 24.4 versus 78.4 ± 10.6, p = 0.04), but not thereaer (gure 4.19; page 116).ere
was no dierence in the baseline to 45 minute increment or percentage change in
score, before and aer placebo (increment in mm: 0.17 ± 39 versus 25.7 ± 24, t −1.76, 5
df, p = 0.138; percentage change: 15.3 ± 77 versus 256.6 ± 560, t −1.07, 5 df, p = 0.334).
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Figure 4.18: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the alert−drowsy domain, before and after the course of placebo. Unlike the lithium group,
significant differences emerged on the second assessment day, after the course of placebo.
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Figure 4.19: Visual analogue scale scores (mean ± sd) spanning methamphetamine administration
for the energetic−lethargic domain, before and after the course of placebo. Unlike the lithium
group, significant differences emerged on the second assessment day, after the course of placebo.
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4.8 results – functional imaging
4.8.1 Main eect of task
In order to establish the main areas of bold activation associated with the rvip task,
the rvip-minus-control contrast data from session 1a for all subjects was submitted
to analysis using a one-sample t-test. Deactivations were generated using the same
rst-level contrasts, but the second-level contrast was multiplied by −1 to create a
control-minus-rvip comparison.
activations
Compared to the control task condition, performing the rvip task resulted in regional
activations in several brain areas, all of which demonstrated a bilateral distribution.
e largest clusters were found in caudal brain regions, notably posterior parietal
(right: 24 · −72 · 54) (le: −26 · −64 · 50) and temporal regions (right: 44 · −64 · 14)
(le: −48 · −72 · 0). Smaller clusters of activation were observed in the dorsolateral
frontal cortex (right: 48 · 2 · 36) (le: −50 · 10 · 30) and the medial aspect of the insula
rostrally (right: 34 · 22 · −2) (le: −28 · 26 · 2).e results of this analysis are presented
in their entirety in table 4.9 on the page that follows.
deactivations
Whilst performing the rvip task condition, certain areas of the brain showed evidence
of deactivation from their state in the control task condition. e most marked
deactivation was in the le inferior parietal lobule (−52 · − 62 · 38), with a more
diminutive cluster apparent on the right (52 · − 76 · 34). Deactivations occurring in
the le hemisphere included the anterior (−8 · 54 · 0) and posterior (−8 · −46 · 34)
regions of the cingulate cortex, and medial aspects of the prefrontal cortex (−8 · 58 ·
34). Comparable changes on the right were not evident.e results of this analysis
are presented in their entirety in table 4.10 on page 119.
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Table 4.9: Main eect of rvip task in all subjects: activations; a random eects model one sample
t-test, SPM{T23}, was applied to all subjects using the rvip-minus-control contrast from session 1a
(family-wise-error correction p < 0.05).e images above depict the clusters rendered onto the icbm152
T1 template (sagittal view to the le of the midline), together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 1906 .000 .000 .001 13.40 7.01 .000 24 –72 54 main effect of task
.000 .001 12.47 6.80 .000 36 –52 48 activations
.000 .016 9.55 6.01 .000 28 –70 40 all subjects
.000 .000 1415 .000 .000 .002 11.64 6.60 .000 –26 –64 50 fwep : 6.210
.000 .012 10.16 6.20 .000 –26 –80 26 fdrp : 8.620
.000 .012 10.14 6.19 .000 –22 –70 54 fwec : 23
.000 .000 1473 .000 .000 .016 9.44 5.98 .000 –48 –72 0 fdrc : 23
.000 .016 9.39 5.98 .000 –40 –64 –10
.000 .032 8.87 5.79 .000 –38 –74 –4
.000 .000 408 .000 .001 .043 8.62 5.70 .000 48 2 36
.001 .070 8.18 5.55 .000 52 6 44
.002 .076 8.02 5.49 .000 56 12 28
.000 .000 274 .000 .001 .057 8.43 5.64 .000 –50 10 30
.022 .440 6.66 4.92 .000 –52 6 40
.000 .000 171 .000 .001 .070 8.17 5.54 .000 28 2 58
.003 .098 7.76 5.39 .000 24 –2 50
.000 .007 130 .000 .001 .070 8.15 5.53 .000 34 22 –2
.000 .000 1119 .000 .002 .070 8.10 5.52 .000 44 –68 –14
.002 .070 8.10 5.52 .000 34 –86 8
.003 .098 7.80 5.40 .000 34 –60 –18
.000 .004 44 .003 .003 .098 7.81 5.41 .000 –28 26 2
.000 .004 41 .004 .009 .220 7.16 5.14 .000 –28 –4 50
.001 .023 23 .023 .018 .392 6.77 4.97 .000 6 14 48
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 6.21, p = 0.000 (0.050) Degrees of freedom = [1.0, 23.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 13.1 12.9 13.3 mm; 6.6 6.4 6.7 voxel
Expected voxels per cluster, <k> = 4.170 Volume: 1319408 = 164926 vox = 540.9 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 281.68 voxel
118
Table 4.10:Main eect of rvip task in all subjects: deactivations; a random eects model one sample
t-test, SPM{T23}, was applied to all subjects using the control-minus-rvip contrast from session 1a
(family-wise-error correction p < 0.05).e images above depict the clusters rendered onto the icbm152
T1 template (sagittal view to the le of the midline), together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 549 .000 .000 .002 11.46 6.56 .000 –52 –62 38 main effect of task
.000 .031 9.23 5.91 .000 –44 –76 34 deactivations
.000 .000 96 .000 .000 .031 8.98 5.83 .000 52 –72 28 all subjects
.014 .457 6.90 5.03 .000 48 –72 36 fwep : 6.210
.000 .001 57 .001 .003 .190 7.79 5.40 .000 –10 44 42 fdrp : 8.964
.014 .457 6.88 5.02 .000 –12 38 50 fwec : 1
.000 .000 166 .000 .004 .191 7.61 5.33 .000 –8 –46 34 fdrc : 57
.000 .001 70 .000 .004 .191 7.53 5.29 .000 –8 54 0
.000 .000 78 .000 .009 .361 7.12 5.12 .000 –8 58 34
.017 .494 6.79 4.98 .000 –20 58 28
.009 .204 7 .181 .023 .550 6.62 4.90 .000 –18 –48 20
.005 .128 11 .099 .027 .593 6.55 4.87 .000 48 –60 22
.032 .627 1 .627 .042 .842 6.30 4.75 .000 –22 –52 10
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 6.21, p = 0.000 (0.050) Degrees of freedom = [1.0, 23.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 13.1 12.9 13.3 mm; 6.6 6.4 6.7 voxel
Expected voxels per cluster, <k> = 4.170 Volume: 1319408 = 164926 vox = 540.9 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 281.68 voxel
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Table 4.11: Eects of methamphetamine in all subjects – ‘post-dose’ minus ‘pre-dose’ (1b − 1a);
results of a random-eects paired t-test incorporating all subjects, SPM{T23}, the rvip-minus-control
contrasts pre-methamphetamine subtracted from those post-methamphetamine (family-wise-error
correction p < 0.05).e accompanying gure shows the clusters in the glass-brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.001 .021 27 .010 .021 .750 6.73 4.95 .000 –44 –76 30 all subjects
.030 .602 1 .602 .044 .883 6.32 4.76 .000 50 –74 24 subtraction
1b − 1a
fwep : 6.256
fdrp :∞
fwec : 1
fdrc : 27
Height threshold: T = 6.26, p = 0.000 (0.050) Degrees of freedom = [1.0, 23.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.5 12.6 12.8 mm; 6.3 6.3 6.4 voxel
Expected voxels per cluster, <k> = 3.672 Volume: 1304488 = 163061 vox = 593.4 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 253.67 voxel
4.8.2 Eects of methamphetamine
e eects of methamphetamine on bold contrast were gauged by analysing the
subjects as a single group.e rvip-minus-control contrasts generated in the rst
level analysis of sessions 1a and 1b were submitted to a random eects analysis using
a paired t-test. At the group level, the rvip-minus-control contrasts before and aer
methamphetamine were compared by specifying two subtraction contrasts: session
1b−1a (post-minus-pre) and session 1a−1b (pre-minus-post). us, the regions of
increased and decreased activation arising from methamphetamine were established.
subtraction analyses
e 1b−1a comparison revealed two suprathreshold clusters; bilaterally in the inferior
parietal lobules, the cluster on the le (−44 · −76 · 30) was larger than that on the right
(50 · −74 · 24); see table 4.11 above.e 1a−1b comparison yielded no dierences.
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Table 4.12: All subjects ‘post’ minus ‘pre’ methamphetamine in a lenient analysis (p < 0.001 unc.);
results of a random-eects paired t-test incorporating all subjects, SPM{T23}, the rvip-minus-control
contrasts pre-methamphetamine subtracted from those post-methamphetamine (p < 0.001 unc.).e
accompanying images depict the clusters rendered onto the icbm152 T1 template (sagittal view to the
le of the midline), together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 773 .000 .021 .169 6.73 4.95 .000 –44 –76 30 all subjects
.259 .394 5.34 4.26 .000 –46 –68 20 subtraction
.001 .001 489 .000 .044 .199 6.32 4.76 .000 50 –74 24 1b−1a
.341 .394 5.16 4.17 .000 48 –60 22 (p < 0.001 unc.)
.207 .100 113 .026 .074 .253 6.05 4.63 .000 –52 –4 8 fwep : 6.256
.001 .001 473 .000 .178 .394 5.56 4.38 .000 –10 56 –2 fdrp :∞
.369 .394 5.11 4.14 .000 –12 48 0 fwec : 473
.609 .401 4.74 3.92 .000 –12 50 12 fdrc : 185
.000 .000 1875 .000 .301 .394 5.24 4.21 .000 –12 –56 8
.379 .394 5.10 4.13 .000 –14 –38 36
.519 .401 4.87 4.00 .000 –14 –40 44
.500 .230 66 .079 .329 .394 5.19 4.18 .000 34 –22 –16
.000 .000 631 .000 .359 .394 5.13 4.15 .000 –38 –22 54
.529 .401 4.85 3.99 .000 –36 –20 44
.634 .401 4.70 3.90 .000 –54 –22 52
.091 .059 157 .011 .398 .394 5.06 4.11 .000 62 –24 40
.935 .707 4.16 3.56 .000 54 –24 36
.981 .834 3.95 3.42 .000 48 –24 30
.150 .078 130 .018 .492 .401 4.91 4.02 .000 14 56 16
.987 .834 3.90 3.38 .000 8 56 10
.055 .041 185 .006 .580 .401 4.78 3.94 .000 –56 –26 20
.998 .949 3.70 3.25 .001 –40 –22 16
.270 .124 99 .036 .778 .484 4.49 3.76 .000 12 –94 16
.996 .945 3.76 3.29 .001 4 –94 12
.309 .133 92 .042 .956 .793 4.09 3.51 .000 –26 –40 –8
.980 .834 3.96 3.42 .000 –28 –34 –14
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 3.48, p = 0.000 (0.050) Degrees of freedom = [1.0, 23.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.5 12.6 12.8 mm; 6.3 6.3 6.4 voxel
Expected voxels per cluster, <k> = 21.666 Volume: 1304488 = 163061 vox = 593.4 resels
Expected number of clusters, <c> = 8.80 Voxel size: 2×2×2 mm; resel = 253.67 voxel
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Subtracting the pre-methamphetamine from the post-methamphetamine data
might be expected to yield areas of increased activation attributable to the stimu-
lant. Considering the structure of the models and contrasts, such areas of apparent
activation could actually represent a loss of deactivation.e clusters arising in the
1b−1a analysis performed with a family-wise-error correction threshold of p < 0.05
(presented in table 4.11) appeared to fall within the areas of deactivation seen in the
main eect of the rvip task analysis (table 4.10 on page 119). Lowering the thresh-
old of the subtraction analysis (p < 0.001 uncorrected) demonstrated that this was
the case (see table 4.12 on the previous page). erefore, the rvip-minus-control
and control-minus-rvip contrasts were examined in isolation for sessions 1a and
1b. is was achieved at the group-level in spm8 by specifying a simple factorial
second-level analysis using a single factor (rvip-minus-control contrast) with two
levels (before and aer methamphetamine).is was a convenient way of performing
what amounted to one-sample t-tests for the four conditions.
activations
Submitting the rvip-minus-control contrast to the factorial design, the areas of ac-
tivation pre-methamphetamine matched those previously established for the main
eect of the task (table 4.9); the comparison is essentially identical but the factorial
model species potential comparisons, borne out as a greater number of degrees of
freedom, smaller clusters and lower overall z-scores (see table 4.13 on page 123). On
visual inspection, the pattern of activation following methamphetamine appeared
unchanged (see table 4.14 on page 124) – this excepting the appearance of a small
cluster in the region of the le central sulcus (−62 · −16 · 26) and another in the right
dorsolateral prefrontal cortex (40 · 40 · 34), neither of which survived comparison
of sessions. us, the clusters emerging as signicant in our paired t-test subtrac-
tion analysis (table 4.11) were not attributable to methamphetamine increasing bold
contrast activations.
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Table 4.13: Task-related activations pre-methamphetamine (all subjects, n = 24) — a group-wise
analysis within a factorial design, SPM{T46}, in a random eects model using the rvip-minus-control
contrast (1a activations, family-wise-error correction p < 0.05).e accompanying images depict the
clusters rendered onto the icbm152 T1 template (sagittal view to the le of the midline), together with
a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 5424 .000 .000 .000 11.99 ∞ .000 36 –50 46 all subjects
.000 .000 10.21 7.34 .000 24 –70 50 activations
.000 .000 10.02 7.26 .000 28 –70 38 1a
.000 .000 5210 .000 .000 .000 11.06 7.68 .000 –26 –64 48 fwep : 5.249
.000 .000 10.55 7.48 .000 –26 –80 26 fdrp : 6.545
.000 .000 10.14 7.31 .000 –40 –66 –8 fwec : 1
.000 .000 966 .000 .000 .000 8.32 6.47 .000 –50 10 32 fdrc : 73
.000 .005 7.22 5.87 .000 –28 –4 52
.000 .008 8.00 6.30 .000 50 0 46
.000 .000 728 .000 .000 .001 8.09 6.35 .000 52 6 44
.000 .001 8.00 6.30 .000 50 6 34
.000 .001 7.89 6.24 .000 50 12 28
.000 .000 277 .000 .000 .003 7.44 6.00 .000 28 2 60
.000 .000 272 .000 .000 .004 7.29 5.91 .000 6 14 48
.000 .005 7.20 5.86 .000 –4 12 50
.000 .000 223 .000 .000 .005 7.20 5.86 .000 36 24 –2
.000 .002 83 .001 .001 .014 6.77 5.61 .000 –28 26 0
.000 .003 77 .002 .001 .026 6.54 5.47 .000 14 –76 –50
.007 .155 5.92 5.08 .000 24 –76 –50
.000 .003 76 .002 .003 .066 6.23 5.28 .000 –8 –76 –22
.002 .052 27 .044 .010 .206 5.82 5.01 .000 10 –74 –24
.007 .158 13 .146 .010 .207 5.80 5.00 .000 –24 –72 –50
.036 .706 1 .706 .042 .835 5.31 4.67 .000 40 26 28
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 5.25, p = 0.000 (0.050) Degrees of freedom = [1.0, 46.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.8 12.9 13.1 mm; 6.4 6.4 6.5 voxel
Expected voxels per cluster, <k> = 6.483 Volume: 1301856 = 162732 vox = 558.8 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 268.79 voxel
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Table 4.14: Task-related activations post-methamphetamine (all subjects, n = 24) — a group-wise
analysis within a factorial design, SPM{T46}, in a random eects model using the rvip-minus-control
contrast (1b activations, family-wise-error correction p < 0.05).e accompanying images depict the
clusters rendered onto the icbm152 T1 template (sagittal view to the le of the midline), together with
a glass brain projection. Rendering emphasises the small cluster additional to the pattern seen in 1a on
the previous page.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 6723 .000 .000 .000 11.80 ∞ .000 –26 –62 50 all subjects
.000 .000 10.64 7.52 .000 –46 –72 0 activations
.000 .000 10.36 7.40 .000 –16 –72 50 1b
.000 .000 6520 .000 .000 .000 11.08 7.69 .000 24 –72 52 fwep : 5.249
.000 .000 10.78 7.57 .000 34 –50 48 fdrp : 6.397
.000 .000 10.40 7.42 .000 24 –64 48 fwec : 1
.000 .000 1027 .000 .000 .000 8.25 6.43 .000 –54 10 34 fdrc : 33
.000 .002 7.58 6.08 .000 –30 –4 50
.000 .058 6.30 5.32 .000 –60 8 14
.000 .000 787 .000 .000 .001 7.98 6.29 .000 54 10 42
.000 .001 7.92 6.26 .000 48 12 28
.000 .001 7.89 6.24 .000 56 10 30
.000 .001 112 .000 .000 .003 7.39 5.97 .000 12 –78 –46
.000 .000 254 .000 .000 .004 7.27 5.90 .000 28 –2 62
.006 .122 6.01 5.14 .000 40 –8 52
.001 .016 47 .011 .001 .017 6.74 5.60 .000 –28 26 2
.000 .006 66 .003 .001 .034 6.50 5.45 .000 –62 –16 26
.000 .003 188 .000 .002 .045 6.40 5.38 .000 6 14 48
.003 .076 6.19 5.26 .000 –4 10 50
.009 .192 5.85 5.03 .000 8 2 56
.000 .001 114 .000 .003 .076 6.20 5.26 .000 36 18 4
.001 .038 33 .028 .005 .108 6.06 5.17 .000 –50 –42 16
.006 .151 15 .121 .005 .116 6.03 5.15 .000 40 40 34
.021 .480 4 .416 .034 .687 5.38 4.72 .000 –8 –72 –20
.025 .520 3 .485 .035 .687 5.38 4.71 .000 30 –64 –32
.036 .706 1 .706 .035 .687 5.38 4.71 .000 –60 –8 36
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 5.25, p = 0.000 (0.050) Degrees of freedom = [1.0, 46.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.8 12.9 13.1 mm; 6.4 6.4 6.5 voxel
Expected voxels per cluster, <k> = 6.483 Volume: 1301856 = 162732 vox = 558.8 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 268.79 voxel
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deactivations
A striking dierence was observed when the deactivations in sessions 1a and 1b were
visualised, deactivations being the clusters emerging with the control-minus-rvip
contrast.e areas of deactivation emerging in session 1a within the factorial design
(table 4.15 on page 126) largely matched those previously identied in the main eect
of the rvip task analysis (table 4.10). Following methamphetamine, suprathreshold
deactivations all but disappeared (table 4.16; page 127). A single small cluster endured
in the right posterior superior parietal region (54 · −70 · 26). It was concluded that
subtracting the rvip-minus-control contrasts in session 1a from those in 1b shows the
brain regions in which methamphetamine has attenuated deactivation.e asymme-
try of cluster volumes in emerging from that comparison most likely arose because of
the persistence of deactivation in the right parietal region during session 1b.
characterising the deactivation change
e results thus far reported can, in the purest sense, be viewed as dichotomous:
clusters either cross the determined threshold or they do not. With suprathreshold
clusters, higher z-scores are oen taken as evidence of a greater degree of activation
or deactivation, or at least a greater certainty that the activation or deactivation has
occurred. When a previously activated or deactivated region falls below the threshold,
nothing more can be said of it without conducting subsidiary analyses.e apparent
abolition of deactivation following methamphetamine may be just that; it could also
be a modest diminution to below threshold or a reversal to regional activation.
With the spm marsbar toolbox, regions of interest were dened using the clusters
of signicance emerging as deactivations during in session 1a (le and right ipl,
cingulate cortex and medial pfc). Statistical scores for each roi were extracted from
sessions 1a and 1b (essentially the rst-level control-minus-rvip contrasts pre- and
post-methamphetamine, examined separately; table 4.17). e t-score deection
was reduced by methamphetamine in every roi, but scores all remained negative.
Methamphetamine thus diminished the deactivations to below the level of signicance,
but it did not abolish them or reverse the signal change to that of activation.
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Table 4.15: Task-related deactivations pre-methamphetamine (all subjects, n = 24) — a group-wise
analysis within a factorial design, SPM{T46}, in a random eects model using the control-minus-rvip
contrast (1a deactivations, family-wise-error correction p < 0.05).e accompanying images depict
the clusters rendered onto the icbm152 T1 template, together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 326 .000 .000 .000 9.48 7.02 .000 54 –70 26 all subjects
.001 .041 6.80 5.63 .000 48 –60 22 deactivations
.000 .000 639 .000 .000 .000 8.64 6.63 .000 –44 –76 32 1a
.000 .018 7.14 5.83 .000 –52 –68 26 fwep : 5.249
.000 .001 94 .001 .000 .018 7.18 5.85 .000 –8 56 0 fdrp : 6.681
.000 .000 618 .000 .001 .041 6.72 5.58 .000 –8 –44 30 fwec : 5
.002 .116 6.29 5.32 .000 6 –50 26 fdrc : 94
.008 .292 5.87 5.04 .000 –8 –56 18
.007 .171 14 .133 .008 .292 5.89 5.06 .000 14 56 20
.000 .000 145 .000 .009 .292 5.85 5.03 .000 –12 54 34
.010 .292 5.82 5.01 .000 –10 46 42
.011 .296 5.77 4.98 .000 –16 60 26
.002 .061 28 .041 .011 .296 5.79 4.99 .000 –28 32 42
.041 .822 5.32 4.67 .000 –22 38 40
.014 .315 7 .280 .029 .640 5.44 4.76 .000 –12 36 48
.018 .362 5 .362 .031 .642 5.42 4.74 .000 –32 38 –12
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 5.25, p = 0.000 (0.050) Degrees of freedom = [1.0, 46.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.8 12.9 13.1 mm; 6.4 6.4 6.5 voxel
Expected voxels per cluster, <k> = 6.483 Volume: 1301856 = 162732 vox = 558.8 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 268.79 voxel
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Table 4.16: Task-related deactivations post-methamphetamine (all subjects, n = 24) — a group-wise
analysis within a factorial design, SPM{T46}, in a random eects model using the control-minus-rvip
contrast (1b deactivations, family-wise-error correction p < 0.05).e accompanying gure shows the
clusters in the glass-brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.021 .416 4 .416 .020 .386 5.58 4.85 .000 54 –70 26 all subjects
deactivations
1b
fwep : 5.249
fdrp :∞
fwec : 4
fdrc :∞
Height threshold: T = 5.25, p = 0.000 (0.050) Degrees of freedom = [1.0, 46.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.8 12.9 13.1 mm; 6.4 6.4 6.5 voxel
Expected voxels per cluster, <k> = 6.483 Volume: 1301856 = 162732 vox = 558.8 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 268.79 voxel
regions of interest t-score
all subjects voxels x y z 1a 1b
Inferior parietal lobule right 326 54 –70 26 –7.95 –3.63
le 639 –44 –76 –33 –7.07 –4.15
Caudal PCC — 618 –8 –44 30 –6.44 –3.10
Rostral ACC le 94 –8 56 0 –6.95 –2.18
Superior medial PFC le 145 –12 54 34 –6.82 –3.54
Table 4.17: Group t-scores for the regions of interest extracted from the spm factorial analysis
(all subjects, n = 24; control-minus-rvip contrast, before and aer methamphetamine on the rst
assessment day) using the marsbar toolbox. In all of the regions, methamphetamine reduced but did
not abolish or reverse the t-score.
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4.8.3 Within-group analysis – lithium and methamphetamine
e within-group analyses were performed using the full-factorial model (described
in §4.4.6 on pages 93-94), into which the rvip-minus-control contrasts from the
rst-level analyses were submitted and the appropriate comparisons specied.
deactivations
Subtracting the pre-methamphetamine from the post-methamphetamine data on
day one (1b−1a), several suprathreshold clusters were observed (table 4.18; page 129).
Given the distribution, these clusters were assumed to arise from amethamphetamine-
induced reduction in deactivation as previously described. Following the course of
lithium, the same comparison showed no clusters passing the designated thresh-
old (not depicted). is nding may indicate that lithium attenuated the eect of
methamphetamine on task-related deactivations.
Exploring this possibility, the clusters of deactivation for each condition (pre-
and post-methamphetamine, before and aer lithium) were visualised, generating
four results tables (4.19 to 4.22 on pages 130–132). Prior to subjects taking the course
of lithium, the patterns of deactivation before and aer methamphetamine were as
expected (those randomised to lithium did, aer all, comprise the majority of the
‘all-subject’ group). e same comparisons aer lithium were broadly similar, but
with a notable dierence. Aer methamphetamine administration on the rst day, no
suprathreshold deactivation clusters were observed but in the comparable analysis
aer lithium, signicant deactivation was seen in one voxel (−18 · −50 · 14).
e visualisation of the deactivations was repeated with a less stringent threshold
(p < 0.001 uncorrected); see gures 4.20 to 4.23. At this threshold, methamphetamine
appeared to markedly reduce the extent of deactivation aer it was rst administered.
Before the second dose of methamphetamine (session 2a), the task-related deactiva-
tions in those receiving lithium largely matched the pattern seen in session 1a, though
their extent appeared slightly greater. Clusters of deactivation were, however, still in
evidence with methamphetamine administration post-lithium.
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Table 4.18: Eects of methamphetamine – ‘post’ minus ‘pre’ before lithium prescription (1b−1a);
results from the full factorial model, SPM{T88}, in which the rvip-minus-control contrasts pre-
methamphetamine were subtracted from those post-methamphetamine, before lithium in those
randomised to receive it (n = 18, family-wise-error correction p < 0.05).e accompanying images
depict the clusters rendered onto the icbm152 T1 template (sagittal view to the le of the midline),
together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 78 .003 .000 .054 6.25 5.67 .000 –44 –76 28 lithium group
.000 .019 54 .010 .006 .390 5.51 5.09 .000 –6 –44 34 rvip-minus-control
.000 .006 97 .001 .009 .390 5.38 4.99 .000 –10 50 12 1b−1a
.016 .419 5.23 4.87 .000 –4 46 2 fwep : 4.902
.001 .033 40 .022 .010 .390 5.36 4.97 .000 –12 –58 8 fdrp :∞
.020 4.63 5 .386 .025 .555 5.11 4.77 .000 –8 58 0 fwec : 2
.030 .596 2 .596 .039 .767 4.98 4.66 .000 4 52 14 fdrc : 40
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
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Table 4.19: Task-related deactivations pre-methamphetamine and before lithium; full-factorial
random eects model, SPM{T88}, demonstrating the control-minus-rvip contrast in those randomised
receive lithium (1a deactivations, n = 18, family-wise-error correction p < 0.05).e accompanying
images depict the clusters rendered onto the icbm152 T1 template (sagittal view to the le of the
midline), together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 498 .000 .000 .000 8.65 7.34 .000 –44 –76 28 lithium group
.000 .000 900 .000 .000 .000 7.45 6.54 .000 –6 –44 34 deactivations
.001 .031 6.08 5.54 .000 8 –52 26 1a
.001 .040 5.98 5.46 .000 –8 –56 10 fwep : 4.902
.000 .000 143 .000 .000 .010 6.61 5.94 .000 50 –70 24 fdrp : 5.883
.000 .000 200 .000 .000 .011 6.51 5.87 .000 –8 58 0 fwec : 1
.008 .220 5.42 5.02 .000 –12 48 16 fdrc : 143
.000 .000 516 .000 .000 .031 6.17 5.61 .000 –10 46 44
.001 .031 6.09 5.55 .000 –12 54 36
.002 .066 5.78 5.31 .000 –16 38 46
.003 .074 28 .050 .010 .239 5.37 4.98 .000 8 56 22
.030 .671 2 .596 .016 .380 5.23 4.86 .000 40 –76 –40
.015 .390 7 .304 .034 .752 5.02 4.69 .000 12 50 40
.036 .722 1 .722 .043 .864 4.94 4.63 .000 54 30 8
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
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Table 4.20: Task-related deactivations pre-methamphetamine and aer lithium; full-factorial ran-
dom eects model, SPM{T88}, demonstrating the control-minus-rvip contrast in those who received
lithium (2a deactivations, n = 18, family-wise-error correction p < 0.05).e accompanying images
depict the clusters rendered onto the icbm152 T1 template (sagittal view to the le of the midline),
together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 369 .000 .000 .000 8.03 6.93 .000 50 –68 26 lithium group
.000 .000 1342 .000 .000 .000 7.88 6.83 .000 –8 –42 32 deactivations
.000 .017 6.38 5.77 .000 –8 –52 8 2a
.000 .024 6.24 5.66 .000 –4 –26 36 fwep : 4.902
.000 .000 446 .000 .000 .000 7.49 6.57 .000 –44 –74 30 fdrp : 5.975
.000 .000 1225 .000 .000 .001 7.17 6.35 .000 –10 44 42 fwec : 2
.000 .012 6.51 5.87 .000 –12 50 34 fdrc : 369
.001 .038 6.05 5.52 .000 –10 58 24
.003 .106 24 .067 .001 .038 5.98 5.46 .000 –40 –76 –40
.020 .441 5 .386 .009 .217 5.38 4.99 .000 –30 38 12
.007 .184 15 .138 .011 .250 5.33 4.95 .000 8 –52 8
.030 .596 2 .596 .012 .252 5.32 4.94 .000 48 6 –34
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
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Table 4.21: Task-related deactivations post-methamphetamine and before lithium; full-factorial
random eects model, SPM{T88}, for the control-minus-rvip contrast in those randomised receive
lithium (1b deactivations, n = 18, family-wise-error correction p < 0.05), with a glass-brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 lithium group
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 deactivations
no suprathreshold clusters 1b
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwep : 4.902
no suprathreshold clusters fdrp , fwec , fdrc :∞
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
Table 4.22: Task-related deactivations post-methamphetamine and aer lithium; full-factorial ran-
dom eects model, SPM{T88}, demonstrating the control-minus-rvip contrast in those who received
lithium (2b deactivations, n = 18, family-wise-error correction p < 0.05), with a glass-brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.036 .722 1 .722 .042 .843 4.95 4.64 .000 –18 –50 14 lithium group
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 deactivations
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 2b
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwep : 4.902
no suprathreshold clusters fdrp , fwec , fdrc :∞
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
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Figure 4.20: Task-related deactivations pre-methamphetamine and before lithium in all those due
to receive it (session 1a; n = 18, p < 0.001 unc., height threshold t = 3.185,extent threshold k = 0 voxel).
Figure 4.21: Task-related deactivations post-methamphetamine and before lithium in all those due
to receive it (session 1b; n = 18, p < 0.001 unc., height threshold t = 3.185,extent threshold k = 0 voxel).
Figure 4.22: Task-related deactivations pre-methamphetamine and aer lithium in all those who
received it (session 2a; n = 18, p < 0.001 unc., height threshold t = 3.185,extent threshold k = 0 voxel).
Figure 4.23: Task-related deactivations post-methamphetamine and aer lithium in all those who
received it (session 2b; n = 18, p < 0.001 unc., height threshold t = 3.185,extent threshold k = 0 voxel).
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e magnitude of this dierence was gauged in an roi analysis, akin to the one
described on page 125. e principal clusters of deactivation in session 1a served
as the regions of interest (control-minus-rvip contrast, family-wise-error corrected
threshold p < 0.05).ese were used to extract the t-scores from the group data pre-
and post-methamphetamine in the sessions before and aer lithium administration.
e results of these explorations are presented in tables 4.23 and 4.24 on the next
page. Methamphetamine reduced the t-scores in all regions before and aer lithium,
though the magnitude of the reduction appeared to be diminished aer the course of
lithium (not formally tested, for reasons discussed later in this thesis).
Returning to the full-factorial model and repeating the subtraction analyses
(1b−1a; 2b−2a) at the lower threshold (p < 0.001 uncorrected), the inuence of lithium
on the methamphetamine-related reduction in deactivation could be visualised (see
gures 4.24 and 4.25 below). Submitting the contrasts so derived to formal compari-
son, (1b−1a) minus (2b−2a), the dierence was insucient to reach signicance.
Figure 4.24:e dierence in deactivations before and aer methamphetamine in all those due to
receive lithium (n = 18). Using the rvip-minus-control contrast in the full factorial model, sessions
were subtracted: 1b−1a (p < 0.001 uncorrected, height threshold t = 3.185,extent threshold k = 0 voxel).
Figure 4.25: e dierence in deactivations before and aer methamphetamine in all those who
received lithium (n = 18). Using the rvip-minus-control contrast in the full factorial model, sessions
were subtracted: 1b−1a (p < 0.001 uncorrected, height threshold t = 3.185,extent threshold k = 0 voxel).
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regions of interest t score
pre-lithium voxels x y z 1a 1b
Inferior parietal lobule right 143 50 –70 24 –6.12 –3.87
le 498 –44 –76 –28 –7.12 –2.73
Caudal PCC — 900 –6 –44 34 –6.62 –2.02
Rostral ACC le 200 –8 58 0 –6.39 –0.45
Superior medial PFC le 516 –10 46 44 –6.75 –2.53
Table 4.23: T-scores for the regions of interest extracted from the spm factorial analysis (lithium
group, n = 18; control-minus-rvip contrast, pre- and post-methamphetamine prior to lithium in those
due to receive it) using the marsbar toolbox. Methamphetamine reduced the statistical score in all
regions, clusters no longer passing the threshold for signicance with family-wise error correction.
regions of interest t score
post-lithium voxels x y z 2a 2b
Inferior parietal lobule right 143 50 –70 24 –6.83 –4.02
le 498 –44 –76 –28 –7.58 –3.79
Caudal PCC — 900 –6 –44 34 –7.82 –5.05
Rostral ACC le 200 –8 58 0 –5.48 –2.61
Superior medial PFC le 516 –10 46 44 –7.47 –4.78
Table 4.24: T-scores for the regions of interest extracted from the spm factorial analysis (lithium
group, n = 18; control-minus-rvip contrast, pre- and post-methamphetamine aer lithium in those
who received it) using the marsbar toolbox. Methamphetamine reduced the statistical score in all
regions, clusters no longer passing the threshold for signicance with family-wise error correction.
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Figure 4.26: Task-related activations pre-methamphetamine and before lithium; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
due to receive lithium (session 1a, n = 18; p < 0.05 fwe, thresholds in table on the following page).
Figure 4.27: Task-related activations post-methamphetamine and before lithium; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
due to receive lithium (session 1b, n = 18; p < 0.05 fwe, thresholds in table on the following page).
Figure 4.28: Task-related activations pre-methamphetamine and aer lithium; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
who received lithium (session 2a, n = 18; p < 0.05 fwe, thresholds in table on the following page).
Figure 4.29: Task-related activations post-methamphetamine and aer lithium; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
who received lithium (session 2b, n = 18; p < 0.05 fwe, thresholds in table on the following page).
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cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .000 10133 .000 .000 .000 10.60 ∞ .000 34 –52 46 lithium group
.000 .000 9.58 ∞ .000 24 –74 50 activations
.000 .000 9.47 7.82 .000 26 –72 42 1a
.000 .000 1067 .000 .000 .000 8.32 7.13 .000 –44 4 28 fwep : 4.902
.000 .003 6.55 5.90 .000 –46 –4 46 fdrp : 5.800
.000 .012 6.19 5.62 .000 –26 –4 50 fwec : 2
.000 .000 637 .000 .000 .000 7.39 6.50 .000 44 4 30 fdrc : 44
.000 .004 6.52 5.88 .000 48 2 40
.000 .000 337 .000 .000 .001 6.82 6.09 .000 28 –4 50
.000 .009 6.26 5.68 .000 32 –2 58
.000 .000 202 .000 .000 .003 6.58 5.91 .000 34 24 0
.000 .000 197 .000 .000 .004 6.52 5.87 .000 –2 10 52
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 lithium group
.000 .000 9.27 7.81 .000 32 –50 48 activations
.000 .000 8.61 7.31 .000 28 –72 30 1b
.000 .000 4836 .000 .000 .000 9.24 7.69 .000 –22 –66 50 fwep : 4.902
.000 .000 8.58 7.29 .000 –38 –42 38 fdrp : 5.837
.000 .000 8.24 7.07 .000 –26 –80 26 fwec : 2
.000 .000 815 .000 .000 .001 7.17 6.35 .000 –50 8 30 fdrc : 59
.000 .013 6.30 5.70 .000 –28 –6 48
.003 .065 5.74 5.27 .000 –26 –4 56
.000 .000 568 .000 .000 .002 6.87 6.13 .000 48 4 28
.000 .002 6.81 6.08 .000 54 10 30
.004 .101 5.60 5.17 .000 50 0 38
.000 .000 149 .000 .000 .009 6.40 5.78 .000 14 –76 –46
.005 .127 5.53 5.11 .000 24 –72 –50
.000 .000 144 .000 .000 .013 6.28 5.69 .000 –16 –74 –46
.002 .065 5.74 5.28 .000 –8 –76 –38
.000 .000 144 .000 .001 .032 5.97 5.45 .000 –10 –90 –4
.031 .625 5.05 4.72 .000 –22 –88 –4
.000 .001 126 .000 .004 .091 5.63 5.19 .000 28 –6 50
.010 .221 5.36 4.97 .000 26 –4 62
.000 .000 3472 .000 .000 .000 9.56 ∞ .000 34 –50 46 lithium group
.000 .000 8.42 7.19 .000 26 –70 38 activations
.000 .000 8.20 7.05 .000 28 –76 30 2a
.000 .000 3324 .000 .000 .000 8.54 7.27 .000 –26 –78 26 fwep : 4.902
.000 .000 8.40 7.18 .000 –42 –68 –6 fdrp : 5.923
.000 .000 8.16 7.02 .000 –24 -64 46 fwec : 1
.000 .000 501 .000 .000 .000 8.15 7.01 .000 52 8 30 fdrc : 85
.000 .000 631 .000 .000 .000 7.89 6.85 .000 –46 4 30
.000 .003 6.62 5.95 .000 –48 –2 46
.000 .000 222 .000 .000 .008 6.37 5.76 .000 30 –4 54
.000 .000 1690 .000 .000 .000 8.83 7.45 .000 32 –48 46 lithium group
.000 .000 7.49 6.57 .000 26 –70 36 activations
.000 .013 6.34 5.74 .000 24 –72 54 2b
.000 .000 1373 .000 .000 .000 7.84 6.81 .000 –24 –66 50 fwep : 4.902
.000 .002 6.97 6.20 .000 –26 –78 26 fdrp : 6.107
.000 .004 6.71 6.01 .000 –32 –50 48 fwec : 59
.000 .000 430 .000 .000 .000 7.77 6.76 .000 –52 8 34 fdrc : 59
.004 .140 5.60 5.16 .000 –50 0 44
.019 .503 5.18 4.83 .000 –46 –4 50
.000 .000 200 .000 .000 .017 6.22 5.64 .000 –48 –70 –2
.000 .000 140 .000 .005 .149 5.56 5.69 .000 58 12 32
.006 .184 5.49 5.08 .000 48 4 28
.026 .556 5.10 4.76 .000 52 6 42
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
Table 4.25: Statistical values supporting gures 4.25–4.29 on the previous page.
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activations
On formal comparison, methamphetamine was not associated with an increase in
clusters of activation of the bold signal either before or aer lithium (results not
depicted). e pattern of activation in each session matched that expected from
previous analyses (gures 4.26 to 4.29, together with the relevant statistical scores
from spm listed on page 137); the degree and extent of activation appeared somewhat
diminished following lithium, but this did not emerge as signicant on testing (not
depicted).
4.8.4 Within-group analysis – placebo and methamphetamine
e analysis stages conducted for the lithium group were repeated for those allocated
to the placebo group. No dierences in activation or deactivation were observed when
pre- and post-methamphetamine sessions were compared, before or aer the course
of placebo (results not depicted). Given the small size of the placebo group, it must
be acknowledged that a voxel-wise examination of the whole brain may have been
under powered. Scrutinising the contrasts generated in each session, clusters were
small compared to those in of the lithium group, but essentially in the same brain
regions (deactivations: table 4.26; activations: gures 4.30 to 4.33 and table 4.27).
4.8.5 Between-group analysis – lithium and placebo
Moving to a between-group analysis, the eects of methamphetamine on activations
and deactivations before and aer the course of either lithium or placebo were com-
pared. No dierences were seen between the placebo group and the lithium group on
any comparison and at any threshold (results not depicted). Additional exploratory
analyses were not performed.
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session 1a
session 2b
Table 4.26: Task-related deactivations in the placebo group; full-factorial random eects model,
SPM{T88}, listing the control-minus-rvip contrast output for the various session (n = 6, family-wise-
error correction p < 0.05).
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.008 .302 14 .151 .010 .374 5.38 4.99 .000 48 –54 24 placebo group
.017 .341 6 .341 .029 .564 5.07 4.73 .000 –42 –58 22 deactivations
1a
fwep : 4.902
fdrp :∞
fwec : 6
fdrc :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 placebo group
no suprathreshold clusters deactivations
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 1b
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwep : 4.902
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fdrp :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwec :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fdrc :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 placebo group
no suprathreshold clusters deactivations
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 2a
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwep : 4.902
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fdrp :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwec :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fdrc :∞
.009 .181 12 .181 .005 .090 5.57 5.14 .000 –36 –56 18 placebo group
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 deactivations
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 2b
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwep : 4.902
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fdrp :∞
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fwec : 12
.000 .000 5030 .000 .000 .000 9.28 7.72 .000 22 –74 52 fdrc :∞
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
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Figure 4.30: Task-related activations pre-methamphetamine and before placebo; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
due to receive placebo (session 1a, n = 6; p < 0.05 fwe, thresholds in table on the following page).
Figure 4.31: Task-related activations post-methamphetamine and before placebo; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
due to receive placebo (session 1b, n = 6; p < 0.05 fwe, thresholds in table on the following page).
Figure 4.32: Task-related activations pre-methamphetamine and aer placebo; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
who received placebo (session 2a, n = 6; p < 0.05 fwe, thresholds in table on the following page).
Figure 4.33: Task-related activations post-methamphetamine and aer placebo; full factorial
random-eects model, SPM{T88}, demonstrating the rvip-minus-control contrast in all subjects
who received placebo (session 2b, n = 6; p < 0.05 fwe, thresholds in table on the following page).
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cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.000 .003 110 .001 .001 .088 6.05 5.52 .000 –28 –56 46 placebo group
.003 .099 28 .050 .006 .248 5.52 5.10 .000 –44 -44 44 activations
.000 .013 68 .004 .006 .248 5.49 5.08 .000 –26 –76 32 1a
.014 .326 8 .272 .020 .482 5.17 4.82 .000 30 –68 40 fwep : 4.902
.012 .326 9 .244 .020 .482 5.16 4.81 .000 32 –62 48 fdrp :∞
.026 .508 3 .508 .039 .784 4.97 4.66 .000 36 –52 48 fwec : 3
fdrc : 68
.000 .003 294 .000 .000 .006 6.81 6.09 .000 –48 –76 –2 placebo group
.002 .068 5.86 5.37 .000 –44 –46 –16 activations
.002 .068 5.85 5.36 .000 –42 –64 –8 1b
.000 .000 541 .000 .000 .006 6.72 6.02 .000 –28 –56 46 fwep : 4.902
.000 .006 6.71 6.01 .000 –24 –72 34 fdrp : 6.074
.007 .224 5.44 5.04 .000 –16 –70 46 fwec : 7
.000 .000 134 .000 .000 .008 6.52 5.87 .000 –44 –42 44 fdrc : 134
.000 .000 346 .000 .000 .008 6.50 5.85 .000 26 –72 52
.001 .038 6.07 5.54 .000 32 –62 50
.001 .068 5.88 5.38 .000 30 –70 40
.002 .083 29 .046 .003 .108 5.67 5.22 .000 44 14 28
.003 .100 24 .067 .013 .353 5.29 4.92 .000 12 –70 58
.015 .304 7 .304 .013 .353 5.28 4.91 .000 –32 –2 60
.008 .194 14 .151 .021 .478 5.16 4.81 .000 48 –36 46
.015 .304 7 .304 .027 .556 5.08 4.75 .000 20 –62 56
.000 .003 91 .001 .000 .052 6.40 5.79 .000 42 14 28 placebo group
.000 .000 519 .000 .000 .052 6.20 5.63 .000 –46 –42 44 activations
.000 .052 6.20 5.63 .000 –28 –58 50 2a
.001 .062 5.92 5.42 .000 –30 –62 58 fwep : 4.902
.000 .000 410 .000 .001 .052 6.09 5.55 .000 38 –54 56 fdrp :∞
.001 .058 6.02 5.49 .000 36 –50 46 fwec : 1
.001 .062 5.88 5.38 .000 52 –38 46 fdrc : 66
.000 .000 150 .000 .003 .094 5.65 5.21 .000 –44 –66 –10
.007 .166 5.45 5.05 .000 –48 –76 –2
.000 .008 66 .005 .004 .097 5.63 5.19 .000 8 –68 54
.009 .242 12 .181 .007 .166 5.45 5.05 .000 –50 8 44
.017 .390 6 .341 .021 .425 5.16 4.81 .000 –8 –74 50
.036 .722 1 .722 .042 .835 4.95 4.64 .000 14 –80 –48
.000 .000 786 .000 .000 .001 7.37 6.49 .000 –28 –58 50 placebo group
.000 .002 7.04 6.25 .000 –44 –42 44 activations
.001 .040 6.00 5.48 .000 –26 –72 32 2b
.000 .000 438 .000 .000 .003 6.92 6.49 .000 –40 –64 –6 fwep : 4.902
.000 .014 6.45 5.82 .000 –48 –74 –2 fdrp : 5.982
.000 .000 444 .000 .000 .019 6.32 5.73 .000 30 –62 –48 fwec : 1
.001 .040 6.04 5.51 .000 40 –40 42 fdrc : 79
.004 .135 5.61 5.17 .000 24 –64 58
.000 .004 79 .002 .001 .040 6.07 5.53 .000 44 14 28
.011 .257 10 .220 .016 .376 5.23 4.87 .000 –48 12 32
.011 .257 10 .220 .025 .553 5.10 4.76 .000 34 –58 –20
.036 .722 1 .722 .050 .998 4.90 4.60 .000 –44 –46 –14
Height threshold: T = 4.90, p = 0.000 (0.050) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.050) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 7.151 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 0.05 Voxel size: 2×2×2 mm; resel = 243.35 voxel
Table 4.27: Task-related activations in the placebo group; full-factorial random eects model,
SPM{T88}, listing the control-minus-rvip contrast output for the various session (n = 6, family-wise-
error correction p < 0.05).
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4.8.6 Between-group analysis – lithium dose
As the high and low dose lithium groups each contained nine subjects, a voxel-wise
comparison would likely have been inadequately powered.e eects of dose were
therefore investigated by examining the regions in which methamphetamine reduced
the task-related deactivations. It was hypothesised that in those randomised to receive
a high dose of lithium, themethamphetamine-related reduction in deactivation would
be attenuated more than in those allocated to a low dose of lithium.
Using the regions of interest previously dened (deactivations in session 1a for
all subjects allocated to receive lithium, 18 subjects, 5 regions), t-scores and were
extracted using the marsbar toolbox.e results are given in table 4.28 below; the
pattern in t-scores is described rather than formally tested). Before the course of
lithium, methamphetamine resulted in a reduction in the magnitude of the bold
signal deactivation. Following lithium, t-scores fell to a similar degree in the low
dose lithium group but in those allocated to receive high dose lithium, the t-scores
demonstrated a degree of stability.at is to say, high dose lithium attenuated the
eects of methamphetamine whilst low dose lithium failed to do so.
t-score by session
region of interest lithium 1a 1b 2a 2b
Right inferior parietal lobule higher dose −5.96 −4.04 −3.60 −3.65
lower dose −4.76 −1.86 −6.78 −2.14
Le inferior parietal lobule higher dose −5.66 −2.68 −5.38 −4.61
lower dose −5.36 −1.46 −5.60 −2.43
Posterior cingulate cortex higher dose −3.46 −2.27 −5.50 −5.37
lower dose −7.42 −0.82 −5.94 −3.18
Le anterior cingulate cortex higher dose −4.97 −1.46 −3.26 −3.22
lower dose −4.55 0.22 −5.14 −1.18
Le superior medial pfc higher dose −4.71 −3.28 −4.40 −3.14
lower dose −6.10 −1.10 −7.94 −3.91
Table 4.28: T-scores by region of interest according to lithium dose (higher dose, n = 9; lower dose,
n = 9), the regions of interest previously dened (see table 4.23). Lithium appeared to attenuate the
methamphetamine-related reduction in deactivation, more so in the higher dose dose group.
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4.8.7 Lithium and placebo prior to methamphetamine
lithium
e eect of lithium itself was examined by comparing the contrasts generated from
the rst fmri session (pre-methamphetamine and before lithium) with those derived
from the equivalent session following the course of tablets (aer lithium but before
methamphetamine) within the full factoral model. Two analyses were conducted,
namely 1a−2a and 2a−1a, into which the rvip-minus-control contrast was entered.
Clusters emerging from the 1a−2a represented areas of activation present with lithium
but not before; those in the 2a−1a comparison were deactivations.
ere were no dierences in either analysis when multiple comparisons were
corrected at the family-wise level of p < 0.05 (results not depicted). Lowering the
threshold in an exploratory analysis, no areas of deactivation attributable to lithium
emerged. Conversely, several points of activation emerged on formal comparison
(rvip-minus-control 1a−2a, p < 0.001 uncorrected). As demonstrated in table 4.29,
these areas were small and barely passed the threshold for signicance.e largest
cluster of activation was located in the vta (−6 · −18 · −12), tending towards signi-
cance at the cluster level (pfwe = 0.055, punc = 0.008). A smaller cluster was observed
in the ventral striatum (8 · 0 · 12), but barely signicant (pfwe = 0.291, punc = 0.049).
Using the marsbar toolbox, group t-scores for these two clusters were extracted,
before and aer lithium (combined group, n = 18). Initially, both regions showed
deactivation (t-scores 1a: vta = − 2.96; ventral striatum = − 1.19) but aer lithium,
activations were observed (t-scores 2a: vta = 2.16; ventral striatum = 3.83).
placebo
In a comparable analysis, placebowas not associated with the emergence of activations,
but widespread deactivation was observed (rvip-minus-control 2a−1a, p < 0.001
uncorrected).e areas showing deactivation were small, barely passing the threshold
for signicance (table 4.30; page 145).e largest area of deactivation was in the right
ipl (50 · −72 · 24), signicant at the cluster level (pfwe = 0.014, punc = 0.002).
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Table 4.29: Activations arising aer lithium, prior to methamphetamine; full-factorial random
eects model, SPM{T88}, showing areas of activation present aer lithium compared to before it, prior
to methamphetamine (1a versus 2a; n = 18, p < 0.001 uncorrected).e accompanying images depict
the clusters rendered onto the icbm152 T1 template, together with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.055 .144 212 .008 .299 .759 4.31 4.09 .000 –6 –18 –12 before and after
.449 .759 4.13 3.94 .000 –2 –16 –12 lithium
.570 .807 4.01 3.84 .000 14 –18 –10 1a−2a
.664 .873 51 .154 .405 .759 4.18 3.98 .000 –20 –6 –6 (p < 0.001 unc.)
.955 .873 15 .438 .862 .948 3.71 3.56 .000 —24 –30 42 fwep : 4.902
.291 .873 105 .049 .864 .948 3.70 3.56 .000 8 0 12 fdrp :∞
.875 .873 27 .295 .947 .948 3.55 3.43 .000 34 50 –2 fwec :∞
.995 .948 3.31 3.20 .001 36 56 6 fdrc :∞
.980 .873 9 .556 .961 .948 3.51 3.39 .000 –38 –12 38
.973 .873 11 .511 .979 .948 3.44 3.33 .000 36 –54 –12
.993 .873 4 .710 .979 .948 3.44 3.32 .000 –32 –56 –10
.986 .873 5 .672 .988 .948 3.39 3.27 .001 30 6 –10
.986 .873 7 .608 .989 .948 3.38 3.27 .001 0 –48 –14
.989 .873 6 .639 .990 .948 3.37 3.26 .001 18 0 –10
.997 .873 2 .806 .996 .948 3.30 3.19 .001 –32 18 0
.993 .873 4 .710 .990 .948 3.28 3.18 .001 56 –40 8
.997 .873 2 .806 .997 .948 3.27 3.17 .001 –18 –64 –20
.997 .873 2 .806 .998 .948 3.25 3.15 .001 36 –54 –26
.998 .873 1 .873 .998 .948 3.23 3.13 .001 14 32 44
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 3.19, p = 0.001 (0.999) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.999) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 26.557 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 7.06 Voxel size: 2×2×2 mm; resel = 243.36 voxel
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Table 4.30: Deactivations arising aer placebo, prior to methamphetamine; full-factorial random
eects model, SPM{T88}, showing areas of activation present aer placebo compared to before it, prior
to methamphetamine (1a versus 2a; n = 6, p < 0.001 uncorrected).e accompanying images depict
the clusters rendered onto the icbm152 T1 template (sagittal view to the right of the midline), together
with a glass brain projection.
cluster-level peak-level location
p p ke p p p T Z p x y z
fwe fdr unc fwe fdr unc
.125 .189 158 .019 .140 .584 4.58 4.32 .000 –44 –32 60 before and after
.428 .623 4.16 3.96 .000 –56 –24 44 placebo
.881 .678 3.68 3.54 .000 –50 –28 52 2a−1a
.014 .059 311 .002 .234 .584 4.40 4.17 .000 50 –72 24 (p < 0.001 unc.)
.305 .584 4.40 4.17 .000 56 –62 34 fwep : 4.902
.579 .678 4.01 3.83 .000 58 –38 42 fdrp :∞
.094 .189 176 .014 .247 .584 4.38 4.15 .000 10 –60 –64 fwec :∞
.829 .678 3.75 3.60 .000 22 –62 60 fdrc :∞
.855 .678 3.72 3.57 .000 –4 –44 62
.325 .418 98 .056 .325 .584 4.27 4.09 .000 42 38 32
.898 .682 3.65 3.51 .000 42 42 14
.859 .873 29 .277 .391 .623 4.20 4.00 .000 –30 36 –44
.985 .764 3.41 3.30 .000 –38 36 36
.790 .873 37 .221 .635 .678 3.95 3.78 .000 –54 –52 38
.955 .873 15 .438 .681 .678 3.91 3.74 .000 18 –16 56
.912 .873 22 .344 .717 .678 3.87 3.71 .000 54 8 –20
.955 .873 15 .438 .798 .678 3.79 3.63 .000 –36 24 46
.799 .873 36 .277 .810 .678 3.77 3.62 .000 18 –86 –22
.994 .827 3.33 3.23 .001 26 -86 –16
table shows 3 local maxima more than 8.0 mm apart
Height threshold: T = 3.19, p = 0.001 (0.999) Degrees of freedom = [1.0, 88.0]
Extent threshold: k = 0 voxels, p = 1.000 (0.999) fwhm = 12.4 12.5 12.6 mm; 6.2 6.2 6.3 voxel
Expected voxels per cluster, <k> = 26.557 Volume: 1260680 = 157585 vox = 597.0 resels
Expected number of clusters, <c> = 7.06 Voxel size: 2×2×2 mm; resel = 243.36 voxel
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4.9 discussion
e study presented in this chapter investigated whether lithium could diminish the
eects of methamphetamine and in doing so, demonstrate its ability to attenuate
dopaminergic neurotransmission. In the strictest sense and by the most conserva-
tive criteria, the null hypothesis was not rejected. at is to say, no dierence was
observed on any measure when those taking lithium were compared to those taking
placebo. A within-group analysis demonstrated no dierence in the response to
methamphetamine before and aer the course of placebo tablets, other that a slight
exaggeration of its subjective eects according to visual analogue scale ratings. In the
within-group analysis of all subjects taking lithium, an attenuation of the eects of
methamphetamine was observed – subjective eects were diminished and the deacti-
vation in bold contrast that occurs when tasks are performed, which was reduced by
methamphetamine, was partially restored. Examining the signal change in the key
regions of interest, the eects of methamphetamine were most evidently modied in
those randomised to receive a higher dose of lithium. Lithium itself slowed response
times in the rvip task condition and appeared to alter the bold signal contrast in
striatal andmidbrain areas, consistent with amodulation of the dopaminergic systems
of the brain.
is discussion section rst examines the eects of methampetamine in light of
the work of others and as a reection of manipulations in the dopaminergic systems.
e eects on bold signal are summarised and the deactivations discussed in terms
of the default-mode network theories.e mechanisms by which methamphetamine
may bring about its eects on bold contrast are then appraised. Considering the
various within-group analyses, it is argued that converging lines of evidence support
the notion that lithium is able to attenuate the eects of the methamphetamine in
man. Reecting on the negative result for the null hypothesis, the design and power
of the study – together with its strengths and weaknesses – requires discussion.is is
reserved for the nal chapter of this thesis, in which the additional analyses proposed
for this data, together with potential directions for future work, are considered.
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Methamphetamine model
Amphetamines have long been used to model psychiatric illness, mania in particular
(Jacobs and Silverstone, 1986). By acting to increase synaptic levels of monoamines in
the brain (Sulzer et al., 2005), various features of manic presentations can be replicated
in healthy subjects. Whilst this thesis sought to examine the dopaminergic systems,
amphetamines are known to increase activity in all monoaminergic pathways. To gain
a degree of specicity for dopamine, certain strategies were employed and converging
lines of evidence examined.
First, methamphetamine was employed as the pharmacological challenge. Akin to
d-amphetamine, methamphetamine has actions on all three monoaminergic systems
but the timing of its eects are more predictable. Second, as subjects performed a
task requiring sustained attention, they likely recruited activity in the noradrenergic
and dopaminergic systems of the brain (MacDonald et al., 2000); the control task
condition required a degree of attention, but the rvip task condition was harder and
placed greater demands on executive function, arguably emphasising dopaminergic
activity (McTavish et al., 2001).ird, fmriwas employed, its purpose being to localise
the regions of the brain aected by the interventions – it was hypothesised that regions
innervated by dopamine would demonstrate a change in activity, evidenced by an
alteration in bold contrast.
subjective effects
Methamphetamine induced a change in the mental state of the subjects in this study.
Established using standardised and validated visual analogue scales, administration
resulted in subjects feeling more alert, excited, clear-headed, energetic, quick-witted,
procient and gregarious.is nding was not unexpected in the least, arming the
model, replicating the work of others and serving as a reminder as to why metham-
phetamine is a drug of abuse. Hearn et al. (2004) examined the subjective eects of
methamphetamine on healthy subjects together with a pharmacological manipulation
of the stress axis in a complicated, placebo-controlled study with a cross-over design.
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e dose and administration of methamphetamine exactly matched the protocol used
in this thesis, apart from the dierence in environmental ambience (clinical laboratory
compared to clinical scanner). Using an alternate set of vas ratings, Hearn et al. (2004)
reported increased scores on ‘mind-race’ and ‘buzz’ domains aermethamphetamine
was given; they observed no signicant change on the scales employed in this thesis
(those developed by Bond and Lader, 1974).
effects on rvip task performance
e eects of methamphetamine on the measures of task performance were largely as
expected. Examining all subjects on the rst day of assessment, before randomisation
to receive either lithium or placebo, methamphetamine hastened response times
and increased false alarm rates during the rvip task condition. In the control task
condition of the same session, the median response latency similarly fell but false
alarm rates remained low, unchanged by the stimulant challenge.e hit rate and
sensitivity index values in the rvip and control task conditions were unaltered by the
administration of methamphetamine.
Compared to the control condition, performing the rvip task requires more
attention and a degree of conict resolution. Subjects may adopt the strategy of
being vigilant for potential full sequences, responding if and when the correct third
target digit appears.at is, if the numbers 2 and 4 are seen consecutively, a subject’s
attention becomes focussed on whether or not the next digit will be the number 6.
e possibility of anticipating the completion of sequences explains why response
times were swier in the rvip task condition compared to the control condition,
in which targets appear without warning. e increase in false alarm rate in the
face of stable accuracy suggests that the decision to respond was disturbed – aer
methamphetamine, subjectsmay have tended to respond in the armative whenever a
potential sequence was identied, failing to inhibit responses to incorrect completions.
A change in response patterns to a ‘trigger-happy’ style suggests that the processes of
the executive network of the attentional systems has altered, so implicating dopamine
(MacDonald et al., 2000; McTavish et al., 2001).
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In a study conducted locally, methamphetamine was found to increase hit rates
and sensitivity index scores on the rvip task, reducing response latency but with no
eect on response bias in healthy subjects (Hearn et al., 2004).e ndings of the
study conducted in this thesis more closely match those reported by Goodwin’s group
(McTavish et al., 2001), in which responses were hastened and B′′ scores rose. It was
not possible to calculate the response bias for subjects in the mrc-lamp study, largely
due to the use of a blocked design. Response bias cannot be derived if a subject returns
a perfect score – all targets detected and no false responses made. In a continuous
version of the rvip, perfect performances are rare; divided into short blocks, a faultless
performance in at least one of the blocks was not uncommon. Mean hit rates and
false alarm rates were calculated for individual blocks, the values then averaged to
determine performance for each task condition. Handled in a similar manner, if a
subject’s response bias could not be calculated for one of the blocks, then the mean
for all of the blocks was undeterminable. Excluding the relevant blocks would have
skewed the results; grouping scores into a single block would have misrepresented
the manner in which the task was conducted.
functional imaging findings
Compared to the control task condition, performing the rvip task condition increased
bold signal in posterior parietal and temporal regions, the dorsolateral frontal cortex
and the medial aspect of the rostral insula bilaterally. Deactivations were observed
bilaterally in the inferior parietal lobules and in the le hemisphere, posterior and
anterior cingulate cortices together with medial aspects of the prefrontal cortex.ese
results directly replicate the ndings of previous pet (Coull et al., 1996) and fmri
studies (Lawrence et al., 2003) investigating the rvip task.
e physiological basis of bold signal activation is well characterised (see §2.5;
pages 41–44), there being a consensus that increases in contrast represent presynaptic
activity in the regions where they are present (Logothetis, 2002).us, performing
the rvip task can be said to engage the processes of all three attentional networks
delineated by Fan et al. (2005). Deactivations are more poorly understood and until
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recently were largely overlooked; this possibly as a consequence of interpreting the
imaging ndings within the paradigms of psychology (Morcom and Fletcher, 2007;
Raichle and Snyder, 2007). In the clinical laboratory setting, experiments are usually
designed such that a control condition is contrasted with a task condition in which
greater demands are placed on the system under investigation. By extrapolation,
subtracting the functional images acquired in a control task scenario from those
gathered during the performance of a demanding task should demonstrate the areas
in which brain activity increased – bold activations. Activity increases were expected
and specically sought; that certain brain functions might lessen or cease during the
performance of a complex task was not on the agenda, though as it transpires this
may be the case. Reverse subtractions (control task minus the demanding task) are
thought to gauge that process (Raichle et al., 2001) – bold deactivations.
Deactivations in certain brain regions are consistently observed, falling mostly
along the medial surface (precuneus, anterior and posterior cingulate, prefrontal) but
also in the inferior parietal lobules (Raichle et al., 2001). e pattern is consistent
with various tasks, its degree determined by the intensity of the task (Frankenstein
et al., 2003; McKiernan et al., 2003).ese brain areas are now described collectively
as the default mode regions, the term implying that they are active at rest and become
less active once a task is started. Deactivations in the default mode regions have
attracted a great deal of debate and remain a contentious topic (Raichle and Snyder,
2007). What is accepted is that deactivations occur (Mazoyer et al., 2001); what is
debated is whether the regions comprise a network, serve a purpose at rest and in a
wider sense, what ‘rest’ can be said to represent (Morcom and Fletcher, 2007). It has
been argued that the default regions actually form a neuronal network (Greicius et al.,
2003), supporting evidence provided by fmri studies of the resting state as well as
electrophysiological investigations (van den Heuvel and Hulsho Pol, 2010). Resting
state studies rely on the detection of low frequency uctuations in the bold signal
which are thought to reect communication within networks (Biswal et al., 1995), the
idea being that areas with synchronous uctuations are connected. Using probabilistic
independent components analysis or seed region correlation techniques, the default
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regions have been found to be linked (Fox and Raichle, 2007).e approaches are
bewildering and it is not known if they can be trusted. Further, even if the regions are
connected, the function of the network is unclear – the notion that it has something
to do with day-dreaming holds a certain attraction (Raichle and Snyder, 2007).
Returning to the study in hand, methamphetamine did not alter the rvip task-
related activations but attenuated the deactivations in all regions. An exploratory
region of interest analysis indicated that following administration of the stimulant,
deactivations persisted but were of lesser magnitude, falling below the threshold
of signicance on whole-brain voxel wise comparison. is nding is a challenge
to interpret, requiring an examination not only of the pharmacological actions of
methamphetamine but also the manner by which bold contrast is generated.
It could be argued that methamphetamine acts directly on the default mode net-
work, accepting it is a valid construct. Some regions of the proposed network, mostly
the frontal components, are served by dopamine and the inter-relationship between
activations, deactivations and dopaminergic activity has been investigated (Nagano-
Saito et al., 2009; Tomasi et al., 2010; Delaveau et al., 2010). In the mrc-lamp study,
methamphetamine attenuated deactivation across the network, not just the frontal
regions; this nding attracts at least three interpretations. First, dopamine is not
constrained to the frontal regions, its neurones being widely distributed. Patients with
Parkinson’s disease fail to deactivate posterior midline and lateral default mode re-
gions, but deactivation is restored aer l-dopa administration (Delaveau et al., 2010).
e eects of methampetamine may be similarly widespread. Second, networks being
what they are, were methamphetamine to manipulate just the frontal components
then it could reasonably be proposed that activity in the linked regions would follow
suit.is may not actually be the case, the default mode network increasingly being
considered as a fractionated system (Andrews-Hanna et al., 2010). Deactivations
may be observed in isolation in each of the default mode regions, with the degree of
deactivation in the medial prefrontal cortex proportional to the complexity of the task
(Nagano-Saito et al., 2009). In healthy subjects, a greater degree of deactivation in
the ventral acc is associated with increased dat availability in the striatum (Tomasi
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et al., 2010) – lower synaptic dopamine equates to more deactivation, mirroring the
ndings of this thesis. Administration of apomorphine, a dopamine agonist, fosters
deactivation in the ventral medial pfc in elderly subjects (Nagano-Saito et al., 2009).
Dopamine depletion strategies, however, lessen the deactivation across anterior and
posterior default mode regions (?). Clearly, the relationship between dopaminergic ac-
tivity and the degree of deactivation, even within a single region, is complex.e third
explanation invokes the mixed pharmacological properties of methamphetamine,
positing that alterations in deactivations in posterior regions of the network have
a basis in the manipulations of noradrenergic neurotransmission. Whilst tradition
would have us avoid plurality, the complexity of the situation may necessitate it.
Adopting an alternative stance, it could be proposed that the actions of metham-
phetamine are removed from the default mode network, or at least that the network
is not the primary site of its eects. Indeed, the existence of such a network need not
be invoked, just that certain parts of the brain demonstrate a characteristic reduction
in bold signal on embarking upon a task.e characteristics of the deactivations
are paramount; crudely, they occur with any task and to an extent determined by the
diculty of the task. Consequently, musing over the specicity of the rvip task for
dopaminergic regions of the brain may be of little value in terms of understanding the
deactivations. Methamphetamine may simply have acted to make the task easier to
complete, thereby lessening the extent of the deactivations. It must be acknowledged
that these actions could be subtle, diuse and undetected by the analysis performed.
What can be said of methamphetamine is that it lessened the dierence between
the control task condition and the rvip task condition, at least in terms of bold
contrast generation. e generation of bold contrast is sensitive to the baseline
state of the brain (Morcom and Fletcher, 2007), a concept pertinent to negative bold
responses (deactivations). As discussed, negative deections in bold signal compared
to rest occur when tasks are performed; lowering activity in the brain to below rest
and then embarking on the task results in a negative bold signal change of greater
magnitude (Pasley et al., 2007) – the brain deactivates not by a xed amount, but to
a xed point. Note that the experiment performed by Pasley et al. (2007) served to
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demonstrate that negative bold signal deections are most likely a consequence of
neural deactivation rather than non-neural haemodynamic artefacts.
e eects of methamphetamine on the baseline condition are therefore of some
importance. If, for argument’s sake, the state of the brain during the control task
condition is taken as being unchanged by methamphetamine, the lessening of the
deactivation seen with the stimulant would imply that the subjects remained closer to
the baseline state when engaging in the rvip task – from a stable baseline, less bold
signal deactivation equates to a smaller reduction in neuronal deactivation. Taken to
the extreme, methamphetamine would be said to constrain subjects to the state of
rest.is seems somewhat counterintuitive, contrary to the change in performance
on the rvip task and the subjective eects of the drug. It makes more sense to argue
that the baseline state changed, that methamphetamine induced a degree of arousal
that spanned that rvip task and control conditions. In this state of arousal, attention
may have been heightened and more closely approximated to the level required for
the successful completion of the rvip task condition. In eect, subjects deactivate
from an already deactivated position.
e complexities of contrast comparison mean that reductions in deactivations
may masquerade as activations in some analyses, possibly explaining the inconsisten-
cies in the reported eects of amphetamines in bold fmri studies (see §4.2.1; page 80).
e nding that methamphetamine attenuates deactivation rearms its importance
as a model of psychiatric illness. Recently, McKenna et al. (2010) argued that reports
of ‘hyperfrontality’ in schizophrenia may actually represent failures of deactivation
in the default mode network. Compared to healthy subjects, deactivations in those
with chronic schizophrenia (n = 32) during a working memory task were of lesser
magnitude, at least in the anterior midline node of the network. McKenna et al. (2010)
also found that patients with bipolar disorder similarly failed to deactivate frontal
regions, though to a lesser extent compared to schizophrenia. It is unclear whether
the deactivation ndings in these two illness reects their contrasting pathologies or
the eects of medication, lithium in particular.
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4.9.1 Lithium and methamphetamine
functional imaging findings
Having established that methamphetamine reduced the magnitude of deactivation
in the default mode regions, the eects of lithium on that process were examined.
In a within-group analysis, the reduction in deactivation attributable to metham-
phetamine was attenuated by lithium. e eect was partial, and likely greatest in
those randomised to receive a higher dose of lithium.
Lithium has been previously been shown to modify the eects of amphetamine on
the bold signal (Bell et al., 2005a). In a parallel design study, subjects were randomised
to receive either placebo (n = 12) or lithium (n = 9) at a xed dose of 900mg per day for
two weeks before undergoing investigation. Performing various neuropsychological
tasks before and aer 25 mg of d-amphetamine, lithium reportedly lessened the
extent of activations associated with the stimulant more than placebo.e eect was
observed during a spatial attention paradigm but not during a task that challenged
working memory. Bell et al.’s (2005a) study may be compared to the investigation
conducted in this chapter and so warrants further consideration.
e most obvious dierence in the results of the studies was that Bell et al. (2005a)
demonstrated a dierence in bold signal change between lithium and placebo groups.
In themrc-lamp study, the within-group analyses showed that lithium attenuated the
eects of methamphetamine whilst placebo did not.e lack of a dierence between
the lithium and placebo interventions in the between-group analysis was most likely a
type 2 error – with only six subjects in the placebo group, the study reported here was
underpowered for such a comparison. Factors likely to lessen the power of the study,
pure numbers aside, include the inter-subject variability in response to amphetamine,
the nature of the fmri analysis and the range of lithium doses used.
Bell et al. (2005a) found a dierence between small groups (lithium n = 9, placebo
n = 12) with a range of serum concentrations of lithium (0.39–0.77 mm) slightly lower
than those achieved in this thesis.eir positive nding may be a reection of the
image analysis strategy employed. In the mrc-lamp study, the entire brain was exam-
154
ined in a voxel-wise manner; the eects of methamphetamine were delineated and
in the same subjects, the modication of these eects by lithium was examined. Bell
et al. (2005a) applied regions of interest derived from a previous study to focus their
analysis, but in doing so made the assumption that the eects of d-amphetamine were
consistent across subjects and studies. Using these roi, a small volume comparison
was performed. Statistically more powerful at the level of analysis, the strategy is
weakened by its circularity – one may see what one is looking for.
Ostensibly the reverse of the ndings in this thesis, Bell et al. (2005a) reported that
lithium reduced the extent of bold activations caused by d-amphetamine. It may be
argued that the ndings are comparable. Recall that in the initial subtraction analysis
exploring the eects of methamphetamine on the bold signal, apparent activations
were resolved as attenuations of deactivation. It is unclear from Bell et al.’s paper how
the contrasts were specied, but it is conceivable that the ‘activation’ reported was
actually a reduction in deactivation, with lithium lessening that reduction.
In terms of neurotransmitter systems, the bold signal is neither specic nor
quantitative – implicating dopamine in the eects of lithium requires additional
reasoning with empirical support. In regions innervated by dopamine, the bold
signal varies with manipulations of the activity of the neurotransmitter. Following
amphetamine administration to rodents, bold signal change matches microdialysis
measures of dopamine release in the striatum, further correlating with pet regional
cerebral blood ow assessments (Chen et al., 1997). In the nucleus accumbens of
rodents, antagonism of d1-receptors prevents amphetamine-related increases in bold
signal (Dixon et al., 2005) despite the ongoing release of dopamine (Choi et al.,
2006); antagonism of d2-receptors has a lesser eect on bold activations (Dixon
et al., 2005). As d1-receptors are not present on presynaptic membranes (Greengard,
2001b), dopaminergic ring may cause bold signal activation through postsynaptic
mechanisms, in the striatum at least (Knutson andGibbs, 2007). When amphetamines
are given to rodents, the reduction in bold signal seen in cortical regions is attenuated
by sulpiride (a d2-receptor antagonist), but less so with d1-receptor blockade (Dixon
et al., 2005). Dopamine-driven deactivations may therefore have a presynaptic basis.
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Lithium is known to have numerous eects on dopaminergic neurotransmission.
Whilst not a receptor binder, a wealth of data supports the assertion that it modulates
second messenger systems downstream of dopamine receptors, so modifying the
functioning of postsynaptic neurones (see §1.4.2).e study reported in this chapter
failed to replicate the ndings of Dixon et al. (2005) – methamphetamine did not
increase bold signal in the striatum. Consequently, the notion that lithium may
attenuate the eects of amphetamines through postsynapticmodulation of d1-receptor
functioning could not be explored. e absence of striatal activation may reect
the neuropsychological task employed, dopamine release in the nucleus accumbens
classically associated with the anticipation of reward (Knutson and Gibbs, 2007).
Despite the ndings of Dixon et al. (2005), there is a consensus that bold signal
activation most likely reects regional presynaptic activity in the brain (Logothetis,
2002). Whilst the situation is less clear for deactivations (Frankenstein et al., 2003),
extrapolation may be justiable since changes in neuronal activity appear to underpin
reductions in bold signal (Pasley et al., 2007). Lithium has been shown to reduce
the synthesis and release of dopamine in some (Rastogi and Singhal, 1977; Baptista
et al., 1993), but not all (Reches et al., 1984; Berggren, 1985) preclinical studies. Clear-
ance of dopamine from the synapse is increased (Ahluwalia and Singhal, 1981), the
net eect presumably a reduction in dopaminergic signalling. In a recent series of
placebo-controlled experiments using rodents, lithium was found to attenuate the
behavioural eects of d-amphetamine and decrease the release of dopamine in the
nucleus accumbens (McQuade, 2010); apomorphine, a postsynaptic dopamine re-
ceptor agonist, induced behaviours similar to those seen with amphetamine, but its
eects were not altered by lithium.us, lithium may act presynaptically in reducing
dopaminergic neurotransmission – a conclusion consistent with its attenuation of the
eects of methamphetamine on bold signal deactivation.
neuropsychological measurements
Lithium diminished the subjective eects of amphetamine, according to vas scores.
is nding harks back to early observations of the eects of lithium in recreational
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drug users (Flemenbaum, 1975). Strictly, in terms of neuropsychological task per-
formance, lithium did not attenuate the eects of methamphetamine. at is, the
reduction in median response latency caused by the stimulant was not diminished.
It is of interest then to consider why a dissociation should be present between the
neuropsychological and fmrimodalities of assessment.
Assuming, for the sake of argument, that rvip task performance and bold signal
are purely determined by dopaminergic system activity, they should change in concert.
e generation of bold contrast is somewhat more complex, driven in large part by
the eects of vasoactive substances released from neurones and astrocytes (Attwell
and Iadecola, 2002). A major pathway leading to nitric oxide production, and so feed-
forward vasodilatation in the capillary bed, involves the activation of glutamatergic
receptors with a cascade of eects in calcium-dependent second messenger systems.
By attenuating calcium release and inux, lithium dampens the eects of glutamate
receptor stimulation (Sourial-Bassillious et al., 2009). Activation of various receptors
including dopaminergic ones yields cox and aa, which in themselves have vasoactive
properties. Chronic administration of lithium has been shown to selectively reduce aa
turnover rates and cox-2 concentrations (Rapoport and Bosetti, 2002).us, whilst
performance on the rvip task may be sensitive to the eects of lithium on neuronal
activity, generation of the bold signal may be targeted at several sites. Blocked fmri
experiments may, however, be relatively insensitive to decoupling of the neurovascular
response, at least in temporal terms. Nevertheless, these concerns serve as a reminder
that whilst a degree of reductionism may be laudable, fmri and neuropsychological
tasks are ultimately measuring dierent things.
4.9.2 Lithium and placebo prior to methamphetamine
Given the design of the study, it was possible to investigate the eects of lithium and
placebo on performance during the task of sustained attention, within the context of
functional imaging. In the group randomised to receive lithium, median response
latency was greater aer the course of tablets; placebo had no eect on any measure.
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Lithium has consistently been associated with a sense of ‘mental slowing’ accord-
ing to the subjective reports of patients (Joe et al., 1988; Lenzer et al., 1989).ese
complaints have been borne out on formal testing, lithium impairing performance on
tasks assessing psychomotor speed (Shaw et al., 1987; Kocsis et al., 1993; Jauhar et al.,
1993). Attention, however, appears to be unaected in patient groups and healthy
subjects (Pachet and Wisniewski, 2003).e ndings of the study reported in this
chapter – accuracy scores and false alarm rates unaltered by lithium, but subjects
responding more slowly – are therefore consistent with the eld at large.
e fmri ndings of the eects of lithium and placebo in their own right are
something of a challenge to interpret in the context of an examination of sustained
attention. Comparing the pre-methamphetamine session aer lithium with the pre-
methamphetamine session prior to its administration, bold activations were evident
in the vta and ventral striatum without signicant deactivations at the cluster level.
e placebo group showed deactivations only, these being present in the default mode
regions and most notably the inferior parietal lobules and precuneus. Activation in
the vta and ventral striatum has been linked to the anticipation of reward, rather
than the receipt or pleasurable experience of the reward (Carter et al., 2009). One
would expect them, therefore, to have no business appearing during the completion
of the rvip task. e analysis described is a complex one (comparing a contrast
of contrasts) in which emerging clusters may have more to do with the dierence
between the assessment days than the tasks undertaken.e principal dierence was
of course the intervention with lithium or placebo, but it must also be recognised
that the pre-methamphetamine sessions diered in other respects. On the second
occasion, subjects were familiar with the scanner environment but more importantly,
had previous experience of methamphetamine. It was highly likely that they were
looking forward to their second dose during the rst session of the second day, hence
the activity in reward circuitry.
e question then is why should activation in the vta and ventral striatum be
present in the lithium group but not the placebo group. Exposure to stimuli that
have become associated with the eects of a drug can induce the eects of the drug
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itself, subjectively and objectively (Carter and Tiany, 1999; Weiss, 2005).is cued-
response has a neurobiological basis in the dopaminergic systems, demonstrated
most pointedly in a recent pet study (Boileau et al., 2007). In healthy subjects, the
repeated oral amphetamine administration reduced [11c]raclopride binding potentials
in the caudate and putamen compared to their baseline scan, indicative of increased
dopamine release in these regions. When on one of the assessment days, unbeknown
to the subjects, the amphetamine capsule actually contained a placebo compound,
[11c]raclopride bindings fell compared to baseline and did not dier from the reduc-
tion induced by amphetamine – the anticipation of amphetamine brought about its
eects. It could be argued that in the mrc-lamp study, the placebo group were antici-
pating the eects of methamphetamine and therefore, to some extent, experiencing
its eects – hence the deactivation pattern emerging in the default mode regions.e
attenuation of dopaminergic neurotransmission ascribed to lithiummay have con-
strained this response, such that although subjects were expecting methamphetamine,
the transition to the state of arousal seen in the placebo group was lacking – hence
the activation in the vta and ventral striatum.
4.10 conclusion
e study presented in this chapter provides indirect evidence in support of the notion
that lithium can attenuate over-activity in the dopaminergic pathways of the human
brain. Used as a model of mania, methamphetamine induced subjective eects and
changes in bold signal deactivation that were partially diminished by lithium. In a
task requiring sustained attention, lithium itself slowed response times but did not
lessen the eects of methamphetamine on that, or any other measure of performance.
e implications of these ndings – together with an appraisal of the strengths and
weaknesses of the study – are discussed in the nal chapter of this thesis.
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5 lithium & brain structure
Intriguingly, mri studies indicate that lithium increases the volume of grey matter
in the human brain – a nding widely interpreted as evidence that lithium may
enhance neuroplasticity, engendering hope and rearming its importance as an
illness modifying drug. Such optimism rather predicates an increase in grey matter
being genuine and benecial, but the actual mechanism underlying the imaging
ndings has not been established empirically in man. In this chapter an alternative to
the neuroplasticity explanation is advanced, namely that the change in grey matter
volume is artefactual, arising from an alteration in the characteristics of the mr signal.
Specically, it is hypothesised that lithium reduces the longitudinal relaxation time of
protons, thereby changing the signal intensity of T1-weighted images which in turn
aects the classication of tissues during the analysis process.is assertion is tested
through the analysis of structural and quantitative images, acquired in a longitudinal
study of healthy men allocated to receive either lithium or placebo.
5.1 background
e rst study in this eld was a longitudinal investigation testing the hypothesis that
lithium has neurotrophic eects in vivo, manifest by an increase in greymatter volume
(Moore et al., 2000b). Ten subjects with bipolar disorder underwent mr investigation
before and aer treatment with lithium for a period of four weeks. Analysis comprised
the use of a semi-automated technique in which the grey and white matter voxels were
delineated from csf, followed by the calculation of the segmented tissue volumes.
An increase in grey matter volume of 3% was reported (approximating to 24 cm3),
with no change in white matter volume.e ndings were linked to elevations in the
brain metabolite naa – a putative marker of neuronal integrity – which occurred to
the greatest degree in the brain areas with highest grey matter densities (Moore et al.,
2000a).
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In subjects with bipolar disorder, the volumetric nding has been replicated in
hypothesis-driven, cross-sectional studies (Sassi et al., 2002; Bearden et al., 2007,
2008; Yucel et al., 2008; Germaná et al., 2010) and prospective studies (Moore et al.,
2005, 2009; Kim et al., 2008; Lyoo et al., 2010). Similar eects are observed when
healthy subjects take lithium (Leow et al., 2005; Monkul et al., 2007), though the mrs
ndings have not been substantiated (Brambilla et al., 2004).
When grey matter is reportedly increased, the magnitude is typically between
two and ten percent – the largest volume dierences emerge from the cross-sectional
investigations. e increase has been conrmed to arise with just one month of
treatment, occurring in the hippocampus, amygdala, anterior cingulate and prefrontal
cortex (Monkul et al., 2007; Bearden et al., 2008; Yucel et al., 2008; Moore et al., 2009;
Germaná et al., 2010). A plateau seems to be reached aer a few months (Lyoo et al.,
2010) but in cross-sectional studies, the relationship between volume change, dose
and treatment duration over greater periods is dicult to discern (Bearden et al.,
2007). Some studies have found that increases in grey matter are associated with a
favourable clinical response (Moore et al., 2005, 2009; Lyoo et al., 2010).
5.1.1 Interpretations of the volumetric ndings
e imaging ndings demand an explanation, but the polemic nature of the eld has
polarised the interpretations.us, two major theories currently vie for supremacy:
cellular hydration versus neuroplasticity.at these explanations have been pitched
as opposing is not clearly explained by their biological basis or plausibility – indeed
the theories are not mutually exclusive and may actually be inseparable.
hydration theories
In essence this theory is simple – lithium as a salt aects water homeostasis, so the
grey matter volume increase reects elevated cellular water content.is explanation
was briey entertained by the authors of the index study (Moore et al., 2000b), but
dismissed because they found no increase in their mrs estimates of brain water. It has
not been systematically examined in man since this assertion.
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Nevertheless, the proposal has empirical support from preclinical work. When
compared to those receiving placebo, rats treated with lithium for ve weeks have
more water in the frontal grey matter (dissected wet brain weight 3% greater than dry
brain weight; Phatak et al., 2006). Although this may be of insucient magnitude to
directly account for the volume changes in some studies (e.g., Bearden et al., 2007;
Regenold et al., 2008), it does approximate to the changes seen in the longitudinal
studies of man with a similar time scale (Moore et al., 2000b, 2009; Monkul et al.,
2007; Kim et al., 2008; Lyoo et al., 2010). It should be noted, however, that the change
in water content observed by Phatak et al. (2006) did not reach signicance for other
brain areas and an mri assessment of brain volume change was lacking.
neuroplasticity theories
By some margin, the majority of authors favour an interpretation invoking lithium’s Early reports used
the descriptives
neuroprotective
and neurotrophic
interchangeably.
Latterly the term
neuroplasticity has
found favour.
purported enhancement of neuroplasticity (see §1.4.4 on page 14). Neuroprotective
theorists claim support from mrs work showing that lithium increases brain naa
concentration. Elevation of naa levels following lithium treatment has been observed
in subjects with bipolar disorder (Moore et al., 2000a), seemingly proportional to the
amount of grey matter in the region examined. When combined with the substantial
preclinical data, the argument in favour of neuroplasticity appears to be compelling.
Enthusiasm for this explanation may be tempered on empirical and theoretical
grounds. First, the ndings ofMoore et al. (2000a) require replication as a comparable
study healthy subjects showed neither volume increase nor naa change with lithium
(Brambilla et al., 2004). Second, chronic administration of lithium to rats has no
eect on neocortical volume, density of neurons, total number of neurons or mean
volume of neurons, and does not increase their brain volume (Licht et al., 1994, 2003).
ird, the neuroplasticity conclusion is reached through inference, there being no
direct evidence for lithium-driven neurogenesis in the human brain.
e interpretation of the naa nding is challenging, as the neurobiological role
of naa is far from established (Moett et al., 2007). Increased naa concentration
may favour neuroprotection over neurotoxicity, but it does not resolve the proposed
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conict between neuroprotection and hydration as naa estimates are not independent
of brain water. Functioning as an osmotic regulator, changes in naa concentration
could be a cause or consequence of altered hydration. Further, if mrsmeasurements
of naa concentration are normalised to estimates of brain water – as with the study
of Moore et al. (2000a) – increasing the actual amount of water in the brain would
reduce the estimated naa concentration, water signal being the denominator.
neurotoxicity theories
e neuroprotective interpretation is refreshingly optimistic since an identical but
opposing argument structure could be advanced – cellular swelling due to a neurotoxic
eect of lithium. Whilst important to consider in theory, that subjects in the studies to
date were either carefully titrated to the correct serum concentration or were already
tolerating an established treatment regime makes a neurotoxic explanation unlikely.
Fountoulakis et al. (2008) have recently weighed the evidence for and against the
neuroprotective and neurotoxic eects of lithium, incorporating the imaging ndings
within a balanced review of a sizeable eld.
altered mri contrast
Several authors have recognised that in theory, the changes detected in grey matter
could arise from an alteration in signal contrast secondary to an undened eect
of lithium (Moore et al., 2000b; Monkul et al., 2007). None have acceded the point
and the concept has not been explored.is thesis proposes a mechanism for such a
contrast change, asserting that a change in signal intensity secondary to a reduction
in the longitudinal relaxation time of water may better explain the imaging ndings.
5.1.2 Lithium and the magnetic resonance signal
To justify an experiment investigating this matter, two premises must be established.
First, it should be possible for alterations in the contrast of an image to be misin-
terpreted as a volume increase during analysis. Second, lithium must be capable of
altering the mri signal such that this occurs.
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tissue characterisation
Magnetic resonance imaging utilises the specic behaviour of protons in a magnetic
eld following radiofrequency excitation, the principles of which were covered in
Chapter 2. To recap the most salient points, structural images are usually T1-weighted;
the degree of contrast is inversely proportional to the T1 time of protons. Such contrast
is relative and based on the voxel intensities at a specic acquisition time, the absolute
T1 values not being determined. When algorithms such as vbmmake a judgement
on what sort of tissue a voxel is most likely to contain, they do so on the basis of its
intensity prole, weighted by its position in the brain and the class allocated to the
neighbouring voxels (see §2.3.3).
e output of classication may be considered as categorical data, the dominant
tissue in a voxel taken to represent its whole for the purpose of volumetric estimation.
For much of the time, classication is straightforward – regions of relatively pure
tissue class are not uncommon and in such cases the voxels tend towards homogeneity.
Although the intensity proles of white and grey matter overlap, in most cases they
are suciently distinct to permit accurate discrimination.e problems arise when
partial volume eects are encountered, wherein the contents of a voxel are not wholly
accounted for by a single tissue.
partial volume effects
Partial volume eects can arise because of genuine tissue mixing in areas such as the
thalamus, or because of inadequate image resolution when the voxel spans distinct
tissues.e signal prole of such voxels may span the range of intensities common to
more than one tissue class – allocation becomes a matter of probability. Voxels subject
to partial volume eects must either be excluded from analysis or allocated to a tissue
type even in cases of uncertainty. Critically, changes in image contrast resulting from
alterations in T1 relaxation could alter tissue allocation in marginal cases, resulting in
a dierence in apparent volume.
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tissue misclassification
Recall the rst premise, that tissue misclassication must be a possibility. Discussing
how confounding eects can aect the validity of segmentation, Ashburner and
Friston (2000, page 808) observe that ‘Subtle but systematic dierences in image
contrast or noise can easily become statistically signicant when a large number of
subjects are entered in a study.’ Although in the example provided they cautioned
against collectively analysing data acquired from dierent scanners, the concern
equally applies to systematic changes brought about by drugs.
Salgado-Pineda et al. (2006) tested the hypothesis that a drug-related change in T1
would aect the image intensity and thereby alter the number of voxels attributed to
grey matter during vbm analysis. Comparing a single dose of l-dopa with placebo in
a randomised cross-over study of healthy subjects, T1-weighted images were acquired
before and aer drug administration (mean 105 minutes). More voxels were classied
as grey matter aer l-dopa administration, exclusively in the substantia nigra and the
vta – the sites of its actions. It is dicult to envisage a neurotrophic mechanism for
true changes in grey matter volume secondary to l-dopa occurring in less than two
hours.ere was, however, a change in the intensity of the midbrain voxels which was
thought to account for their altered classication; the signal change probably arose
from the eects of l-dopa on the cellular milieu and functional status.
lithium and proton relaxation
In support of the second premise – that lithium could cause a change in the mri
signal without altering brain volume – there are two pieces of empirical work. First,
Rangelguerra et al. (1983) conducted a longitudinal investigation of 20 patients with
bipolar disorder, gauging proton relaxation times before and aer treatment with
lithium. In all cases, lithium shortened the T1 of protons in the brain. Second, sim-
ply adding lithium chloride to water shortens the T1 of its protons (Fabricand and
Goldberg, 1967); the magnitude of this eect is small but linearly related to the con-
centration of lithium. Consequently, the situation is such that not only could the grey
matter volume increase be illusory, it may also be driven by a non-biological process.
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5.2 study objectives
e study that follows explores the idea that the increase in grey matter attributed
to lithium arises not from an actual change in the volume of the brain, but from an
alteration in the magnetic resonance relaxation time of protons in tissues exposed to
the drug. In essence, it is proposed that the apparent volume change is an artefact of
the signal acquisition and image analysis process.
e tools and techniques required to investigate this matter are readily available to
the researcher. What is required is a comparison of assessments of grey matter volume
measurement, taken before and aer lithium, using two dierent image analysis
strategies – one relying on voxel intensity to derive tissue volumes and another less
dependent on such. Optimised vbm fulls the rst requirement, siena the second (see
§2.3.3). If there is a discrepancy between the measured volume change using the two
techniques, it should arise in the context of an alteration in image intensity. It is now
possible to measure the relaxation times of tissues in vivo at the voxel-level using high
resolutionT1-mapping techniques (the principles of relaxometry are described in §2.4).
e necessary scan sequences – T1-weighted imaging and quantitative assessments
of longitudinal relaxation – may be implemented on a clinical scanner. With the
concerns raised and the tools selected, the following hypothesis was proposed:
In analysing T1-weighted images acquired before and aer the adminis-
tration of lithium to healthy subjects, increased grey matter volume will
be reported by automated techniques that segment tissues on the basis of
image intensity, but not with algorithms that primarily detect boundary
shis. Further, quantitative T1–mapping techniques will show a reduction
in the spin-lattice relaxation times of protons following lithium, with this
eect sucient to account for the volumetric imaging ndings.
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5.3 study methodology
5.3.1 Study design
e study conducted was an open-label, longitudinal investigation during which
healthy subjects received lithium tablets for eleven days, randomly allocated to a Akin to mrc-lamp,
the study spanned
an equilibration
period followed by
one week at the
target level.
high or low dose regime. Hereaer referred to as the mrc-lite study, subjects were
scanned before and immediately aer completing the course of tablets. e study
protocol was approved by an lrec and funded by the mrc.
e T1-weighted images collected in the mrc-lamp study were also included,
increasing the power of the analysis and permitting a comparison against placebo.
Quantitative T1 sequences were acquired from six participants in themrc-lamp study.
5.3.2 Subject recruitment
Recruitment and screening procedures largely matched those of the mrc-lamp study
(§4.4.2–3), though the inclusion and exclusion criteria diered slightly. Subjects
were able to enrol in the mrc-lite study regardless of handedness or past history of
stimulant use. As most of the volunteers contacting the team were interested in the
fmri study, subjects in the mrc-lite study tended to be those deemed unsuitable for
stimulant administration or those who, on reection, were disinclined to take it.
5.3.3 Lithium administration
e dose of lithium carbonate was calculated as previously described (§4.4.5), with
the necessary blood samples acquired during the screening visit.e dosing strategy,
administration period and tablet preparation in the mrc-lite study matched that
of the mrc-lamp study, diering only in the open-label nature of the intervention.
All subjects were randomly allocated to receive either a high dose or a low dose of
lithium, aiming for blood levels of 0.5 and 0.9 mm respectively. Subjects were asked
to ll in a simple diary indicating whether or not they took their medication on each
of the study days, and then completed the lisers on returning for their second scan.
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5.3.4 Scan acquisition
Data was acquired from all participants using the same 3Twhole body Philips Achieva
System using an 8-channel sense head coil. Aer the acquisition of a T1-weighted
image (3d t1_ffe sequence: tr = 9.6 ms, te = 4.6 ms; ip angle = 8○, fov = 240 × 180× 240 mm, contiguous isometric voxel size 1 mm), a fast quantitative T1 measurement
was performed using a custom inversion recovery prepared epi sequence (feepi
sequence: tr = 15 s, te = 24 ms, tir = 0.25 to 2.5 s in 12 uniform steps, matrix 128 ×
128, 72 slices, isotropic 2 mm resolution), followed by a low resolution B0 eld-map
using a dual echo gre (3d ffe sequence, tr = 27 ms, te = 2.6, 6.1 ms).
5.3.5 Analysis
e characteristics of the subjects and their medication regimes, together with the
serum lithium concentrations achieved and side eects experienced, were analysed
using spss (v.17, spss inc., usa). Image analysis was performed on a personal computer
running a Linux operating system (Ubuntu 8.04 lts) – an admixture of proprietary,
open-source and locally developed soware packages were used (spm, mricro, fsl,
mriguru and matlab®). Group summary statistics are reported as mean values ± sd,
unless otherwise stated.
voxel-based morphometry
Preprocessing T1-weighted anatomical images were segmented into three tissue com-
partments using the vbm mode of spm8. In normalising the images to a standard
template, the option of modulation was selected such that the intensity of each voxel
represented a volume measure. Segmented, normalised images were smoothed with
a Gaussian kernel of 12 mm fwhm prior to voxel-wise comparison.
Voxel-wise analysis e smoothed images of the subjects receiving lithium were
submitted to a voxel-wise comparison by paired t-test in a random-eects model; like-
wise the placebo group. Regional volumetric dierences thus detected were deemed
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to be signicant at p < 0.05 following fwe correction. Exploratory analyses employed
a lower initial height threshold (p < 0.001 uncorrected), signicance ascribed at a
corrected cluster-level threshold of p < 0.05.
Tissue volumes Global volumes for grey matter, white matter and csf were derived
from the relevant segmented images using the ‘get_totals’ function in spm, accessed
through the matlab® command-line.e percentage volume change for each tissue
compartment in every subject was calculated using equation 4.4 (page 107), and a
group mean derived.
siena algorithm
e percentage brain volume change between the two scan sessions was also estimated
with the siena algorithm.is package relies on segmentation only in so much as to
detect the edges of the brain tissues; to limit partial volume eects, a two-compartment
model was selected (brain tissue and csf), thus determining whether the brain as a
whole enlarged following lithium.e automated procedure was initiated with the
terminal command-line code: siena <input_file> <output_file> −2
quantitative t1 analysis
Regional T1 histogram generation e following stages of analysis were performed
using mriguru, a locally developed package that enables T1-maps to be constructed
and the relevant data extracted from specied brain regions. Separately, T1-weighted
and quantitative T1 images in proprietary par-rec format were converted to analyse
format before brain extraction (mriguru implements the bet algorithm of fsl).
e quantitative, brain-extracted T1 image for each subject was then reordered and
unwarped using their phasemap.ese images were divided into 16 regions of interest
for each tissue class (grey matter, white matter and csf; 48 in total).
e regions of interest were dened at the lobar level, eight for each hemisphere
and classied as follows: frontal (superior and inferior), parietal, parietal-temporal,
temporal, temporal-occipital, occipital, cerebellum. Regional division was performed
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in native space, lessening the errors associated with partial volume eects compared to
standard space operations (Aribisala and Blamire, 2009).e process used a standard
space brain roi template which was transformed into native space for each subject,
based on a multi-step registration using their T1-weighted, brain-extracted image.
e same T1-weighted image was then segmented to create three masks, one for each
tissue compartment (grey matter, white matter and csf).ese masks were combined
with the transformed brain template to generate tissue specic anatomical regions of
interest, in turn applied to the processed T1-map.
Quantitative T1 times were calculated on a pixel by pixel basis, and an isotropic 3d
relaxation map produced. For each roi, the mriguru algorithm automatically deter-
mined the T1 relaxation time for grey and white matter, yielding a regional histogram
of values – those from the cerebellum were excluded as its mixed tissue produces a
bimodal distribution. e subjects’ mean T1 values for each region were analysed
according to group and medication status (before and aer lithium or placebo) using
t-tests.
Voxel-based relaxometry e low resolution tted quantitative T1 map of each sub-
ject was co-registered to their high resolution brain-extracted T1-weighted counterpart
before normalisation to a T1 template.e spm package proved unsuitable for this
step as the images were brain-extracted and their orientations diered aer prepro-
cessing. Using the advanced options within the fsl linear registration package flirt,
co-registration was achieved in all but one case.e ‘incorrectly orientated’ search
parameters were applied (x, y and z axis search angles of −180○ to +180○), with
registration to the fsl standard brain-extracted template (mni152_t1_2mm_brain.nii).
e co-registered images were then smoothed with a Gaussian kernel of 12 mm
fwhm before being submitted to voxel-wise comparison by paired t-test using spm. An
initial height threshold of p < 0.001 was used, with a subsequent corrected cluster-level
threshold of p < 0.05 to identify clusters passing correction for multiple comparisons.
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5.4 results
5.4.1 Subject characteristics
Eight subjects enrolled directly into the mrc-lite study and 24 into the mrc-lamp
study, of whom 18 received lithium carbonate. One of the subjects in the mrc-lite
study had a poor quality scan which le a total of 25 lithium-treated, and six placebo-
treated subjects with images suitable for analysis. One of the quantitative T1 images
from the mrc-lamp study could not be adequately coregistered, and this individual
was excluded from relevant analyses.
All of the subjects were male and between 18–35 years of age; average alcohol
consumption was within recommended limits (see table 5.1).e lithium and placebo
groups did not dier in the characteristics of their subjects on formal comparison.
5.4.2 Medication regimes
By self-report, subjects took their tablets on the majority of days, with no individual
missing more than one dose.e mean duration of the course of tablets was 10.4 ±
1.6 days (all subjects, n = 31), with no dierence between the groups. In those who
received lithium, this resulted in a mean serum level of 0.64 ± 0.3 mm (all subjects on
lithium, n = 25).ose randomised to receive a higher dose of lithium had greater
serum concentrations of lithium than the lower dose group (higher dose group 0.82 ±
0.30 versus low dose group 0.47 ± 0.16 mm ; 2-sample t-test : t 3.77, 23 df, p < 0.001).
Side eects arising from the lithium/placebo tablets were few, rarely greater than
mild intensity on the lisers. A one-way anova of the lisers scores showed a dier-
ence within the three groups (f 4.73, 2 df, p = 0.017). Post-hoc analysis revealed no
dierence between the lower dose lithium group and placebo, but the higher dose
group reported more side eects than other subjects (Tukey’s hsd: higher versus
lower p = 0.048; higher versus placebo p = 0.032). On no occasion were side eects
sucient to prevent a subject from completing the course of tablets, and no serious
adverse events were reported.
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placebo group lithium groups
lower dose higher dose
characteristics
Age (years) 25.4 ± 4.0 22.9 ± 5.0 21.8 ± 2.6
Body mass index (kg/m2) 24.3 ± 2.1 24.2 ± 1.9 24.5 ± 3.2
Alcohol (units per week) 18.3 ± 9.1 18.0 ± 7.9 17.9 ± 13.8
treatment details
Duration of treatment (days) 10.2 ± 1.5 10.5 ± 1.7 10.4 ± 1.6
Side eects (lisers score) 1.3 ± 1.5 2.5 ± 2.4 5.8 ± 4.5
Priadel™dose (mg per day) — 923 ± 192 1367 ± 317
Serum lithium level (mm) — 0.47 ± 0.16 0.82 ± 0.30
Table 5.1: Descriptive statistics (mean ± sd) according to group for the mrc-lite study. Lithium
group: higher dose (n = 12), lower dose (n = 13); placebo group (n = 6).
5.4.3 Voxel-based morphometry volumes
lithium group
Grey matter volume increased aer lithium (volume in cm3: pre-lithium 749.6 ± 80.8,
post-lithium 758.0 ± 83.3; t −3.63, 23 df, p = 0.001).is equated to a increase in grey
matter volume of 1.11% when all those taking lithium were analysed. White matter
was unchanged whilst the volume of the csf compartment reduced (pre-lithium 273.1± 40.2, post-lithium 264.7 ± 41.5; t 3.24, 23 df, p = 0.003); see table 5.2 on page 173.
At a trend-level, percentage grey matter volume change correlated with the serum
lithium level (r = 0.337; p = 0.099); the inverse was found for csf (r = − 0.341; p =
0.096).e higher and lower dose groups did not dier in the percentage grey matter
volume change (higher dose = 1.64 ± 1.71%, lower dose = 0.63 ± 1.28%; t −1.68, 23 df,
p = 0.11).e sample was divided post-hoc into high (n = 12) and low (n = 13) serum
concentration groups, above and below 0.7 mm respectively (higher concentration =
0.88 ± 0.19 mm; lower group = 0.41 ± 0.14 mm). A trend for the percentage change in
grey matter volume to be greater in the high-concentration group was detected (high
concentration = 1.71 ± 1.65%, low concentration = 0.57 ± 1.30%; t 1.93, 23 df, p = 0.066).
Grey matter volume increased in the high-concentration group (pre-lithium 749.5 ±
74.3, post-lithium 762.5 ± 78.3; t −3.55, 11 df, p = 0.005), but not the low-concentration
group (pre-lithium 749.6 ± 89.4, post-lithium 753.8 ± 90.6; t −1.67, 11 df, p = 0.12).
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grey matter white matter cerebral fluid
lithium
Pre-treatment 749.6 ± 80.8 552.6 ± 64.1 273.1 ± 40.2
Post-treatment 758.0 ± 83.3 554.1 ± 58.4 264.7 ± 41.5
placebo
Pre-treatment 707.6 ± 84.0 543.6 ± 77.6 279.5 ± 34.1
Post-treatment 699.7 ± 88.5 550.3 ± 80.1 277.1 ± 31.9
Table 5.2: Tissue volumes by vbm analysis, with volumes as mean ± sd in cm3. e lithium
group reported here includes all subjects (n = 25), placebo group (n = 6).
placebo group
In the placebo group, no signicant dierence was demonstrated for grey matter or
csf volumes, but an increase in white matter volume was found over the time period
of the study (543.6 ± 77.6 versus 550.3 ± 80.1; t −4.14, 5 df, p < 0.01).
between groups
Percentage change tissue volumes were compared in those receiving lithium (n = 25)
and placebo (n = 6). Percentage grey matter volume change diered between the
two groups (lithium versus placebo; t 2.67, 29 df, p = 0.012), but white matter did not
(lithium versus placebo; t −0.76, 29 df, p = 0.455).
5.4.4 Voxel-wise comparison using vbm
Submitting data from all subjects who received lithium to a voxel-wise comparison
revealed no clusters representing volume increase at the fwe correction threshold
of p < 0.05. Specifying a factorial design by dose in spm, a comparable analysis was
performed for the higher and lower dose lithium groups. Subtracting the pre-lithium
from the post-lithium images in the higher dose group at the fwe correction threshold
of p < 0.05, greymatter volume increase was seen in a solitary cluster (−6 · 0 ·20; voxels
= 31, t = 5.41, p = 0.015).ose taking a lower dose of lithium also demonstrated a
regional increase in grey matter volume on vbm, a single cluster passing the threshold
for signicance (−14 · −22 ·4; voxels = 10, t = 5.31, p = 0.028); see gure 5.1.
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Figure 5.1: Regional greymatter changeby voxel-basedmorphometry for the groups randomised
to receive higher (n = 12) and lower (n = 13) doses of lithium (height threshold T = 4.95, extent
threshold k = 0 voxels, p < 0.05 FWE). The scale represents the t-score for the rendered voxels.
5.4.5 Volume change using the siena algorithm
Percentage brain volume change over the course of the study was determined for each
subject, and the group means compared – mean pbvc values were small, with no
dierence between the lithium and placebo groups (placebo group − 0.01% ± 0.17;
lithium group 0.24 ± 0.48; t −1.23, 29 df, p = 0.23).
5.4.6 Proton T1 relaxation time
Following lithium administration, there was a small but signicant reduction in mean
grey matter proton T1 relaxation time when mean values derived from the histograms
of all brain regions were compared (1474 ± 98ms to 1466 ± 94ms; z −2.65, 168 ranks, p
= 0.008). Considering each lobar region in turn, before and aer lithium, trend-level
reductions in the mean grey matter proton T1 were found in the temporal-occipital
region on the le (1501 ± 56 ms versus 1482 ± 51 ms; z −1.83, 12 ranks, p = 0.060) and
the occipital region on the right (1520 ± 69 ms versus 1503 ± 70 ms; z −1.73, 12 ranks,
p = 0.084). White matter proton T1 values were unchanged following lithium.
At a trend-level, percentage grey matter volume change correlated negatively with
the change in grey matter T1 values (r = − 0.500; p = 0.098); likewise serum lithium
concentration and grey matter T1 values (r = − 0.517; p = 0.085).
Submitting the grey and white matter T1-maps separately to a voxel-wise paired
t-test analysis, no signicant regional dierences emerged for either tissue class.
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5.5 discussion
e results of this study could be interpreted as supporting the a priori hypothesis
that lithium does not increase the actual volume of grey matter but rather reduces
the proton longitudinal relaxation time, which emerges as an apparent structural
change when the vbm technique is applied. In the following discussion the existing
imaging data is appraised; the results of the mrc-lite study presented in this chapter
are considered in this context and the overall ndings of the eld summarised.e
potential value of the vbm ndings are highlighted, as are the shortcomings of the
various other techniques applied.e proposed mechanisms by which lithium may
bring about the observed ndings are then explored, as are the reasons why a denitive
conclusion may be elusive.
5.5.1 Volumetric consequences of lithium administration
In themrc-lite study, short-term administration of lithium to healthy men increased
grey matter volume on vbm, leaving white matter volume unchanged.is nding
replicates previous automated image analysis studies of the eects of lithium in healthy
volunteers (Leow et al., 2005; Monkul et al., 2007) and patients with bipolar disorder Clinical imaging
studies to date have
almost exclusively
investigated either
bipolar disorder or
healthy subjects,
despite there being
a strong case for
studying unipolar
disorder.
(Moore et al., 2000b, 2005, 2009; Kim et al., 2008; Lyoo et al., 2010).e consistency
of the observations suggests that the image analysis techniques are detecting a genuine
dierence in the mri data before and aer lithium. In the following discussion, that
dierence is not disputed but the interpretation of grey matter volume increasing as a
result of enhanced neuroplasticity or altered cellular hydration is critically reviewed.
First, a note on magnitude. Within the context of other studies, the mean increase
in grey matter volume of 1.11% reported in this thesis is small.ere are many reasons
why this may be the case, notably the dierences in the study designs, the duration of
lithium administration and the specics of the analyses undertaken. A powerful factor
in the magnitude of the volume change is likely the choice of subjects – studies of
healthy subjects yield smaller ndings than those of patients with bipolar disorder. It
must be recognised that the eects of lithiumon anormal brainmay dier substantially
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from those occuring in illness states. Neuroprotective explanations, for example, are
to be eschewed in the absence of a stressor and a cellular insult may be a requisite for
the initiation of neurogenesis.
study design
Longitudinal studies e strongest design of study is the initiation of lithium with Prospective studies
· moore 2000
· leow 2005
· monkul 2007
· kim 2008
· moore 2009
· lyoo 2010
prospective follow-up. Subjects act as their own controls, selection bias is reduced and
the accuracy of brain volume measurement is better than in cross-sectional studies.
Moore et al. (2009) recently reported an extension to their original study of ten patients
(2000b), adding 18 more subjects with bipolar disorder and nding that lithium
increased total grey matter aer one month, signicantly so in the prefrontal cortex.
Independently replicated in bipolar disorder (Kim et al., 2008) and healthy controls
(Leow et al., 2005), a volume increase of 2–4% typies the longitudinal studies, though
the eect is sometimes seen only in frontal cortical regions (Monkul et al., 2007).
Lyoo et al. (2010), in the only published prospective study examining a comparator
intervention, found that lithium increased grey matter volume by approximately 3%
over a period of several weeks. No change in volume was observed in patients treated
with sodium valproate; healthy subjects not in receipt of an intervention acted as a
control group, and demonstrated stable brain volumes. White matter volumes were
unchanged in all groups.
Cross-sectional studies A greater number of cross-sectional studies than prospective
ones have been conducted – themajority have demonstrated a lithium-related increase
in grey matter, though some have not (Brambilla et al., 2002; Chen et al., 2007). When
increases are reported, they are generally of a greater magnitude than those in the
longitudinal investigations, substantially so in some studies. In terms of design, the
principal weakness is that of selection bias towards, or against, lithium treatment
in the patient groups. Such biases may exaggerate the magnitude of the ndings.
Cross-sectional comparisons of patients and healthy subjects are likely to be marred
by true pathological dierences unrelated to lithium.
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e results of the a priori cross-sectional studies are mixed. Sassi et al. (2002) A priori studies
· sassi 2002
· brambilla 2002
· yucel 2008
· bearden 2008
· germaniá 2010
found that patients on lithium had much larger grey matter volumes than their un-
treated counterparts and healthy controls (748 versus 676 and 639 ml respectively).
In a study of the hippocampus in bipolar disorder, Yucel et al. (2008) compared
patients taking lithium with those receiving either sodium valproate/lamotrigine or
no medication – the hippocampus (and its head) was larger in patients taking lithium
compared to unmedicated subjects and healthy controls, intermediate volumes being
found in the sodium valproate/lamotrigine group. Using surface-based anatomic
mapping, Bearden et al. (2008) reported that the hippocampal volume of patients
with bipolar disorder receiving lithium was 13.9% larger than that of unmedicated
patients and 10.3% larger than healthy control subjects. Aiming to replicate dimin-
ished sgpfc volumes in bipolar disorder, Brambilla et al. (2002) hypothesised that
subjects receiving lithium would not dier from healthy controls – as it happens, no
abnormalities were detected and lithium had no bearing on the volumetric measures.
It is now routine to consider lithium when discussing structural imaging ndings Post-hoc analyses
· beyer 2004
· javadapour2007
· bearden 2007
· chen 2007
· scherk 2008
in the aective disorders – several authors have interrogated their data post-hoc.
Beyer et al. (2004) reported that elderly subjects with bipolar disorder had larger le
hippocampal volumes compared to age matched controls, attributing this dierence
to lithium. In a region of interest study, Javadapour et al. (2007) found that subjects
with bipolar disorder had larger right acc volumes compared to healthy controls, with
a striking increase of 26% reported – the dierence was signicant in those taking
lithium, but not with other medications. A recent optimized vbm study compared
healthy subjects to those with bipolar disorder and found no dierence in global grey
matter volumes (Chen et al., 2007). When advanced techniques are used to map
cortical grey matter, patients with bipolar disorder appear to have substantially greater
tissue densities compared to controls (Bearden et al., 2007) – translating to a volume
excess of about 9%, this dierence was considered ‘entirely attributable to patients
treated with lithium’.
e volumetric ndings of themrc-lite study here reported most closely approxi-
mate to those of the longitudinal studies, but the magnitude falls short of the reported
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range.is indicates that other aspects of the interventions and assessments require
scrutiny. In the sections that follow, the inuence of the duration of treatment, the
dose administered and the clinical eects of lithium are considered.
duration of treatment
e most obvious reason for the diminutive grey matter volume increase in the study
reported here is the short period of lithium administration. Subjects in the mrc-lite
study took lithium for approximately 11 days, only the last week of which could be
considered to be at a stable target serum level. Logically, regardless of the mechanism
at play, volumetric increase on mri must develop over time, eventually reaching a
plateau. A simple linear correlation between duration of treatment and grey matter
volume change is therefore unlikely, and in any case has not been found (Sassi et al.,
2002). Bearden et al. (2007) reported a signicant association between grey matter
volume change and duration of treatment, nding a quadratic relationship between the
two variables once the logarithm of the time on medication was plotted – something
of a challenge to interpret.
e data from the study of Kim et al. (2008) supports an early eect as the increase
in grey matter observed in the lithium group was evident at four weeks, unchanged at
the end of the fourmonth long study. In the studies ofMoore et al., (2000b; 2005; 2009)
scans were performed aer one month on lithium, but the actual eective treatment
duration may have been substantially less because of the titration schedule used. Lyoo
et al. (2010) charted the course of grey matter volume change in patients with bipolar
disorder and a healthy comparator group. Patients were randomly allocated to receive
either lithium (n = 13) or valproate (n = 9), and were naïve to these medications
prior to enrolment. Analysing 93 scans from 36 individuals, lithium but not valproate
was associated with an increase in grey matter volume (2.56%, equivalent to 17.6
cm3). Fitted to a quadratic mixed-eect regression model, the increase in grey matter
volume peaked at 10-12 weeks.e tted data of Lyoo et al. support the vbm ndings
of this thesis – subjects in the mrc-lite study took lithium for a brief period it is
possible that a greater volume change may have been observed over a longer course.
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at the ndings of this thesis largely match those of Lyoo et al. (2010) may also
reect the purity of the initiation of lithium. Importantly, patients in the studies of
Moore et al., (2000b; 2005; 2009) were not necessarily lithium-naïve and those taking
the drug at enrolment entered a two week washout period prior to the ostensible
initiation of lithium treatment. is would be expected to have marked eects on
mental state, theoretical eects on brain structure, probably generated a selection bias
akin to the cross-sectional studies and in terms of wash-out and reversal of cellular
eects, was of insucient duration.e contribution of these eects to the magnitude
and direction of brain volume change is too complicated to predict.
serum concentration of lithium
Clinical studies have investigated patients either maintained at a therapeutic level or
titrated to such a level as part of the protocol, the latter invariably the case for the
healthy subject work. e range of serum levels in a given study is therefore quite
narrow, with a target level of around 0.8 mm being common. No dose-eect studies
have been conducted. As correlations across a limited range of values are unlikely to
be meaningful, it is not surprising that few studies have included an analysis of the
relationship between grey matter volume change and serum lithium level. By way of
example, Moore et al. (2009) found no such correlation and the target level dictated
by their protocol resulted in a restricted range of serum lithium levels (0.9 ± 0.2 mm).
In this thesis, no signicant correlation between grey matter volume change and
serum lithium concentration was observed, but an association at a trend-level was
noted.e notion that greater concentrations of lithium induce more volume change
on vbmwas supported by the dierence between the high and low serum level groups.
In the group achieving a high serum concentration, the mean lithium level was 0.88
mm and their 1.73% grey matter volume increase using the values derived from vbm
was closer to the changes reported in comparable longitudinal clinical studies (Moore
et al., 2000b, 2005, 2009). It is important not to over emphasise this observation as
the division of subjects was performed post-hoc, with no dierence observed in the
percentage grey matter volume change when the a priori groups were compared.
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relationship to clinical variables
In the index study (Moore et al., 2000b), grey matter increases were observed in eight
of the ten participants, and similar proportions have been reported in other studies.
is begs the question of whether a subgroup can be dened in which the eects of
lithium are manifest through imaging.
e therapeutic response to lithium is probably the most important of the vari-
ables to consider. In the longitudinal studies of bipolar disorder, most patients were
depressed at the time of enrolment and response to lithium assessed with standard
mood rating scales. Kim et al. (2008) found that grey matter volume increase was
associated with clinical improvement. In a more detailed analysis, Moore et al. (2009)
demonstrated an increase in grey matter volume in 20 of their 27 patients, comprising
9 of 10 lithium-responders and 11 of 17 non-responders. A trend-level correlation be-
tween response (ham_dmood rating scale score) and grey matter increase was found
(p = 0.075). For prefrontal cortical grey matter volumes, a main-eect of lithium and
a trend towards a treatment-by-response interaction was shown (p = 0.07), in which
lithium-responders had a signicant volume increase (p = 0.003) but non-responders
did not. In the longitudinal study of Lyoo et al. (2010), patients responded equally
well to treatment with lithium or valproate, but only in those taking lithium did the
improvements in depressive symptoms correlate with grey matter volume increase
(Spearman ρ = − 0.59, p = 0.03). In the cross-sectional studies, therapeutic response
has not been formally gauged and so comparative analyses have not been possible.
Obviously therapeutic eects cannot inform the discussion of the results of this
thesis, all the subjects being healthy volunteers.e closest approximation would be
the lisers scores and the rvip task performance in those completing the mrc-lamp
study.ese measures arguably focus on the detrimental eects of lithium, which
may have little to do with its therapeutic potential. Further, arguing that the subjects
with the greatest side eects are comparable to the patients who respond overlooks
the fact that the true comparison should be with those patients who were less able to
tolerate lithium. Such patients are unlikely to have completed the scanning studies.
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5.5.2 Summary of the reported ndings
e mri studies describing a lithium-related increase in grey matter volume have a
degree of consistency that suggests the observation is valid. To reiterate, that lithium
has a detectable eect on grey matter is not disputed in this thesis, rather the assump-
tion that the imaging ndings represent a tangible increase in the physical volume of
the brain. When discussing the potential mechanisms by which lithium may cause
this eect, it may be of use to consider whether a pattern to the ndings exists.
• e most important observation is that the change in grey matter can occur in those
with bipolar disorder and in healthy subjects.
• e magnitude of the eect of lithium appears to be more marked in patients than in
healthy subjects, and may be related to treatment response in the former.
• e grey matter dierence occurs within in a time-scale consistent with the onset of
the therapeutic eects of lithium, reaching a plateau within a few months.
• Serum levels in the therapeutic range appear to be necessary.
• e eect is seen across brain regions, the largest reported changes being in prefrontal
and hippocampal areas.
5.5.3 Synthesising the imaging ndings
All of the mri studies investigating the the eect of lithium on brain structure have,
by necessity, applied a processing step to distinguish grey matter from adjacent tissue
classes. Various dierent automated and semi-automated image analysis packages
have been used, but it would be reasonable to assert that all made use of the voxel
intensity prole whilst segmenting the brain.
e vbm package relies heavily on intensity whilst segmenting the brain and in
the study reported here, showed a lithium-related increase in grey matter volume.e
siena algorithm uses voxel intensity to dene the brain/csf boundary, the volume
change determined by analysing the boundary movement between scan sessions.
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Using siena, no dierence was detected in the mean percentage brain volume change
for the placebo and lithium groups. No change in volume was observed in the placebo
group and the mean change of 0.24% in the lithium subjects was barely above the
0.2% error range for this technique.
If the vbm ndings represented a true change in brain structure, siena should
havematched it inmagnitude – as predicted, this was not the case. It was hypothesised
that the vbm ndings would be better explained by an alteration in voxel intensity,
in turn due to lithium reducing the proton T1 time. Analysis of the quantitative T1
data revealed a reduction in proton T1 when mean values for grey matter in all lobar
regions of interest were compared (excluding cerebellum). Divided by regions, the
reduction in T1 values in the grey matter was signicant in the superior frontal lobes,
an area of apparent volume increase on vbm voxel-wise comparison.e mean T1
reduction correlated with the vbm-derived percentage grey matter volume change
at a trend-level. Collectively, these ndings substantiate the a priori hypothesis and
question the conclusions of the eld at large.
5.5.4 Consequences of a reduced proton T1
It has previously been established than an increase in voxel intensity can be misin-
terpreted as a regional increase in grey matter volume with vbm (Salgado-Pineda
et al., 2006). With T1-weighted imaging, reducing the proton T1 increases the signal
intensity and may reduce the contrast between tissue types; in grey matter, voxel
intensity proles would more closely approximate to those of white matter. Why then,
if contrast is to blame, does lithium not cause an increase in white matter volume?
is is a dicult question to answer, and one clearly open to conjecture. It may
be assumed that the categorisation of existing white matter voxels is unchanged by
lithium as no change in their T1 was observed. Likewise, an enormous change in
signal would be required to confuse pure csf with brain tissue. Grey matter voxels
are inherently dicult to classify as their intensities overlap both csf and white
matter proles, making them the likely site of segmentation errors in areas prone
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to partial volume eects. In voxels containing a mixture of white and grey matter,
reducing the T1 should increase the likelihood of it being allocated to the white matter
class. In voxels containing grey matter and csf, one could argue that the increased
signal intensity would exaggerate the contribution of the grey matter and swing the
classication away from csf.e grey matter/csf boundary of the cortex is highly
convoluted and the number of voxels prone to partial volume eects is large, greater
than in the white matter and arguably greater than at the white matter/grey matter
boundary (Rueda et al., 2010). A systematic reduction in grey matter T1 may emerge
as misclassication in these areas, explaining why the grey matter increase almost
exactly matched the csf reduction in this thesis. In support of this account, vbm
localised the grey matter increase to the le lateral ventricle and thalamus (gure 5.1),
the mixed tissue of this nucleus making it prone to partial volume eects.
It must be said that the reduction in proton T1 observed, although signicant, was
small. Rangelguerra et al. (1983) reported a substantial reduction in the proton T1 of
patients with bipolar disorder (264 ± 88 ms before lithium, 208 ± 80 ms aer; n = 20). e absolute values
for T1 are shorter
because the study
was conducted at a
lower eld strength.
In keeping with the reported volumetric ndings, it may be that the magnitude of the
eect of lithium in normal subjects is lesser, though the dierence between the results
presented here and those of Rangelguerra et al. (1983) are striking. Nevertheless, the
change in relaxation time described in this thesis may be sucient to bring about the
required change in voxel intensity.
S = S0 (1 − e−tr/t1) sinα(1 − cosα) e−tr/t1 (5.1)
Signal intensity in T1-weighted imaging can be calculated using equation 5.1 (above).
In themrc-lite study, repetition time, echo time and ip angle were consistent across
the sessions (tr = 9.6 ms, te = 4.6 ms, α = 8○) such that alterations in signal intensity
must reect a dierence in the T1 of protons. Submitting the mean T1 values before
and aer lithium (1474 ms and 1466 ms respectively) to equation 5.1 and comparing
the values, a 0.4% increase in grey matter signal intensity returned.e sensitivity of
vbm to a systematic dierence of this magnitude requires further investigation.
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5.5.5 Lithium-driven mechanisms of proton T1 reduction
Introduced as a premise (Rangelguerra et al., 1983) and conrmed by investigation,
lithium appears to reduce the longitudinal relaxation time of protons in the brain of
man. Whilst it is of interest that this occurrence could explain the volumetric ndings
from mri studies, the mechanism by which proton relaxation is altered may arguably
be of greater importance.at it could feasibly be related to the therapeutic eects
of lithium may prove to be of some signicance. A number of mechanisms could be
proposed but, given the origins of the mri signal, the interaction between lithium and
water warrants the most attention.
key properties of water
In isolation, a water molecule can be considered as a tiny v-shaped structure of the ‘Water is h2o,
hydrogen two parts,
oxygen one, but
there is also a third
thing that makes
water and nobody
knows what that is’.
D.H. Lawrence
Pansies (1929)
formula h2o. In bulk, water may not simply be a random collection of these molecules
but rather a complex network of hydrogen-bonded units which en masse give rise to
anomalous liquid properties (Ball, 2008). It has been argued that in pure bulk water,
themolecules have a propensity to cluster and transiently adopt various congurations,
the nature of which is determined in large part by hydrogen bonding (Chaplin, 2000).
e extent of the order in this structuring is inuenced by various ambient factors such
as temperature, pressure and applied electromagnetic radiation. Various models of
the structure of bulk water have been proposed and contested, some more outlandish
than others and none gaining universal acceptance(Wallqvist and Mountain, 1999).
e main stumbling-block is the paucity of empirical data to support the existence
of complex molecular congurations in bulk water – hydrogen bonds break and
reform over picosecond time scales such that the proposed structures could exist only
eetingly (Eaves et al., 2005). Nevertheless, bulk water has been ‘conceptualized as a
mixture of two rapidly interconverting species: a less dense, more structured form,
and a more dense, less structured arrangement’ – Zhang and Cremer (2006, citing
Chalikian (2001)).
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water structure in ionic solutions
Compared to the models of pure bulk water, evidence for the structuring of water
in the presence of other ions has a stronger foundation. Water molecules are highly
polarised and strongly attracted to ions, clustering around them to form an ordered
primary hydration shell (Marcus, 2009).is shell may further alter the structuring
of the neighbouring water molecules resulting in a larger, secondary hydration shell.
e potency of various ions diers in this regard, as does their propensity to increase
or decrease the structuring of water. Ions which bring order to the structure of water
are termed kosmotropes, those diminishing the order are chaotropes; they are ranked
in the Hofmeister series, the robustness of which is greater for anions than cations.
kosmotropic chaotropic
cations Ca2+ > Mg2+ > Li+ > Na+ K+ > Rb+ > Cs+ > NH4+
anions SO42− > HPO42− Cl− > NO3−
Adding a kosmotrope to water can be thought of as making it more ‘ice-like’ (Ball,
2008) – its density is reduced and solutes are less likely to dissolve. A greater degree Structuring water
reduces its density,
so the addition of
lithium should
cause an increase in
the volume of water.
is eect will be
minuscule at the
levels attained
during treatment –
this consequence of
kosmotropy must
not be confused
with the proposed
eects on mri
signal intensity and
derived volumes.
of structure equates to a more ecient spin-lattice energy transfer. It should be no
surprise then, that the proton T1 of an aqueous solution of lithium chloride is shorter
than that of pure water (Fabricand and Goldberg, 1967). Indeed, the eects of ions on
the T1 of water closely follows the Hofmeister series (see gure 5.2).e question is
whether this fundamental eect accounts for ndings reported in this thesis.
lithium & bulk water proton t1
When lithium interacts with water molecules, its positive charge attracts the oxygen
atom to create a primary hydration shell with outward facing hydrogen (Hermansson
and Wojcik, 1998). Until recently, ions were thought to aect the structuring of water
throughout its bulk by altering the strength of hydrogen bonds, kosmotropes such as
lithium increasing the stability of clusters.is may not be the most suitable model
to aid interpretation, as much of the eect of ions is restricted to the immediate
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Figure 5.2: Plot of T1 relaxation times of water protons versus crystal radii of alkali cations in aqueous
solutions of alkali halides. Study performed at nmr frequency of 100 MHz on 4M solutions of alkali
chlorides. (gure and caption reproduced from Rangelguerra et al. (1983))
hydration shell and the Hofmeister series pertains only to ions near a surface (Zhang
and Cremer, 2006; Marcus, 2009). Water molecules beyond the hydration shell of
the ion may remain randomly arranged, or at least not dierently ordered than pure
bulk water. Nevertheless, the small ionic radius and dense nuclear charge of lithium
attracts more water molecules than sodium (Marcus, 2009), likely accounting for
its more marked eects on proton T1 (Rangelguerra et al., 1983). Presumably the
localised eects of lithium on the relaxation of adjacent water molecules averages out
as a T1 reduction within the whole mr sampling volume.
In aqueous solution, proton T1 is inversely related to lithium concentration (Fab-
ricand and Goldberg, 1967). Extrapolated to therapeutic levels, with relaxation times
adjusted to clinical eld strengths, a very modest T1 change would be envisaged.e
eect of lithium on water structure is therefore unlikely to be of sucient magnitude
to explain ndings in this thesis.e potency of a kosmotrope may, however, depend
not just on its concentration but also on the presence of ambient factors. Application
of a high magnetic eld may have altered the water structuring potential of lithium,
though there is no sound basis to favour a dramatic increase in structuring potency
over a comparable decrease. Nevertheless, this fundamental physical eect in its
purest form – no matter how minor – must be considered to contribute to the proton
T1 reduction and hence apparent grey matter volume change.
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the importance of proteins
e Hofmeister series has empirical origins, the ions rst being ranked in this way
by their propensity to stabilise or destabilise solutions containing egg-white protein.
As a diluent, water is not inert and in hydrating proteins it modies their three-
dimensional structure, an occurrence necessary for the protein to function (Ball,
2008). Water in close proximity to proteins is more structured than bulk water and
factors which aect the ease with which this structuring is adopted may determine the
conformational state of the protein, hence its functional status.us, kosmotropes
foster the hydration, solubility, folding and stability of proteins; the converse is true
of chaotropic ions.
e interaction between water, proteins and ions is potentially of great importance
in understanding the eects of lithium on mr images. First, it serves as a reminder
that the cellular environment is very dierent to that of a simple aqueous solution
and that the number of sites where lithium can act may be substantially greater. In
addition to the direct action of the ion on adjacent water molecules, its ability to alter
the conformational state of proteins may widen the eld of its eects – altering the
structure of water across the entire protein may magnify the ionic reduction in proton
T1 of cellular water compared to aqueous solutions.
Second, it may explain the localisation of proton T1 reduction to grey matter.
e csf can be considered as a relatively simple aqueous solution, immune to the
postulated eects of proteins on relaxation parameters. White matter, with its high
lipid content, may restrict the range of the eects of lithium as the ion’s large hydration
sphere (Marcus, 2009) will inhibit its mobility in such environments. Grey matter is
laden with hydrophillic molecules, is the site of many of the eects of lithium and of
the brain tissues, it is the most vulnerable to partial volume misclassication.
ird, it implies an association between the biological actions of lithium and the
magnitude of mri signal change. Lithium is thought to bring about a number of its
eects through altering the functional status of key intracellular enzymes, potentially
competing with the co-enzyme magnesium to alter calcium-dependent signalling
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processes in the neuronal cell bodies (Birch, 1976).e hydrating eects of lithium
more closely approximate to calcium and magnesium than to sodium and potassium,
with the former ions being stronger kosmotropes than the latter. Localisation, signal
distortion and therapeutic action may thus converge.
5.5.6 Signal change in complex systems
us far, the lithium ion has been considered the primary and direct cause of proton
T1 reduction, invoking its kosmotropic actions to explain this eect and as a possible
parallel, its pharmacological properties. What if the direction of this argument were
to be reversed? Could the proton T1 reduction simply be a product of the myriad
actions and eects of lithium, the consequence of diverse or disparate mechanisms Historically, unied
theories which
converge on a
single action of
lithium tend to fare
poorly; sometimes
the worth of an
extreme view lies
not in its validity,
but in the clarity it
may bring to the
middle ground.
rather than the agent of change? To do so would bring the argument full-circle, the
neuroplasticity and hydration theories once more having currency in the debate – this
time not through a tangible change in volume, but rather as modiers of the cellular
milieu and so the T1 of protons in the brain.
cellular hydration and the mr signal
Simply increasing the amount of water in brain tissue might be expected to increase
its T1 towards that of csf. Whilst this is typically seen with oedema (Kato et al., 1986),
the reverse can also occur (Yun et al., 2007). It may be inaccurate to conceptualise the
tissue changes brought about by lithium as analogous to pathological oedema and so
in terms of the mri signal, the consequences of lithium increasing cellular hydration
are open to speculation. Myoinositol is an osmoregulator and so it could be argued
that the interaction between lithium and the components of the pi-cycle mediate
the ndings of the volumetric mri studies. Free myoinositol levels are elevated in
mania (Gani et al., 1993), so the eects of lithium on water homeostasis may be more
marked in patients than in healthy subjects. Further, lobar variations in myoinositol
concentration (Silverstone et al., 2005) may explain the regional dierences in the
mri ndings. However, the eects of lithium on hydration in the rat brain were not
thought to be mediated through myoinositol (Phatak et al., 2006).
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cellular growth and the mr signal
Neuroplasticity theories present less of a problem, but only in so much as there is
no data to guide the debate. It is eminently possible that the T1 characteristics of
new or regenerating neurones dier from those of stable populations, something
amenable to empirical testing should neurogenesis actually be established to occur
in the adult human brain. It must also be recognised that the pathophysiological
processes underpinning bipolar disorder may increase the T1 of tissues, only for it
to be normalised by lithium (Rangelguerra et al., 1983; Besson et al., 1987). Such
observations also serve as a reminder that healthy subjects and patients may respond
dierently to the administration of lithium.
5.6 conclusion
e data presented in this chapter gives credence to the theory that the lithium-related
increase in grey matter observed using mri arises not from a tangible change in
brain volume, but from an alteration in relaxation properties of the tissues under
investigation. In a longitudinal study of lithium administration to healthy subjects,
grey matter volume increase was observed using vbm, but not with boundary-shi
techniques; a small but signicant reduction in grey matter proton T1 accompanied
these ndings. A trend-level inverse relationship between grey matter volume change
on vbm and grey matter T1 time was observed; likewise grey matter T1 reductions
and serum lithium concentration.e implications, strengths and weaknesses of the
study are discussed in the nal chapter of this thesis.
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6 lithium spectroscopy
Whilst much is known of the pharmacokinetics of lithium inman, a complete account
of its distribution in cells and tissues is lacking. Were this situation to be rectied,
pharmacodynamic theories may be better modelled and important clinical questions
addressed. It is the nature of lithium that has hindered progress – it cannot be usefully
labelled, has no helpful particle-emitting isotopes and is not thought to displace
receptor ligands; traditional spectroscopy techniques are only applicable in vitro and
lithium may redistribute too rapidly for such methods to be of value in postmortem
examination. Magnetic resonance spectroscopy – a technique proven in the natural
sciences – has been applied in the biomedical eld to good eect. In addition to
possessing certain advantages as a method for determining the concentration of
lithium in vitro, mrs has permitted the detection of lithium in vivo.e feasibility
of determining the concentration of lithium in the human brain is well established,
but the technique is restricted to a few specialist centres; progress has been slow and
along somewhat divergent avenues.
is chapter describes a series of lithium mrs experiments which, building on
existent approaches and expanding current knowledge, converge on an objective with
novel elements: determining the absolute concentration of lithium in the human
brain in a time scale suited to clinical use, in a manner that permits comment to be
made on its level in dierent tissue classes.
6.1 background
6.1.1 e distribution of lithium in tissues
Following its administration, lithium distributes throughout the mammalian body
(Birch and Hullin, 1972; Birch and Jenner, 1973; Ebadi et al., 1974; Stern et al., 1977). In
doing so, its concentration remains within the same order of magnitude in almost all
tissues (Birch, 1991) – table 6.1 on the following page. It is notable that with chronic
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Birch Birch Ebadi Stern
(1972) (1973) (1974) (1977)
regime Chronic Chronic Acute Acute Chronic
duration 18 month 28 day — — 12 day
route po po iv ip ip
daily lithium intake
(mmol Kg−1) 0.8 0.8 7.2 0.6 0.6
time after last dose
(hours) 12 12 24 12 12
tissue concentration
(mmol Kg−1)
Brain 0.18 0.18 1.22
Muscle 0.30 0.22 1.60
Bone 1.38 1.15 1.59
Liver 0.15 0.53
Kidney 0.53 1.35
Spleen 0.97
Serum 0.17 0.14 1.22 0.08 0.21
Pituitary 0.26 0.39
yroid 0.31 0.43
Adrenal 0.15 0.24
Table 6.1: Concentration of lithium in dierent tissues following dierent treatment regimens in rats,
administered orally (po), intravenously (iv) and via intraperitoneal (ip) routes (from Birch 1991).
administration, lithium appears to concentrate in bones, perhaps a consequence of
the diagonal relationship with calcium (§1.1). Furthermore, endocrine glands attain
higher concentrations than the serum, an observation of relevance to common side
eects such as thyroid dysfunction.e distribution of lithium in the rat brain has
been examined using atomic absorption techniques, in which small volumes of tissue
are typically dissected and homogenised before submission to analysis. Reviewed
by Ramaprasad (2005), post-mortem examination following chronic administration
initially indicated an even distribution of lithium throughout the rat brain (Dav-
enport, 1950). Subsequently, heterogeneous distributions were observed, lithium
reaching higher concentrations in the hypothalamus, putamen and neocortex (Ozawa
et al., 1976), and intermediate levels in the thalamus, septal nuclei, dentate gyrus and
hippocampus (Nelson et al., 1980).
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6.1.2 Distribution of lithium in the human brain
Few post-mortem studies examining the distribution of lithium in the human brain
have been reported. Francis and Traill (1970) reported two cases, both patients having
received lithium for only a few days prior to death. Concentrations of lithium were
found to be highest in the basal ganglia and pituitary, and lowest in the spinal cord.
In slight contrast, Spirtes (1976) observed higher concentrations in the hypothalamus
and white matter than in the grey matter, thalamus and cerebellum – the patient
examined suered from bipolar disorder in life, and died from alcohol and opioid
toxicity. Such studies are dicult to interpret, but with the advent of clinical mrs, and
latterly the availability of high eld strength scanners, it is now possible to explore
the pharmacokinetics of lithium in man (Renshaw and Wicklund, 1988).
6.1.3 Magnetic resonance properties of lithium
In order to appraise the use of lithium mrs, a basic understanding of its magnetic
resonance properties is required (the principles of magnetic resonance spectroscopy
were outlined earlier in section 2.6). Naturally occurring lithium contains two isotopes
and although both are visible using mrs, their respective properties dier. In the case
of 6Li (I = 1), the combination of its low abundance (7.42%) and slow relaxation (T1 >
1000 s) means that it is poorly suited to clinical mrs. Conversely, the 7Li nucleus is
more abundant (92.58%), has a moderately low sensitivity compared to protons and
an estimated T1 time that makes experiments long but not impracticable (see tables
2.2 and 6.2).
at 7Li yields a spectral singlet simplies its delineation, but its nature precludes
compartmental discrimination on the basis of tissue specic chemical shi. Its Larmor
frequency at a given eld strength can, however, be manipulated with shi-reagents.
is property may be utilised during quantication and potentially exploited in the
determination of intracellular concentrations, at least in vitro (Komoroski, 2000).
Akin to the other alkali metals, 7Li (I = 3⁄2) is a quadrupolar species but in clinical
and preclinical studies, these relaxation properties appear suciently weak for it
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tissue subjects b0 field reported t1 time
(t) (s)
rodent studies
Ramaprasad (1992) head 4.7 3–4
Ramaprasad (1998) head 7 2.4
human studies
Renshaw (1988) muscle 1 1.8 7.0
Komoroski (1993) head 1 1.5 4.6
Gonzalez (1993) head 2 1.5 4.2
Riedl (1997) head 2 1.5 3.2–3.5
Girard (2001) head 4 1.5 4.0–4.3
Kushnir (1993) head 5 2.0 3.5 ± 0.25
Moore (2003) head 1 4.0 4.7
Table 6.2: T1 relaxation times for lithium in which the data t a monoexponential decay.
to have been treated as a dipole (Komoroski, 2000). Single exponential modelling
of its relaxation in vivo in man places the T1 between three and ve seconds, with
shorter values closer to two seconds in the rat (Ramaprasad et al., 1992; Ramaprasad,
1998).ere appears to be variability in the T1 time between subjects, and dierences
according to eld strength. In the rodent studies reviewed by Ramaprasad (2005), T2
relaxation was found to have fast and slow components in the ranges 3–80 ms and
125–320 ms respectively. Little is known of the T2 relaxation of lithium in man, but
the 7Li isotope yields a single narrow spectral line in vivo, suggesting a swi decay.
6.1.4 Synopsis of the lithium mrs eld
e feasibility of detecting lithium in the human brain was demonstrated by Renshaw
and Wicklund (1988), their experiment also being notable as the rst to detect an
exogenously administered substance of any kind using themrs technique. In addition
to the necessity of replication, early studies sought to establish the amount of 7Li
in large tissue regions, localised by surface coil placement (Komoroski et al., 1990, Strictly speaking,
the early studies
with surface coils
assayed lithium
levels in the head,
extracerebral
structures being
included in the
sampling volumes.
1993; Gyulai et al., 1991; Kato et al., 1992, 1993, 1994, 1996; Kushnir et al., 1993).e
concentration of 7Li in the brain was almost invariably found to be lower than that in
the serum, brain-to-serum ratios of 0.5–0.9 typifying the above studies.
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From these and later studies, a simple or consistent correlation between brain and
serum concentrations of 7Li has not emerged, perhaps explained by its compartmental
pharmacokinetics. It appears that 7Li is rapidly absorbed into the serum, entering
tissues fairly swily and crossing the blood-brain barrier within an hour (Renshaw and
Wicklund, 1988). Tissue accumulation lags behind serum uctuations, peaking earlier
in muscle than in brain (Komoroski et al., 1990). Similarly, elimination from serum is
more rapid than from muscle, in turn more rapid than from brain (Komoroski et al.,
1993).e half-life of 7Li in the brain is around 30 hours compared to an average of 20
hours for lithium in the serum; brain-to-serum ratios thus increase with time since
last dose despite falling concentrations (Plenge et al., 1994).
Having established a framework and tissue-specic pharmacokinetics, 7Li mrs
studies moved to address the relationship between brain concentration and clinical
parameters. Whilst some authors contested that brain concentrations more readily
correlated with side-eect burden than serum levels (Kato et al., 1996), the value of
7Li mrs as a predictor of therapeutic response is not universally upheld.
González et al. (1993) introduced the use of volume coils, overcame transmission
and sensitivity constraints with adiabatic pulse sequences and B1 eld corrections, and
selected their repetition times and reference methods to achieve absolute quantitation;
admirable snr within acceptable scan durations resulted.eir methods have since
been replicated and adapted (Sachs et al., 1995; Soares et al., 2001; Moore et al., 2002).
A more recent goal of the eld has been the charting of the distribution of 7Li
by spectroscopic imaging, favouring the use of volume coils (Komoroski, 2005).
Based on post-mortem studies and the ndings of rodent mrs studies in which very
long scan times are possible (Komoroski and Pearce, 2004), regional dierences in
the distribution of 7Li were anticipated in man. is appeared not to be the case,
with uniformity of the 7Li signal across brain regions reported (Girard et al., 2001).
Realistically, spectroscopic imaging is unlikely to achieve anything other than a crude
localisation, typical voxel resolutions being 4.3 × 4.3 × 6 cm.e 7Li nucleus yields
a singlet – much like protons in water – so it may be possible to visualise it with
strategies akin to mri. Early work supports this notion, with millimetre resolution
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possible (Boada et al., 2010; Lee et al., 2010). Regrettably, the nature of the pulse
sequences used in the reported imaging studies render the absolute quantitation of
7Li an impracticality, relative dierences in estimated concentrations being the reality.
us to date, no human study has combined adequate resolution with an appropriate
strategy to discern absolute 7Li concentrations according to brain structure or tissue
class.
6.2 experimental objectives & strategies
e principal aim of the work presented in this chapter was to develop a technique
to measure the in vivo concentration of lithium in the human. Experiments were
performedwith a bespoke surface coil interfaced with a 3T clinical scanner. Secondary
objectives at the outset were the acquisition of data in a time-scale suitable for potential
application in a clinical setting and the determination of lithium concentration in
dierent tissue classes, specically comparing grey and white matter. It transpired
that characterising the relaxation properties of lithium was paramount to achieving
these aims. In preparing the techniques, the work of González et al. (1993) took a
central position; their methods and strategies were adopted and adapted as follows:
• Combining a high eld strength scanner with a surface coil to optimize the snr.
• B1 eld modelling to correct for the inhomogeneous sensitivity of our coil, together
with adiabatic rf pulses to address the comparable transmission prole.
• Minimising partial saturation eects by using repetition times informed by locally
determined empirical estimates of the 7Li T1 in solution and in vivo.
• Quantitation of brain 7Li by way of a coil-mounted external reference, calibrated
against known concentrations of lithium chloride in aqueous solution.
• Estimation of the concentration of 7Li in dierent brain tissues, using a morphometric
segmentation analysis of T1-weighted images to determine the proportion of grey and
white matter in the volume sampled by mrs.
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e experimental process was necessarily iterative, optimisation of the funda-
mental techniques only possible through pilot appraisal of the more advanced, yet
ultimately contingent stages. In this account, a logical ow is taken in favour of an
unabridged chronological narrative, at each stage summarising the key principles
together with the techniques and ndings of others.
6.3 instrumentation & methodology
6.3.1 Radiofrequency coil
An rf coil should be suited to requirements of the experiment at hand, in this case
necessitating the construction of a new device.e rst consideration in the develop-
ment of an rf coil is its conguration and for 7Li, various designs have been reported:
principally surface coils; latterly volume coils; coil arrays to a lesser extent.
Surface coils Yielding high snr by focusing on specic regions of interest, surface
coils can localise signal by virtue of placement in addition to acquisition parameters.
e transmission and reception proles of surface coils are characteristically inhomo-
geneous, resulting in substantial variations in tip angles over the sample volume and
reductions in the snr with depth.
Volume coils Capable of covering the entire head, such coils may be used to sample
large volumes and tissues at depth.eir principal disadvantage is a low snr, a major
limiting factor to resolution with low sensitivity nuclei. Bird-cage designs oer the
advantage of homogeneous B1 elds, but they are dicult to construct – proprietary
phosphorous head-coils may be re-tuned to the frequency of 7Li with relative ease.
Dual arrays Using a volume coil for pulse transmission and a surface coil for signal
detection combines the benets of homogeneous excitation with a favourable snr.
Such arrays present technical challenges which undermine this potential, notably
phase incompatibility and eld misalignment.
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To achieve swi quantitation and tissue discrimination, a high snr was deemed
desirable and whole brain imaging unnecessary – the decision was made to perform
the experiments with a surface coil.e shortcomings of a surface coil are not insur-
mountable and the strategies utilised are described at the appropriate junctures in the
sections that follow.e salient points of the coil design are summarised below.
coil design
A simple transceiver surface coil was constructed in-house, 8 cm in diameter, and
tuned to 49.6 MHz using variable capacitors.e coil circuitry was housed in a locally
manufactured polyurethane case of 8 mm thickness, with a central positional marker
and an access port for the external standard reference. Tuning and matching rods
extended from the housing, accessible at arm’s length during scanning.e device,
hereaer referred to as the 7Li coil, was designed for placement over the frontoparietal
regions of the head, combining biological relevance with ease of positioning against
anatomical surface markers.e 7Li coil was secured to a cushioned head restraint
using Velcro™attachments.
scanner-coil interface
All experiments were performed on the same 3T Achieva whole body scanner (Philips
Medical Systems, Best,e Netherlands) equipped with a second broadband channel
for non-proton nuclei.e 7Li coil interfaced with the scanner through a ‘pig-tail’
connector, the cable incorporating a 1⁄4λ sleeve balun.e cable was lightly secured
in place to prevent movement during signal acquisition and subjects were shielded
from direct contact with it.
6.3.2 Phantoms
volume phantoms
e phantoms for our studies were prepared in-house using plastic containers of A phantom is an
articial object with
established
characteristics,
used to test and/or
monitor the
performance of an
mr system.
various dimensions. In all instances the solute was analysis water, to which crystalline
lithium chloride and sodium chloride was added as required.
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external reference standard
An external standard reference marker was mounted on the coil – directly above its Solutions were
prepared by Dr
Richard McQuade,
Institute of
Neuroscience,
Newcastle
University.
centre and within the housing – comprising a hollow polyurethane sphere of uni-
form thickness, sealed aer being lled with an aqueous solution containing lithium
chloride and dysprosium chloride. Dysprosium acts as a shi reagent, displacing
the 7Li resonance to enable the discrimination of signals acquired concurrently from
the subject and marker.e development and validation of the external reference is
described in more detail later in this chapter.
6.3.3 Subjects
developmental stages
To permit methodological developments, access to a pool of subjects with appreciable
levels of 7Li in their brains was required; namely the participants in the mrc-lamp
and mrc-lite studies. Subjects were drawn from these studies as and when they were
required, largely determined by the rate of experimental advances.us, recruitment
in the development phase was not systematic, there being no guarantee of an even
distribution of subjects on high and low dose lithium regimes. Application of the
developmental 7Li mrs techniques fell within the ethical approval granted for the
mrc-lamp and mrc-lite studies.
mrc-lisp study
e development process culminated in a pilot study (mrc-lisp) in which a small
sample of subjects were invited to take lithium carbonate before returning to undergo
mrs examination, specically the discrimination of lithium level by tissue class. No
baseline scans were required and the majority of subjects were investigated on the
same day, minimising variations in scanner performance. Details of the subjects and
the study design are provided in §6.8. Conducting a pilot investigation fell within the
remit of the initial research proposal, approved by an lrec and funded by the mrc.
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6.3.4 Analysis
All statistical analysis was performed using spss (v.17, spss inc., usa), with group
data are reported as mean ± sd for each variable. Analysis of the spectroscopy data
throughout this chapter was performed by Dr Fiona Smith.
6.4 pulse development & calibration
At the outset of the experimental series, use of two pulse sequences was envisaged: a
simple block pulse and a more sophisticated adiabatic pulse, the testing, calibration
and application of which are described below. In all instances, the energy delivered to
the subjects through the coil fell within specic absorption rate guidelines.
6.4.1 Block pulses
e form of a block pulse is simple – rf amplitude is constant when present and the
transition between on and o states is abrupt, creating a squared prole. All things
being equal, the tip angle is a product of the amplitude and duration of transmission.
With block pulses, the tip angle can be easily varied and a range of frequencies excited.
Block pulses were used in the initial exploratory stages of this project as well as during
signal acquisition from the reference compound in the nal quantitative protocol.
calibration
For the calibration series a cuboid phantomwas placed over the 7Li coil, its dimensions experiment
· calibration run
· aqueous phantom
· 2 litre plastic tub
· 100 mm LiCl·H2O
· block pulse
covering the active volume of the coil.e container was lled with 2000 ml of an
aqueous solution of lithium chloride, 100 mm in strength (this high concentration
was chosen to ensure adequate coil loading and signal detection). Positioned in the
scanner bore, tuning andmatchingwas optimised before a pulse-acquisition series was
run. A range of pulse durations were applied within a tr of 1000 ms, 60 unlocalised
averages acquired on each occasion. Each fid underwent Fourier transformation,
apodisation, line-width broadening of 20 Hz and phase shiing by visual inspection.
e spectra were processed using the amares algorithm within the jmrui soware
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Figure 6.1: Pulse calibration series for the lithium coil using an aqueous phantom of 2000 ml
volume, containing lithium chloride at a concentration of 100 mM. The parameters of the pulse
giving rise to the largest signal were used to ‘request’ a 90○ tip in future experiments.
package. Peak areas so derived were plotted against pulse duration; the parameters
for a 90° pulse were taken as those which resulted in the maximum signal over the
series (see gure 6.1 above).e process was repeated using a phantom containing
lithium chloride at a concentration of 3 mm, the results of which demonstrated that
the calibration was upheld at near-therapeutic levels.
limitations
With surface coils, inhomogeneous B1 elds principally occur when block pulse
sequences are applied and are no small matter, intensity changing ten-fold within
the sensitive volume of a coil. is is of course borne out as a variation in the tip
angles induced, their magnitude falling with distance from the coil; the receive prole
ts an identical pattern, sensitivity being lower at greater depths. Combining these
properties means that adequate snr can only be obtained for limited volume, roughly
hemispherical with a depth approximately equalling the coil diameter. A 90° tip will
be achieved in a fraction of this volume.
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To gauge the limitations of the 7Li coil, signal was obtained from a small phantom experiment
· signal by depth
· aqueous phantom
· 1.5 ml glass vial
· 100 mm LiCl·H2O
· block pulse
placed at various distances from the coil. A 1.5 ml glass vial lled with an aqueous
solution of lithium chloride (100mm) was placed inside the central bore of an annulus-
shaped, ve litre aqueous phantom.is proprietary phantom was designed to ensure
adequate coil loading whilst allowing small samples to be placed at various distances
from the coil surface. Aer tuning and matching, pulse calibration was performed
with the vial abutting the coil housing. A pulse-acquisition experiment was conducted,
in which 40 averages were collected for several tip angles at a series of depths (tr =
1000 ms).e requested pulse angles (30 · 60 · 90 · 135 · 180 · 270°) were derived from
the calibration run; the depth ranged from 15–140 mm in 5 mm increments, the oset
due to the coil housing and vial base.
Consider the signal returned for each pulse angle requested in the region close
to the coil (gure 6.2): requesting a 90° tip produces the maximum positive signal;
applying a 270° pulse results in a comparable negative signal; the 180° pulse yields the
null. Now consider the signal as a function of depth for each pulse, acknowledging that
the B1 eld intensity reduces with distance from the coil. For a given pulse, moving
away from the point of calibration results in a tip angle that is smaller than requested.
With a calibrated 90° pulse, signal intensity progressively declines; the signal from
stronger pulses shows a sinusoidal pattern in which the maximum positive deection
represents the depth at which the B1 eld has induced a 90° tip.e sinusoidal forms
are damped – the maximum positive deection from the 270° pulse is smaller than its
counterpart from the 90° pulse.is is a consequence of the receive prole of the coil.
As expected, the combined inhomogeneities in transmission and reception pre-
cluded useful detection beyond 8 cm. Whilst these empirical ndings are of interest,
it is neither practical nor desirable to chart the complete prole of our surface coil.
e receive prole can be corrected using the computer models described presently;
transmission inhomogeneity eects can be overcome by using adiabatic pulses.
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Figure 6.2: Profile of the lithium coil determined empirically. A small vial containing an aqueous
solution of lithium (100 mm) was moved away from the coil in 5 mm increments. Signal was
acquired at each depth, with various tip-angles requested. The 90○ series (coloured line) shows
diminishing signal with depth. Larger tip-angles returned their maximum signal intensities at
greater depths, but their maximum intensities were smaller than that of the 90○ tip series − this
arose from the lowering of the receive sensitivity of the surface coil with distance.
6.4.2 Adiabatic pulses
Adiabatic pulses are fundamentally dierent to the transmission sequences thus far
described. With a block pulse, the B1 eld is applied fully but intermittently and when
present it excites the full range of selected frequencies simultaneously. In the case
of adiabatic pulses the frequency of the excitation varies with time throughout the
application of the rf waves. e rf frequency and amplitude are swept according
to the adiabatic condition from o-resonance to on-resonance. When the adiabatic
condition is satised, the tip angle of the net magnetisation vector is uniform and
independent of B1 amplitude, provided that a certain threshold has been crossed.
Calibration need only be performed once, establishing the rate of sweep and B1
threshold necessary to achieve the desired tip angle. Pulses resulting in a 90° tip are
usually referred to as adiabatic half-passage excitations, full-passage denoting 180°
conditions.
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Figure 6.3: Modelled B1 field for the lithium coil − this was used to derive the receive profile of
the coil, enabling the correction of sensitivity loss with depth.
6.5 receive profile
e receive prole of a surface coil matches that of its transmission – signal detection
falls with depth but the problem cannot be overcome at the interface between the
subject and the scanner. By characterising the receive prole, signal intensity can be
systematically corrected during the analysis process. Replicating the work of Haase
et al. (1984), the B1 eld of the
7Li coil was modelled using matlab® functions. In
block pulse transmission, the tip angle achieved is proportional to the B1 eld; in
eect, the B1 map also describes the sensitivity in detecting signals.is model was
used to weight the signal received according to depth, its prole depicted in gure 6.3.
6.6 relaxation characteristics
For the reasons outlined in §2.6.4, it is desirable to understand the relaxation prop-
erties of the nucleus under investigation at the eld strength used. In essence, to
quantify a substance the degree of signal saturation must be known. Data on 7Li T1
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in vivo is scarce and in man, limited to a few small studies or solitary reports, most
of which involved subjects receiving lithium as treatment for an aective disorder.
Consequently, normative group data is lacking. In the studies estimating the T1 of
7Li in man, data has generally been tted to a monoexponential decay – when tested,
biexponential models have not signicantly improved the results. e notable ex- Monoexponential
decays are found
with dipolar spins,
biexponential with
quadrupolar.
Biexponential
decays are usually
described as having
fast and slow
components.
ception, in preclinical studies, is the nding of Renshaw et al. (1986). Investigating
the relaxation characteristics in a puppy head at 1.8T, a biexponential decay with
fast and slow components of 3.5 and 6.6 seconds (30% and 70% respectively) was
observed.is nding stimulated much debate, and it remains unclear if the ndings
are best explained by the contribution of dierent tissues to the relaxation data (such
as muscle), or by genuine biexponential decay in vivo.
6.6.1 Aqueous solution
e T1 of lithium in aqueous solution is of interest and importance for a number of
reasons. First, aqueous phantoms are easy to construct and a variety of compositions
can tested – the relaxation of 7Li should not alter with concentration, but estimates of
the likely snr in vivo can be made on aqueous phantoms without inconveniencing
subjects. Second, in quantifying brain lithium concentration, use of an external
reference was envisaged; this was most likely to be a solution containing lithium, the
parameters of which had to be established.e methods used to determine the T1
time of a sample are outlined in §2.6.5 on page 54.
block pulse
Determination of the T1 time of lithium in solution was performed using a saturation
recovery technique (steady-state, spectral bandwidth = 8000 Hz, fov = 350 mm,
2048 data points, 20 averages, 8 phase cycles, no volume selection; tr range: 5 to 75
s).e fid at each pulse duration underwent Fourier transformation, apodisation,
line-width broadening of 20 Hz and phase shiing by visual inspection.e spectra
were processed using the amares algorithm within the jmrui soware package. Peak
areas were plotted against repetition time and the T1 determined by nding the best
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t of the data to a curve given by the saturation expression below (equation 6.1, where
S is the signal intensity).e experiment was repeated on three occasions over several
days, from which the mean T1 time was derived.
S(tr) = S∞(1 − e−tr/t1) (6.1)
In a 2000 ml cuboid phantom containing an aqueous solution of 50 mm lithium
chloride, the mean T1 of lithium was 13.5 ± 0.65 s. It was envisaged that block pulses
would be used to acquire signal from the external standard during in vivo work;
this scenario was simulated by placing a hollow polyurethane sphere containing the
lithium solution (50 mm) in a cuboid phantom loaded with normal saline. Repeating
the saturation recovery experiment with 40 averages yielded a T1 of 17.1 ± 0.85 s.
e discrepancy between the T1 values was thought to be due to the inhomoge-
neous B1 eld and receive prole of the coil. It was likely that a 90○ tip angle would
have been achieved over the entirety of the small sphere, but only part of the volume
phantom – in other regions, the block pulse would have excited a greater range of tip
angles. Spins tipped by degrees less than 90○ attain equilibrium more swily, and in
contributing the the sample as a whole, spuriously reduce the T1 determined in the
experiment. Consequently, the T1 derived from the sphere was accepted.
e data from one of the saturation recovery experiments using the 2000 ml
phantom is shown in gure 6.4 (on page 206). e decay curve was made to pass
through zero as is usually the case, and it can be seen that the T1 relaxation of lithium
in aqueous solution may t a single exponential decay. Intriguingly, signal intensity
increased as repetition times approached zero – a nding that was consistent across ex-
periments and phantom concentrations.e prole was not obviously biexponential
and the occurrence was attributed to the phenomenon of steady-state free precession.
When samples are re-excited too swily, dephasing of spins may be incomplete and a
transverse component of the net magnetisation vector can persist; this is eectively
incorporated into the longitudinal component that arises with the next excitation,
adding to the signal subsequently detected.
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Figure 6.4: T1 relaxation data for an aqueous solution of 50 mM lithium chloride in a 2000 ml
volume phantom. The increase in signal intensity with the shortest TR is discussed in the text.
Figure 6.5: (a) LithiumMRS spectra in vivo in a healthy subject; the lithium in the reference sample
(coil marker) is shifted by the addition of dysprosium chloride. (b) Estimation of the T1 relaxation
time in the healthy human brain; adiabatic pulse sequence and an 8 cm surface coil (2.4 ± 0.4 s).
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Figure 6.6: Bloch simulation of a block-pulse and adiabatic pulse sequence for the lithium coil.
6.6.2 Human subjects
T1 measurements were made in the brains of healthy male subjects participating in
the mrc-lite study (n = 7, age 22 ± 4 years, duration of lithium administration 11± 1.6 days, serum lithium concentration 0.61 ± 0.3 mm). Data was acquired using a
non-localised steady-state saturation sequence in which a 90° adiabatic half-passage
excitation was applied over ve repetition times (6 ms pulse duration, spectral width
of 8000 Hz and 2048 data points). Forty averages were acquired at each tr (1000 ·
2500 · 5000 · 7500 · 10000 ms), translating to a scan duration of just under 18 minutes.
An example in vivo spectrum and T1 tting is provided in gure 6.5 on the previous
page. Direct tting of the saturation-recovery data yielded a T1 of 2.0 ± 0.4 seconds.
e T1 calculation assumed that a 90° uniform excitation was achieved across the
whole volume. To justify this, the theoretical spatial B1 distribution of the surface
coil was used in a Bloch simulation of the complete adiabatic acquisition sequence
(gure 6.6 above).e reliability of the saturation according to depth from the coil
was determined, thereby estimating the potential error in the calculated T1 value.
is model was conrmed by 1d chemical shi imaging (csi) in an extended aqueous
phantom of known T1 relaxation time. At most, the measured T1 underestimated the
true value by 5%.
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6.7 quantification techniques
e nal stage of development was to establish the parameters which would allow the
signal derived from a subject’s brain to be quantied.is required the production
and testing of solutions containing lithium and a shi reagent.
6.7.1 Reference compound
Various strategies exist to quantify signal from mrs investigations (see §2.6.4). As
there are negligible amounts of lithium in the normal human brain, external reference
compounds must be used. ere are two fundamental approaches to the use of
external references, at least in terms of timing: concurrent and consecutive data
acquisition. With consecutive techniques the phantom is scanned at about the same
time as the subject, andwill usually be constructed in such a way that its characteristics
match those of the subject in some way – doping the phantom to ensure similarity
of T1 values, normalising to water signals and so forth. is strategy can be time
consuming. Concurrent data collection acquires signal from the reference at the time
of scanning, usually with a small reference marker close to the coil. For 7Li, the main
problem is the small size of its chemical shi in vivo – unmodied, the data from the
subject and reference would be indistinguishable other than by location.
author lithium volume shift reagent shift
Renshaw (1988) 50 mm 10 ml 25 mm dysprosium tripolyphosphate 10–15 ppm
Komoroski (1990) 25 mm – 12.5 mm dysprosium (tripolyphosphate)2 15.7 ppm
Gullapalli (1991) 50 mm – 10 mm dysprosium tripolyphosphate –
Kato (1992–1994) 15 mm 15 ml 25 mm dysprosium ttha –
Kushnir (1993) 0.4–0.8 mm 2000 ml phosphoric acid –
Gonzalez (1993) 500 mm 10 mm tube 135 mm dysprosium chloride 15 ppm
Sachs (1995) – – dysprosium tripolyphosphate –
Riedl (1997) – 20 ml 2.5 mm dysprosium ttha 3 ppm
Komoroski (1997) 5 mm 25 mm sphere 1 mm [Na3H2Tm(DOTP)·NaCl] in 15% D2O –
Komoroski (1998) 0.48 mm 30 ml 0.48 mm [Na3H2Tm(DOTP)·NaCl] –
Ramaprasad (1998) – – dysprosium tripolyphosphate –
Soares (2001) 20 mm 60 ml 25 mm dysprosium chloride 5 ppm
Table 6.3: Shi reagents in lithiummrs studies, arranged in approximately chronological order.
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Shi reagents are powerful compounds which can alter the resonance frequency
of spins. In the eld of 7Li mrs, by far the most commonly used shi reagent is
dysprosium (see table 6.3), a heavy metal with toxic properties. Dysprosium is not
suited for administration to humans and has limited value for in vivo work anyway,
it not entering cells. It is, however, well suited to external phantom work. As a shi
reagent it needs to be in close proximity to the lithium ion. is can be achieved
either by using high concentrations or by combining chelating agents. Dysprosium is
expensive and so the latter option is preferred as lower concentrations are required.
Following the comprehensive description of Renshaw and Wicklund (1988), a
solution of 50 mm lithium chloride and 25 mm dysprosium tripolyphosphate was
prepared. Chelating agents tend to deteriorate over time and the moieties no longer
coordinate – in the studies in table 6.3, reference compounds were reportedly sta-
ble over a period of months. is was not the case in the series of developmental
experiments conducted for this thesis. Apparent in the progressive loss of shi and
a broadening of the spectral peak, deterioration rendered the reference standard
unusable. A simple ionic solution of lithium and dysprosium chloride (albeit in high
concentration) was favoured and found to be stable over time (LiCl 50 mM · DyCl3
135 mM) with an adequate down-eld shi (gure 6.5 on page 206).
6.8 spectroscopic imaging pilot study
6.8.1 Study design
e development process culminated in a pilot study (mrc-lisp) in which a small
sample of subjects (n = 5) underwent mrs examination to determine lithium level by
tissue class. Four subjects were recruited directly into this project, taking lithium for
a period of time before having a single mr examination; spectroscopic data was also
acquired from one subject in the mrc-lamp study. In general, subject recruitment,
screening and enrolment procedures matched those of the mrc-lite study, as did the
duration of lithium carbonate administration. For those entering the pilot study di-
rectly, the target serum concentration was set at 0.8 mm with open-label prescription,
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ensuring detectable levels whilst limiting the risk of toxicity. For these individuals,
csi was collected on the same day, minimising variations in scanner performance –
the duration between data acquisition and last dose varied but the interval between
brain and serum level sampling was xed at 30 minutes.e mrc-lamp study sub-
ject underwent spectroscopic examination aer completing the procedures of fmri
study, lengthening the time between last dose and data acquisition, but maintaining
blindness for the purposes of post-methamphetamine rating scales.
e subjects (n = 5) were all men, with a mean age of 20.5 ± 1.0 years. Lithium
was taken on average for 8.2 ± 0.45 days, resulting in a serum level of 0.96 ± 0.13 mm.
6.8.2 Acquisition
Spatially localised 7Li data were acquired using a 1d-si sequence with the spatial
encoding place positioned parallel to the coil plane (adiabatic half-passage excitation,
pulse duration 6 ms, tr = 6500 ms, 12 encode steps, fov = 12 cm, spectral width
8000 Hz, 2048 data points, weighted k-space averaging, 3 averages, total scan time ≈ 4
minutes). Variation in coil performance between subjects was assessed by measuring
the pulse width for non-selective 90° excitation of the external reference (fully relaxed
hard pulse, tr = 60 s, 4 ip angles, single average).
6.8.3 Quantitation
e calculation of 7Li concentration in vivowas made relative to calibration phantoms.
e 1d-si sequence was applied to eight extended volume aqueous phantoms, each
containing one of four concentrations of lithium chloride (0.1, 0.3, 1.0 and 3.0 mm)
at two dierent saline strengths (150 or 300 mm). Signal strength versus depth was
determined for each concentration and normalised to the signal from the reference
compound to create calibration curves.e in vivo spectra were again normalised
to the external reference and the results compared with the calibration curves to
determine uncorrected 7Li concentration. Signal arising from blood was corrected
for, the volume of brain vasculature assumed to be 5% (González et al., 1993).
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6.8.4 Localisation
For each subject, the volume the tissues contributing to each spectral row was cal-
culated as follows. Grey and white matter segmented images (native space) were
prepared in spm8, onto which a mask of the sampled volume was overlaid.is mask
was derived from the receive prole of the coil – its correct orientation and position
was determined by scrutinising the scout images acquired in preparation of the csi
sequence.emask was then split into 1 cm thick slices, simulating the csi acquisition.
e relative proportions of each tissue in the sections of the mask were used to scale
the mrs data in order to achieve the nal corrected 7Li concentration in each si row.
6.8.5 Statistical analysis
Correlation between the serum lithium levels and the mean brain 7Li concentration
over all si slices was assessed using bivariate analysis, taking a signicance level of p <
0.05 (two tailed).
6.8.6 Results
Spectroscopic imaging data from four subjects was suitable for analysis, with an
example from a single subject presented in gure 6.7 on page 212. Signal was easily
discernible to a depth of 6 cm.e rapid reduction in signal intensity with distance
from the coil reects the sensitive prole, corrected using our B1 model for the
purposes of quantitation.e snr at 3-4 cm was 20, with a total acquisition time of
approximately 4 minutes.
e 7Li concentrations by depth, including the mean of all subjects, are presented
in gure 6.8.e calculated average brain 7Li concentration for all subjects over all
slices was 0.71 ± 0.19 mm. Contrasted with the serum level of 0.9 ± 0.16 mm, the mean
brain-to-serum ratio was 0.78 ± 0.26.ere was no signicant correlation between
serum lithium level and brain 7Li concentration. No dierence in 7Li concentration
was observed between white and grey matter (gure 6.9 on page 213).
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Figure 6.7: Single subject’s CSI spectra with slice thickness equal to 1 cm (the slice nearest the
axis label is closest to the coil surface) − signal can be easily discerned at a depth of 6 cm
Figure 6.8: Lithium concentration by depth using one-dimensional spectroscopic imaging in vivo.
Data points indicatemean values± sd for the group of healthy subjects studied (n = 4), correcting
for the sensitivity profile of the surface coil.
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Figure 6.9: Lithium concentration according to percentage grey matter (% GM) in the SI slice.
In the majority of subjects, SI slices contained fairly equal proportions of white an grey matter.
Subjects 2 and 4 yielded data from slices containing a low percentage of grey matter, in which
the concentration of lithium did not appear to deviate from the values returned from slices with
a higher proportion of grey matter.
6.9 discussion
is chapter described the development and application of 7Li magnetic resonance
spectroscopy at 3T using a clinical scanner. It was demonstrated that adequate signal
to noise ratio could be achieved at a depth of at least 6 cm using a surface coil,
through the combination of adiabatic pulse sequences and receive-prole modelling.
Acquisition times for the 1d csi sequence remained under 5 minutes, with total scan
times including calibration and T1-weighted imaging approximating to 25 minutes.
is discussion section places the key results in context, and highlights the most
important contributions to the 7Li mrs eld.
6.9.1 Subject populations
Much of the 7Li mrs research in human subjects has been restricted to measurements
in patients prescribed lithium as part of their medication regime for bipolar disorder
(Gyulai et al., 1991; Kato et al., 1992, 1993, 1994, 1996; González et al., 1993; Komoroski
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et al., 1993; Kushnir et al., 1993; Riedl et al., 1997; Soares et al., 2000; Moore et al.,
2002, 2003; Forester et al., 2008).e initial ndings of these studies suggested that
there is a correlation between the brain and serum lithium levels and also between
brain to serum ratio and age (reviewed by Soares et al., 2000), although in a recent
investigation this latter relationship was not upheld in older subjects (Forester et al.,
2008). Other studies have also suggested that there is limited correlation between these
measures (González et al., 1993; Kato et al., 1996).e extremely limited data in healthy
subjects (Renshaw and Wicklund, 1988; Plenge et al., 1994) means that it is dicult to
disentangle what may be specic eects in small patient cohorts from general eects
of ageing. It is therefore important to dene normative data for full interpretation of
clinical studies.e ndings of this thesis may be considered an initial step towards
this goal – young, healthy men taking lithium were found to have a brain to serum
lithium ratio of 0.78 ± 0.26. is ratio is consistent with data from patients of the
same age (Moore et al., 2002). Understanding the relationship between administered
dose, brain level and serum concentration is of some importance in this age group,
it being close to the mean age of onset of the bipolar disorder, when medication is
likely to be initiated for the rst time. In the mrc-lisp study reported here, the lack
of a signicant correlation between brain and serum lithium concentration may have
been due to the narrow range of serum levels achieved in the subjects.
6.9.2 Relaxation properties of lithium
e most important contribution of this thesis to the eld of 7Li mrs is arguably the
determination of the T1 time of lithium in a sizeable group of subjects. Knowledge of
the relaxation characteristics of a nucleus in vivo is required for its concentration to
be accurately determined.e most common approach in quantitative studies has
been to adopt fully relaxed acquisition conditions, thus eliminating the need for any
T1 relaxation correction (González et al., 1993; Soares et al., 2000).is strategy is
consistent with the use of signal dierencing based localisation schemes such as image
selected in vivo spectroscopy (isis) as well as with simple adiabatic 90° excitation with
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surface coils. Previous studies have measured 7Li T1 in human brain at various eld
strengths (Komoroski et al., 1993; Kushnir et al., 1993; González et al., 1993; Riedl et al.,
1997; Girard et al., 2001; Moore et al., 2003), but no data exist at 3T.is prompted
Soares et al. (2000) to acquire data with a 15 s tr – the ndings of this thesis suggest
that a shorter trmay be applied whilst maintaining full saturation of signal.
In the largest group of subjects thus far investigated at any eld strength, the T1 of
7Li in vivo at 3T was found to be 2.0 ± 0.4 seconds. It is of interest to consider why
this value is relatively low compared to the published literature. From table 6.2 (page
193) it can be seen that most studies have reported the T1 of
7Li to be around three to
four seconds, though a value of 2.4 seconds was found in the rat at 7T.is direction
of this discrepancy is somewhat unexpected, as longitudinal relaxation times usually
increase proportionally with the applied eld strength.
e greatest potential source of error in the method applied in this chapter would
be the failure to achieve 90° excitation, leading to lower saturation than expected.
Validation of the method used was performed by combining a simulation of the rf
coil performance with experimental validation – an aqueous phantom using a small
point-source sample at coil isocentre where adiabatic excitation gave uniform 90°
excitation.e model and studies indicated that the maximum error in calculated
T1 was 5%, suggesting that the T1 value of
7Li in vivo was no greater than 2.1 seconds.
Greater T1 times previously reported may be a consequence of the use of block pulses.
In this thesis, the T1 of
7Li was determined using a saturation recovery sequence;
others have favoured inversion recovery techniques. Saturation recovery techniques
are more time ecient, but potentially less accurate, possibly accounting for the
dierence in reported relaxation times.e standard deviation of the T1 estimation
reported here suggests that this was not the case.e positioning of the surface coil
was such that contamination of signal from tissues other than the brain was unlikely –
were muscle to be contributing to the T1 estimate, it would most likely increase its
value (Renshaw andWicklund, 1988). It is conceivable that the short T1 represented
the detection of the fast component of a biexponential decay, though the pattern of
the data would suggest otherwise, tting to a single exponential function.
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6.9.3 Concentration of lithium in dierent brain tissues
Spatial data on the distribution of lithium may inform theories of its action, as well
as progressing the debate regarding its eects on the mr signal derived from grey
matter. Ramaprasad et al. (1992) performed 2d spectroscopic cerebral imaging at high
eld in rats treated with lithium for a short period of time – distribution was uneven
within the brain, though the resolution was poor. Similar ndings have recently
been demonstrated in man using 7Li mr imaging (Boada et al., 2010; Lee et al., 2010),
consistent with the post-mortem examinations reported decades previously (Francis
and Traill, 1970; Spirtes, 1976). Such techniques were not, however, quantitative.
As with all non-proton mrs investigations, protocol design must balance locali-
sation, spatial resolution and adequate snr with a clinically acceptable examination
length. Spatial information in clinical studies has varied from simple surface coil
localisation (Kushnir et al., 1993; Kato et al., 1996), or slab localised 1d isis with exam-
ination times of minutes (González et al., 1993; Soares et al., 2001; Moore et al., 2002;
Forester et al., 2008) through to 2d spectroscopic imaging requiring 55 minutes of data
averaging (Girard et al., 2001). In the mrc-lisp study reported here, a combination of
surface coil localisation with a 1d-si adiabatic sequence was used, separating spectra
from 10 mm thick planes parallel to the surface coil (essentially sagittal orientation).
is protocol required a data collection time of 4 minutes and provided sucient
spatial resolution to examine dierences with depth and the relationship between
grey and white matter concentration.e coil was placed over the frontal region of
the head, minimising the amount of skeletal muscle which may have contaminated
data from the brain. Although any signal from muscle would be separated from brain
signal by the si encoding scheme, no such signal could be discerned.
Lithium concentration showed a trend to increase with depth into the brain, but a
regression of local concentration against percentage grey matter contribution showed
no signicant dierence according to tissue class.e 1d-simeasurement did not,
however, provide complete localisation – an objective for future research.
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7 discussion
e human brain can be conceptualised in many ways – developmentally by way of its
genetic determinants, environmental inuences and evolution; structurally through
gross anatomy, regional connectivity, cellularmorphology andmolecular composition;
functionally as neurochemical systems, metabolic processes and emergent behaviours;
analytically in the construct of the psyche; spiritually and philosophically in terms that
convey a dierent meaning.e experience and the eects of psychoactive substances
can be interpreted across these realms, as can many of the techniques used to study
this most fascinating organ.
e overarching aim of this thesis was to explore the interaction between lithium
and the human brain using magnetic resonance techniques.e experimental work
conducted was presented as three studies, each warranting its own chapter but over-
lapping for the purposes of some analyses. First, the eects of lithium on cerebral
dopaminergic systems were examined in a randomised, placebo-controlled, bold
fmri study during which healthy subjects performed a task requiring their sustained
attention, before and aer receiving methamphetamine. Second, the notion that
lithium could increase the volume of grey matter in the brain was explored and ques-
tioned through the application of quantitative structural imaging techniques. Finally,
developmental work in the eld of lithium mrs was undertaken with the goal of
measuring the concentration of lithium in dierent brain tissues. In this concluding
chapter, the implications of the results of these studies are discussed, their strengths
and weaknesses considered, and suggestions for future research proered.
7.1 lithium & dopamine
A great deal of evidence supports the notion that lithium can attenuate over-activity
in the dopaminergic systems of the human brain. Much of this evidence was reviewed
during the preparation of this thesis, at least that pertaining to bipolar disorder. Used
as a model of mania in the mrc-lamp study, methamphetamine reproduced some of
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the features of the condition and lithium was found to lessen its subjective eects.e
eects of methamphetamine on the bold signal required thoughtful interpretation,
ultimately emerging as a reduction in the deactivation within the default mode regions
observedwhen subjects embarked upon the rvip task. Lithium attenuated these eects
in a within-group analysis; placebo did not. is dierence between lithium and
placebo did not, however, emerge as signicant in a between-group comparison.
e most obvious eect of lithium itself was to slow the speed with which subjects
responded to targets during the rvip task, its eects on the bold signal before the
second dose of methamphetamine being more dicult to interpret.
7.1.1 Strengths, weaknesses and future directions
e eects of lithium on amphetamine administration as a model of mania has
previously been investigated using bold fmri (Bell et al., 2005b); the study presented
in this thesis is novel by way of its longitudinal design and the randomisation of
subjects to high and low dose lithium regimes.e principal weakness of the mrc-
lamp studywas that it was under-powered for a between-group comparison of lithium
and placebo, this a consequence of the number of subjects enrolled and the analysis
strategy applied.
Around the time of the inception of the mrc-lamp study, the available data
indicated that relatively small group sizes would be sucient to detect a dierence
between lithium and placebo on the eects of amphetamines on the bold signal.
Bell et al. (2005b) assessed the eect of pretreatment with lithium or valproate on
d-amphetamine-induced changes in brain activity in healthy volunteers. Compared
to placebo, lithium attenuated the eects of the stimulant on bold signal during a
word-generation paradigm and the task involving spatial attention.ese dierences
reached signicance on a between-group analysis, with twelve subjects in the placebo
group and nine taking lithium.e target sample-size of the mrc-lamp study was
therefore set as at least nine subjects in each of groups, aiming for a minimum of 27
subjects in total. It is a regretable short-coming of the study that only six subjects
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were enrolled into the placebo group. Close to its planned ceasation the study was
curtailed by an upgrade to the scanner soware – data acquisition was not extended
beyond this point for reasons of quality control and comparability.
Recruitment of subjects was more dicult than expected – nding young men
who were willing to take methamphetamine but who had not taken it before (and who
were also amenable to the idea of receiving lithium) proved something of a challenge.
Most of the potential subjects declined to participate without giving reason, though
the suspicion was that they were unwilling to admit to previous drug-use. Whilst
more subjects may have been recruited had the exclusion criteria been less stringent,
a larger heterogeneous sample does not necessarily translate to a more powerful study
in terms of the interpretation of results. Designing a study-specic website (on which
full details of the proposed research and criteria for participation were presented)
streamlined subject selection. Future studies should capitalise on this – or whatever
the most accessible media is at the time – early in the recruitment process.
Bell et al. (2005b) demonstrated a dierence between lithium and placebo with
range of serum levels similar, if not slightly lower than in the mrc-lamp study; they
administered medication for 14 days.e lack of a dierence between placebo and
lithium in this thesis could indicate that the study duration was too brief. Although
lithium can be antimanic within several days, most of the clinical trials have gauged
its eects over at least three weeks (Poolsup et al., 2000). Whilst ethical considerations
constrain the duration of studies of healthy subjects, the case should be made for
using longer courses of medication in future research.
e stategy adopted for the analysis of the data in the mrc-lamp study requires
consideration. Bell et al. (2005b) examined bold signal change in prespecied regions
of interest derived from a previous study (Willson et al., 2004); the analysis in this
thesis compared all voxels in the functional images. Whilst statistically more powerful,
region of interest analyses are inherently restrictive. By scrutinising the entire brain,
methamphetamine was shown to be associated not with bold activations, but with
the lessening of deactivations – a new nding that would have otherwise have been
missed.
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Methodological strength is usually gained by adopting a longitudinal design.
With stimulant administration, it appears to be a double-edged sword. ere is
substantial individual variation in the response to amphetamines, making a within-
subject, or in this case a within-group comparison desirable. Repeated administration
of stimulants, however, may lead to behavioural sensitisation and the consequences of
anticipating their eects. It was argued in this thesis that subjects allocated to receive
placebo self-replicated the eects of methamphetamine, attaining a state of arousal
prior to the administration of the stimulant on the second occasion; lithium was
thought to prevent this occurrence.is nding requires replication, for it may have
consequences on the optimal design of future experiments.
Subjects in themrc-lamp study were randomly assigned to receive lithium in one
of two regimes, aiming for high or low concentrations chosen to reect those com-
monly advocated for the treatment of mania and the prevention of relapse. For each
subject, the dose was calculated and initiated without titration. Estimating the dose in
this way proved successful, ensuring a uniformity in the duration of administration
that would have been precluded by a titration strategy. In an exploratory analysis,
the eects of methamphetamine on bold deactivations appeared to be attenuated
most in those receiving a higher dose of lithium. Formal comparison of the mean
t-scores extracted in the region of interest analysis was not possible at the time of
submission of this thesis. Future work with the data obtained in this study will include
the extraction and comparison of signal contrast values from the regions of interest in
each individual – whether the comparison should use data extracted from the whole
cluster or a small element of the cluster (removed from the contaminating eects of
csf for example) is a matter to be addressed.
7.1.2 Implications of the ndings
e mrc-lamp study was conrmatory in nature, it being clear that lithium could
act to attenuate dopaminergic system functioning. Indeed, such a study could not be
conducted in good faith without a substantial body of supporting evidence. Observing
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the subjective eects of methamphetamine armed its use as a model of mania;
delineating its eects on deactivations within the default mode regions conrmed its
validity as a manipulation of the brain regions most recently implicated in bipolar
disorder (McKenna et al., 2010). Patients with mania commonly receive antipsychotic
drugs as a rst-line intervention, lithium being added to the treatment of those who
fail to respond (Grunze et al., 2009). Antipsychotic medications are dopaminergic
receptor antagonists, though their therapeutic action derives from a complex interplay
of eects on neurotransmitter systems rather than solitary receptor blockade.e
localisation of the eect of lithium to the presynaptic level, as suggested by the ndings
of this thesis, supports the combination of such drugs.
e use of lithium is not, and never has been, conned to the treatment of mania.
Neuroplasticity theories have widened its indications to include various neurode-
generative conditions, not least the dementias. Patients with dementia commonly
present with features of parkinsonism; a substantial minority Parkinson’s disease
plus dementia or Dementia with Lewy Bodies – archetypal hypodopaminergic states
(Weisman and McKeith, 2007). Lithium is being investigated as a disease-modier in
the dementias by virtue of its purported neuroprotective eects (Hampel et al., 2009;
Lauterbach et al., 2010). Were the conclusions of this thesis to be substantiated – that
lithium reduces dopaminergic activity, most likely through presynaptic eects – the
parkinsonian features in the dementia states may be worsened by its administration.
Intervention with lithium may, on balance, prove to be detrimental.
7.2 lithium & grey matter
A decade has passed since it was rst reported that lithium increases the volume of
grey matter in the brain of man – at least, that is, when assessed by mri techniques.
e nding has been consistently replicated and although the underlying mechanism
has not been established, it is widely accepted that the increase in volume has a basis
in the established ability of lithium to enhance neuroplasticity.
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e decision to investigate the relationship between lithium, grey matter volume
and mr signal arose from approaching the eld with a degree of cynicism. Viewed
critically, though not without prejudice, the interpretations of the nding appeared
awed. If lithium acts to prevent neuronal damage, why does the volume of grey
matter increase in studies of healthy individuals? Given the consistency of the nding,
why was it not detected in early studies of patients with aective disorders – could this
be a consequence of the analysis adopted rather than the state of the brain? Finally,
should it not be a cause for alarm – or headache at least – that a drug intervention
may increase brain tissue volume to such a degree as has been reported?
e mrc-lite study sought to determine whether it was possible that the grey
matter volume increase seen with lithium was actually a consequence of it altering the
relaxation characteristics of protons, thereby altering signal contrast and volumetric
assessments. Evidence was found in support of this notion – volume increase was
observed using vbm but not siena, and a reduction in grey matter T1 was detected.
7.2.1 Implications of the ndings
e implications of these ndings may be marked. If lithium substantially aects
tissue classication, many recent mri studies of bipolar disorder require reappraisal.
If the cellular eects of lithium drive the T1 change, a mechanism for charting the
distribution of its actionmay have emerged – thismay also explain why the volumetric
nding proved so attractive, occurring as it did in brain regions pertinent to bipolar
disorder and theories of action of lithium (ignoring the nding that the lithium-related
naa increase was most marked in the occipital regions (Moore et al., 2000a)).
7.2.2 Strengths, weaknesses and future directions
In the mrc-lite study, established analysis techniques were applied in a simple
longitudinal manner to well characterised, healthy subjects.e number of subjects
studied was comparable to previous investigations in this area.e weakness of the
study lies not so much in its construction or its power to detect volumetric dierences,
but in the nature of the phenomenon under investigation.
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e grey matter T1 reduction reported in this thesis was small, and it is debatable
whether a change of this magnitude would be sucient to disrupt the tissue classi-
cation process during vbm analysis.e determination of grey matter T1 was at the
mercy of the process it sought to investigate – mean values were extracted from lobar
brain regions, but these regions were delineated using a process that required the
segmentation of subjects’ T1-weighted images. Consequently, the T1-maps may have
been distorted by partial volume eects, with csf voxels included in the grey matter
regions diluting the lithium-related change in relaxation times. Estimation of the T1
times therefore needs to be repeated using a dierent segmentation threshold, one
with which it is certain that grey matter, and only grey matter, is extracted.
e rationale for using a short course of lithium requires scrutiny. Subjects who
enrolled directly into the mrc-lite study were given lithium to take for 11 days.
is duration was chosen to match that of the mrc-lamp study, allowing data to be
combined for a more powerful analysis in statistical terms. It was also reasoned that
the neurotrophic eects of lithium would be slow to manifest and that large increases
in grey matter volume occurring acutely would attract a physical account based on
the theorised change inmri signal. During the writing of this thesis, Lyoo et al. (2010)
demonstrated a progressive increase in grey matter volume with time, such that the
results reported here could be interpreted as an early detection of a chronic process
rather than a distinct, acute phenomenon. With hindsight, it would have been better
to use the data from the mrc-lamp study to investigate the acute eects of lithium
and to recruit more subjects directly into the mrc-lite study, administering lithium
for several weeks to gauge the chronic eects of the medication.
Nevertheless, the dierence in grey matter volume change determined using
intensity-based and boundary-shi techniques requires replication – a relatively sim-
ple matter that could be performed using extant data. Given the potential implications
of the relaxometry ndings, replication in a future study would appear to be justied.
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7.3 locating lithium
At the outset of this project as a whole, it was hoped that 7Li mrsmight be integrated
into the mrc-lamp and mrc-lite protocols, combining assessments of the eects of
lithium on brain structure and function with estimates of its regional concentration.
Regrettably, that goal proved to be unrealistic in the time available.e developmental
processes leading to the quantication of brain 7Li concentration took longer than
expected – the construction and testing of the coil was a relatively straightforward
matter but establishing the T1 time of lithium in vivo drained heavily on scan time.
As it transpires, the generation of normative group data for the T1 relaxation
time is probably the most important contribution of this thesis to the 7Li mrs eld.
e mean value determined in healthy subjects using a surface coil with adiabatic
excitation was lower than previous reports in man, but consistent with measures
performed in the rat at high eld strengths. Quantitative pulse sequence construction
requires knowledge of the relaxation properties of the nucleus under investigation in
order to avoid signal saturation.e values reported here should encourage the use
shorter repetition times, reducing the overall scan duration or improving snr should
researcher elect to perform more acquisitions.
In the mrc-lisp study, no dierence in the concentration of lithium in grey and
white matter was found.e sequence applied permitted depth localisation only – the
level of lithium in the dierent tissues was gauged using the segmented T1-weighted
images, providing relative proportions in each si slice. Quantitative strategies are time
consuming and as a consequence, resolutionmay be poor. Whilst the determination of
absolute lithium concentration is a laudable goal, recent advances in lithium imaging
may prove to be of greater value (Boada et al., 2010; Lee et al., 2010). Manipulating
the lithium spectral singlet, as with water in mri, may provide high resolution images
relatively swily. In this thesis, a greater than expected signal intensity occurred as
repetition times approached zero. Should this phenomenon prove to be consistent
and predictable – as would be expected were it due to steady-state free precession – it
could be harnessed to enable rapid lithium imaging using very short repetition times.
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7.4 concluding remarks
Whilst lithium has a long history in medicine, and has been the focus of systematic
research for decades, it is likely that there ismuch still to be learnt about this fascinating
element. Indeed, much may yet be learned from lithium – the importance of illness-
modication, the complexities of mental state, the idiosyncrasies of pharmacokinetics
and the pitfalls and promises of imaging spring to mind.
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